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ABSTRACT 
Clear cell renal cell carcinoma (ccRCC) is characterised by frequent inactivation of the 
VHL tumour suppressor gene and consequent accumulation of HIF2A that drives 
tumourigenesis. The current clinically-approved therapies for ccRCC are those targeting the 
angiogenesis and mTOR signalling pathways, however, the overall patients’ objective response 
rates are still low, and patients rapidly develop resistance towards the administered therapies. An 
incomplete understanding of the underlying molecular mechanisms that support ccRCC 
progression has contributed to the lack of effective diagnostic and/or therapeutic strategies 
developed, especially for the highly mortal advanced stage ccRCC. Thus, the identification of 
cellular networks on which ccRCC cells are highly dependent would facilitate the development 
of better diagnostic and/or therapeutic approaches for ccRCC.  
Super enhancers have been reported to drive the expression of critical transcription 
regulators in various biological contexts including the regulation of cancer phenotypes. 
Previously generated H3K27ac ChIP-Seq data from several ccRCC cell lines has identified 
KLF6, a zinc finger DNA-binding transcription factor, to be associated with one of the strongest 
super enhancers in ccRCC, which could signify a biological relevance to KLF6 in supporting 
ccRCC pathogenesis. Thus, the purpose of this present study was to interrogate the role of KLF6 
in ccRCC, and dissect the KLF6-regulated transcriptional networks and how they can contribute 
in supporting ccRCC pathogenesis.  
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It was discovered that KLF6 expression was supported by a robust super enhancer that 
integrates signals from multiple pathways, including the ccRCC-initiating VHL-HIF2A pathway. 
In line with its regulation by the super enhancer, CRISPR-Cas9 and CRISPRi-mediated 
perturbation of KLF6 led to impaired ccRCC cells growth in vitro and in vivo as well as reducing 
the cells metastatic lung colonisation capability. KLF6 inhibition led to the deregulation of lipid 
homeostasis pathways in ccRCC cells. A dual KLF6 role was identified in modulating lipid 
homeostasis pathways in ccRCC: First, KLF6 directly regulates the expression of several 
important lipid homeostasis genes. Second, KLF6 promotes PDGFB expression, which activates 
the mTORC1 signalling pathway and the key lipid metabolism transcriptional regulators 
SREBF1 and SREBF2. KLF6 and mTORC1 thus co-regulate lipid homeostasis, consequently 
supporting ccRCC cell growth. Furthermore, findings from this study also reveal a molecular 
link between the PDGF and mTORC1 signalling pathways, which are the clinically relevant 
therapeutic targets in ccRCC. In general, the link between super enhancer-driven transcriptional 
networks and essential metabolic pathways described herein may provide clues to the 
mechanisms that maintain the stability of cell identity-defining transcriptional programmes in 
cancer. 
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 “.....to those who have resiliently fought cancer but lost their fight, 
to those who are still battling and suffering from this debilitating disease, 
may one day we could put an end to cancer once and for all.....” 
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1.1 Kidney and urinary system 
Kidneys are part of the urinary system which is also comprised of ureter, bladder, 
prostate (in man) and urethra (Figure 1)1. The urinary system main function is to filter and 
excrete excess water and metabolic waste from the body. These excessive products are filtered 
out from the blood in kidneys and eliminated from the body in the form of urine. The urine is 
transported from kidneys to bladder for storage and excreted from the body via ureter and 
urethra, respectively1,2. In addition to filtration and excretion functions, kidneys also play a role 
as a hormone secretion organ. Kidneys secrete hormones such as erythropoietin to stimulate the 
production of red blood cells in the bone marrow and calcitriol, an activated form of Vitamin D, 
which increases the calcium uptake in the intestine2. Renin, another hormone secreted by 
kidneys, involves in maintaining the blood pressure via renin-angiotensin-aldosterone axis2. 
Thus, the urinary system function is vital to maintain the body homeostasis by regulating the 
water and electrolytes balance, blood pH and pressure as well as removing waste products from 
the body. Impaired in kidney functions due to injury or diseases such as cancer may pose serious 
health problems and could be fatal. 
 
 
 
 
 
 
Figure 1: The human urinary system. Source: https://smart.servier.com 
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Blood filtration and reabsorption of necessary metabolites and waters take place in the 
nephron which is the kidneys “functional unit”3. There are approximately one million nephrons 
in each of human kidney, looping between the renal cortex and renal medulla. The nephron 
consists of two components, (1) the renal corpuscle that comprised of glomerulus and Bowman’s 
capsule, and (2) the renal tubules. The components of renal tubules are proximal convoluted 
tubule, loop of Henle, distal convoluted tubule and collecting duct3. The blood filtration takes 
place in the renal corpuscle. The filtrate that passes into the Bowman’s capsule from the 
glomerulus will travel through the renal tubules. The reabsorption of essential metabolites as 
well as water occurs along the renal tubules before the final filtered waste is emptied into the 
collecting duct and subsequently transported to bladder3. The structure of nephron is depicted in 
figure 2.  
 
 
 
 
 
 
 
 
 
Figure 2: Structure of nephron, the functional unit of the kidneys. Source: 
https://smart.servier.com 
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1.2 Kidney cancer overview 
Like any other major organs in human, cancer can arise in the kidney due to uncontrolled 
cells growth, which is largely caused by genetic and epigenetic alterations that occur inside the 
kidney cells. There is approximately 400,000 new kidney cancer cases and 144,000 deaths from 
kidney cancer reported annually worldwide4, making kidney cancer as the 12th most common 
cancer in the world5. As the seventh most prevalent cancer in the United Kingdom, there were 
about 12,500 new kidney cancer incidences and ~4,400 kidney cancer-related deaths recorded in 
the UK in 20156. The American Cancer Society has recently estimated that there will be 63,000 
new kidney cancer cases and projected 15,000 deaths from kidney cancer in the United States7. 
This figure is expected to steadily rise in the coming years due to lack of effective treatments 
especially against the advanced stage kidney cancer6,7. Kidney cancer patients are usually 
diagnosed after the primary tumour has metastasised to the secondary sites where at this stage, 
the tumour is highly aggressive and normally irresponsive towards conventional chemo- and 
radiotherapies8. If the disease is detected at the early stage, the primary tumour can be removed, 
thus preventing it from spreading to the distant sites8. However, surgical resection might reduce 
the renal function which could possibly lead to chronic renal diseases as well as affecting the 
body biological processes and homeostasis. 
1.3 Types of kidney cancer 
Kidney cancer can be classified into two types; the renal cell carcinoma and transitional 
cell carcinoma. Renal cell carcinoma (RCC) originates from the cells that form the lining of the 
renal tubules. It is the most common type of kidney cancer that accounts for approximately 90% 
of all kidney cancer diagnosed worldwide. Transitional cell carcinoma on the other hand, arises 
in the renal pelvis and makes up about 5-10% of all kidney cancer cases9. RCC can be further 
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classified into several subtypes based on the histological appearance and genetic alterations that 
are associated with that specific subtypes10. The most prevalent RCC subtype is the clear cell or 
commonly known as the clear cell renal cell carcinoma which accounts for ~75% of all kidney 
cancer incidences. Other RCC subtypes are papillary renal cell carcinoma and chromophobe 
renal cell carcinoma in which each accounts for about 10% and 5% of all kidney cancer cases, 
respectively11. In addition to these existing subtypes, there are emergence of novel, 
pathologically-distinct RCC subtypes such as the hereditary leiomyomatosis and renal cell 
carcinoma syndrome-associated RCC and succinate dehydrogenase-deficient renal cell 
carcinoma9. This present study focuses on clear cell renal cell carcinoma, the predominant type 
of kidney cancer that contributes to the most kidney cancer-related deaths.  
1.4 Overview of clear cell renal cell carcinoma  
As previously described, 75% of all kidney cancer incidences are of the clear cell 
subtype. The clear cell renal cell carcinoma (hereinafter referred to as ccRCC) originates in the 
proximal convoluted tubule lining of the renal cortex8. The term “clear cell” arises from the 
ccRCC distinctive clear, glass-like cytoplasm, which is due to the accumulation of cytoplasmic 
lipids and glycogen12,13. Figure 3 shows the example of clear cell histology of the human ccRCC 
cell line xenograft. Alterations in the lipid and glucose metabolism have been observed in 
ccRCC whereby this metabolic rewiring plays a crucial role in supporting ccRCC pathogenesis14-
16. This metabolic rewiring may contribute to the accumulation of cytoplasmic lipid and 
glycogen and consequent formation of the clear cell phenotype. Nonetheless, it still remains less 
understood on the molecular mechanism underpinning the cytoplasmic lipid accumulation in 
ccRCC. In addition, ccRCC is highly vascularized due to the upregulation of pro-angiogenic 
factors such as VEGFA and PDGFB in this tumour type8.  
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Figure 3: Clear cell histology of the human ccRCC cell line xenograft. 
 
ccRCC is well-characterised by the bi-allelic inactivation of the von-Hippel-Lindau 
(VHL) tumour suppressor gene. VHL inactivation, either due to somatic alterations or epigenetic 
silencing, is the hallmark gatekeeper event in ccRCC pathogenesis, contributing to 
approximately 90% of sporadic ccRCC cases17,18. On top of this, inactivation of VHL is also 
implicated in the von-Hippel-Lindau syndrome, a familial form of ccRCC19. Recent multi-region 
sequencing efforts revealed intratumoural heterogeneities in ccRCC in which the ubiquitous 
VHL mutations are predicted to be the truncal event in ccRCC pathogenesis17,20,21. The 
widespread genetic heterogeneities in ccRCC has been the stumbling block in the development 
of efficient therapeutic strategy for ccRCC. Also, incomplete understanding on the underlying 
molecular mechanisms that support ccRCC pathogenesis especially the advanced-stage ccRCC 
contributes to the lack of effective treatments developed for ccRCC. Advanced-stage ccRCC is 
highly metastatic, predominantly to the lung and bones, and associated with high mortality due to 
the tumour irresponsiveness towards conventional therapies. This poses a major problem because 
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significant fraction of ccRCC patients already manifest the metastatic disease at the time of 
diagnosis due to lack of early symptoms. 
1.5 The VHL-HIF pathway in cellular adaptation to hypoxic condition  
VHL gene is located on the short arm of chromosome 3 (3p25) and comprises of 3 exons. 
This gene encodes for pVHL, which along with elongin B, elongin C, cullin-2 and RBX1, forms 
the ubiquitin-mediated proteosomal degradation complex22. This complex functions as an E3 
ubiquitin ligase (hereinafter referred to as VHL complex) that tags its targeted protein for 
proteosomal degradation. The hypoxia-inducible factor alpha subunit (HIFA) is the well-
characterised target of this VHL complex19. To date, there are three HIFA isoforms identified, 
HIF1A, HIF2A and HIF3A23. Out of these three, the HIF1A and HIF2A are the well-studied 
isoforms. Both HIF1A and HIF2A have a similar structure that comprised of (1) N-terminus 
bHLH domain that mediates the DNA binding, (2) protein-protein interaction PAS (Per-ARNT-
Sim) domain (3) oxygen-dependent degradation domain (ODD) and (4) C-terminus 
transactivation domain (N-TAD and C-TAD)24,25. In addition to these HIFA subunits, there is 
also the presence of one beta subunit (HIF1B). The HIF1B subunit has the bHLH and the 
dimerization PAS domains but lack the ODD and NTAD25. The HIF1A, HIF2A and HIF1B 
protein structures are illustrated in figure 4.  
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Figure 4: HIF1A, HIF2A and HIF1B protein structure. Adopted from Chen et al.25  
 
The HIFA forms a heterodimer with HIF1B to drive the transcriptional programmes that 
facilitate cellular adaptation and survival under the hypoxic condition23,26,27. The dimerization of 
these two subunits to form functionally active HIF transcription factor only occurs under the 
hypoxic condition due to HIFA instability and is proteosomal-degraded in the normal oxygen 
level28. The HIF1B on the other hand is constitutively expressed regardless the oxygen level. 
Hence, the hypoxia-responsive transcriptional programmes is driven and highly dependent on 
HIFA availability, thus making this subunit the indispensable component of HIF transcription 
factor complex. Under the normoxic condition where the HIF-driven transcriptional programmes 
are not necessary, the proline residues within the HIFA oxygen-dependent degradation domain 
are hydroxylated by the prolyl hydroxylases. This reaction only occurs in the normal oxygen 
level because the conversion of proline to hydroxyl-proline requires oxygen molecule29,30. The 
VHL complex will then recognise the prolyl-hydroxylated HIFA and subsequently ubiquitin-
tagged it for proteosomal degradation. The VHL complex recognition and proteosomal 
degradation of the prolyl-hydroxylated HIFA under the normoxic condition is illustrated in 
figure 5. 
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Figure 5: VHL complex recognition and proteosomal degradation of HIFA subunit. Adopted 
from Chen et al25 
 
The heterodimer HIFA/B transcription factor (hereinafter referred to as HIFA) recognises 
the hypoxia-responsive element (5’–[A/G] CGTG-3’) located within the regulatory region of its 
downstream targets31. Several well-characterised HIFA downstream targets are the pro-
angiogenic factors such as vascular endothelial growth factor alpha (VEGFA), enzymes involve 
in glucose metabolism reprogramming such as glucose transporter 1 (GLUT1), lactate 
dehydrogenase A (LDHA) and pyruvate dehydrogenase kinase 1 (PDK1) as well as 
erythropoietin (EPO) that play roles in regulating red blood cells production32. The expression of 
these hypoxia-associated genes facilitate the cellular adaptation and increase survival in the low 
oxygen environment. For example, the increase formation of new blood vessels and red blood 
cells will increase the supply of oxygen as well as nutrients to the hypoxic cells. The glucose 
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metabolism reprogramming will lead to efficient utilisation of oxygen by shifting the energy 
production from the high oxygen-dependence oxidative phosphorylation towards glycolysis.   
1.6 The VHL-HIF pathway, gatekeeper in renal tumourigenesis  
VHL is a classic two-hit tumour suppressor gene33 that conforms to the Knudson 
hypothesis on cancer formation34. In the sporadic ccRCC cases, bi-allelic inactivation of VHL 
normally occurs through acquisition of somatic mutations in one of the allele followed by 
deletion or loss of heterozygosity of the other wild-type allele17,35,36. Hyper-methylation of the 
VHL promoter region, which silences the VHL expression, has also been reported in ccRCC 
patients35,37. Patients with the von-Hippel-Lindau syndrome could also develop ccRCC. This is 
the hereditary form of ccRCC in which the affected individuals inherit one mutated VHL allele 
from either father or mother and usually followed by deletion/loss of heterozygosity in the other 
wild-type allele later in their life19. Other than ccRCC, patients with VHL syndrome could also 
develop hemangioblastoma which is a type of tumour that forms in the blood vessels of retinal 
and central nervous system.  
The bi-allelic VHL inactivation in ccRCC leads to continuous HIFA accumulation that 
will in turn aberrantly activate the hypoxic-response transcriptional programmes even in the 
normal oxygen level. The upregulation of these transcriptional programmes in this context could 
promote the formation of tumour. In fact, several of HIFA downstream targets are known to be 
pro-tumourigenic32,38. The angiogenic regulator VEGFA for instance has been implicated in the 
tumourigenesis of many cancer types39. Upregulation of glycolytic enzymes and the glucose 
metabolism reprogramming from the oxygen dependent-oxidative phosphorylation to aerobic 
glycolysis (known as the Warburg effect) are essential to support the tumour cells rapid 
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proliferation40. Despite the inefficient ATP production, intermediates of this aerobic glycolysis 
are utilised for the biosynthesis of macromolecules such as lipid, amino acid and nucleotide that 
are required for cells growth and expansion40. Other well-studied HIFA downstream targets that 
involve in promoting tumourigenesis are cyclin D1 (CCND1)41 and C-X-C chemokine receptor 
type 4 (CXCR4)42. The CCND1 activates cyclin-dependent kinase 4/6 to promote cell cycle 
progression through the G1 phase and G1/S phase transition. The chemokine receptor CXCR4 is 
one of many factors that mediate the metastatic process.  
As discussed in the previous section, dimerization of either HIF1A or HIF2A with the 
constitutively expressed HIF1B activates the HIFA downstream targets. However, there are set 
of genes that are exclusively regulated by each of this HIFA subunit43. Several evidences have 
shown that HIF2A functions as an oncogene in ccRCC whereas the HIF1A may have the 
opposite growth suppressive function44-46. For instance, HIF2A regulates the expression of pro-
tumourigenic genes such as C-MYC46, VEGFA and CCND143 whereas HIF1A antagonises C-
MYC expression47 as well as positively regulating the expression of the pro-apoptotic BNIP343. 
The VHL-deficient ccRCC cell lines as well as the ccRCC clinical samples either co-expressed 
HIF1A and HIF2A or solely the HIF2A28,48. shRNA-mediated HIF2A knockdown suppresses 
ccRCC tumour growth in vivo49. The reintroduction of VHL-resistant exogenous HIF2A 
(mutated VHL-binding site) into the VHL-restored ccRCC cells was able to promote tumour 
growth in vivo49, whereby the re-expression of VHL-resistant exogenous HIF1A was not 
sufficient to promote tumourigenesis50. In fact, a recent study showed that wild-type HIF1A 
suppressed ccRCC growth45. Due to HIF2A pro-tumourigenic role in ccRCC, several small 
molecule inhibitors targeting HIF2A have been developed and tested in ccRCC patients which 
will be discussed in details in section 1.13. 
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1.7 ccRCC genetic heterogeneity and mutational landscapes  
Comprehensive ccRCC molecular analyses were performed via large scale, high-
throughput sequencing efforts with the aim to identify the relevance and critical drivers of 
ccRCC pathogenesis. A better understanding on the molecular mechanisms governing ccRCC 
growth and progression will facilitate the development of novel and efficient diagnostic and/or 
therapeutic strategies for ccRCC. Two independent studies conducted by The Cancer Genome 
Atlas Networks (TCGA) and Sato et al. identified VHL as the most frequently altered gene in 
their ccRCC patient cohort35,36. Mutations in tumour suppressor gene polybromo-1 (PBRM1) 
were the second most prevalent genetic alterations in ccRCC patients35,36,51. This gene encodes 
for BRG1-associated factor 180 (BAF180), a subunit of the SWI/SNF chromatin remodelling. 
Also, loss of PBRM1 was correlated with higher ccRCC tumour grade and poor prognosis52.  
Moreover, other frequently reported genetic alterations in ccRCC are mutations in SET 
domain containing 2(SETD2)53 and BRCA1 associated protein 1(BAP1)54. SETD2 and BAP1 
encode for histone methyltransferase and histone deubiquitinase, respectively, in which both of 
these genes are tumour suppressor that conform to the Knudson’s two-hit hypothesis. In addition, 
BAP1 mutations are observed in the high-grade ccRCC54. The high prevalence of mutations 
observed in the component of chromatin remodelling complex as well as in chromatin-modifying 
enzymes suggest that epigenetic deregulations along with VHL alterations are among the 
important drivers of ccRCC pathogenesis35,53. Interestingly, PBRM1, SETD2 and BAP1 genes are 
all located on the chromosome 3 short arm in the vicinity of the VHL locus, thus making the loss 
of heterozygosity of this region accounts for 90% of all ccRCC cases35. In addition, low 
percentage of genetic alterations (<10%) were also observed in the following genes; phosphatase 
and tensin homolog (PTEN), mechanistic target of rapamycin (mTOR) and p5335.  
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The ccRCC molecular characterisations discussed above were performed via high-
throughput sequencing analyses of bulk ccRCC samples. Hence, in order to examine the 
genomic landscape of ccRCC evolution, multi-regions high-throughput sequencing were carried 
out17,20,21,55,56. Remarkably, these analyses revealed high intratumour genetic heterogeneities in 
ccRCC. Furthermore, construction of predicted ccRCC driver mutations phylogenetic trees 
revealed that ccRCC evolution followed the branched evolutionary pattern instead of linear 
pattern. Due to these high intratumour heterogeneities, it would be more challenging to 
efficiently treat ccRCC patients especially when the therapeutic approaches are designed to 
target a specific driver mutation. Despite these “branching” intratumour heterogeneities, VHL 
inactivation and the chromosome 3p loss of heterozygosity are the truncal events that drive 
ccRCC pathogenesis17,21,56. Most of other predicted ccRCC driver mutations are subclonal. This 
seems to suggest that the opportunity for mutation-based therapeutic approaches in ccRCC are 
limited to dependencies resulting from VHL inactivation. 
1.8 mTOR signalling pathway overview 
The mTOR signalling pathway promotes cells growth and survival by regulating cellular 
metabolism processes as well as the biosynthesis of macromolecules which are the essential 
building blocks for the cells57,58. In addition to driving these processes, the autophagy-mediated 
organelles degradation and protein turnover have been demonstrated to be negatively regulated 
by the mTOR signalling pathway57,58. This signalling cascade can be activated by various intra- 
and extracellular signals such as growth factors, nutrients availability and cellular energy 
status59. Thus, in response to these environmental cues, the mTOR signalling pathway will 
coordinate and tightly regulate the cellular metabolism processes that are required by the cells to 
proliferate and/or survive in that particular environment.  
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Gene encodes for mTOR protein is located on chromosome 1. Function as a 
serine/threonine protein kinase, mTOR is comprised of several domains; the HEAT repeat, focal 
adhesion kinase targeting domain (FAT), FKB12-Rapamycin binding domain (FRB) and the 
catalytic kinase domain60. The simplified structure of mTOR protein is depicted in figure 6. 
mTOR forms complex with a defined set of proteins in order to regulate/phosphorylate its 
downstream targets. To date, there are two distinct mTOR protein complexes identified, the 
mTORC1 and mTORC261. The protein components that constitute these complexes are 
exemplified in figure 7. The mTORC1 complex is sensitive to rapamycin. In contrast, the 
mTORC2 complex is characterised to be insensitive towards acute rapamycin treatment62,63 
Binding of allosteric inhibitor rapamycin-FKB12 (FK506-binding proten12) complex at the 
mTOR FRB domain hinders the substrates recruitment to the mTORC1 complex as well as 
inhibiting the access to its catalytic kinase domain60.  
 
 
 
Figure 6: The structure of mTOR protein. Adopted from Laplante and Sabatini59 
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Figure 7: The mTORC1 and mTORC2 protein complex. Adopted from Zoncu et al61 
 
The mTOR protein is the core and catalytic subunit of these mTORC1 and mTORC2 
protein complex. Some components are shared between these complexes which are the 
mammalian lethal with SEC13 protein 8 (mLST8)64 and DEP domain-containing mTOR-
interacting protein (Deptor)65. There are also components that exclusive to either mTORC1 or 
mTORC2 complex. For example, the regulatory-associated protein of mTOR (Raptor) is part of 
the mTORC1 complex66 whereas the rapamycin-insensitive companion of target of rapamycin 
(Rictor) makes up the mTORC2 complex67. Out of these two complexes, the mechanisms of 
activation and roles of mTORC1 complex have been well-characterised. Nonetheless, there have 
been also plenty of discoveries made in understanding the role of mTORC2 complex. In brief, 
the mTORC1 complex functions as the central regulator of cellular metabolism processes which 
have been described previously. The mTORC2 complex has been identified to be involved in 
cytoskeleton remodelling62,67. Nonetheless, the processes regulated by these mTORC1/2 
complexes are important in order to promote cells growth as well as increasing the cells survival 
in response to the environmental cues. Whilst the mTORC1 signalling pathway can be activated 
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by the environmental cues outlined above, the mTORC2 complex is only responsive towards the 
growth factors activation58.  
1.9 mTORC1 complex upstream activators 
Different environmental cues employ distinct mechanisms in activating the mTORC1 
complex. Herein, the growth factors-mediated mTORC1 complex activation is discussed. 
Growth factors such as insulin/insulin-like growth factor 1 (IGF-1)68 and platelet-derived growth 
factor subunit B (PDGFB)69,70 binds to their respective receptor tyrosine kinase (RTK) and 
subsequently induces the RTK dimerization. This activates the RTK, followed by the 
phosphorylation of phosphoinositide 3-kinase (PI3K) which is the RTK downstream effector59. 
The function of PI3K is to integrate and transduce the environmental cues into intracellular 
signalling cascade. Mechanistically, PI3K catalyses the phosphorylation of phosphatidylinositol 
(4, 5)-biphosphate (PIP2) to phosphatidylinositol (3, 4, 5)-triphosphate (PIP3) in which PIP3 is a 
secondary messenger that relays the intracellular signal to the subsequent downstream effectors 
and finally activates the mTORC1 complex71. 
PIP3 modulates the PDK1-mediated phosphorylation and activation of AKT
71. This 
process is negatively regulated by PTEN which mediates dephosphoryplation of PIP3
72
. Upon 
activation, AKT will in turn phosphorylate the tuberous sclerosis complex (TSC), a GTPase 
activating protein (GAP). AKT-mediated phosphorylation of TSC will result in its 
inactivation68,73. Since TSC function is to convert the active GTP-RHEB (Ras homolog enriched 
in brain) to its inactive GDP-RHEB form, TSC phosphorylation will result in RHEB remains in 
its active form74. This will allow it to subsequently activate the mTORC1 complex which is its 
downstream effector. Thus, TSC serves as the negative regulator of the mTORC1 signalling 
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pathway. The mechanism of growth factor-mediated activation of mTORC1 signalling pathway 
is simplified in figure 8. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: The mechanism of growth factor-mediated activation of mTORC1 signalling pathway. 
Adopted from Yu et al75 
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1.10 The cellular functions of mTORC1 complex.  
 The mTORC1 complex modulates cellular metabolism processes by regulating the 
expression or activity of the upstream regulators of these processes, depending on the type of 
cues received from the environment58,59,76. For instance, growth factors stimulation or abundant 
nutrients availability promotes the protein and lipid biosynthesis whilst inhibiting the autophagy 
processes.  However, in the low cellular energy state marked by a low ATP to ADP ratio, AMP-
activated protein kinase (AMPK) will phosphorylate and activate the TSC complex, negative 
regulator of mTORC1 complex. Therefore, the energy-demanding anabolic processes such as the 
macromolecules biosynthesis will be negatively regulated in the low ATP condition77. The 
mTORC1 complex promotes protein biosynthesis by modulating the mRNA translation process 
and ribosome biogenesis via the phosphorylation of eukaryotic initiation factor 4E (eIF-4E)-
binding protein 1 (4E-BP1) and p70-ribosomal S6 kinase (p70 S6 kinase), respectively. 
Phosphorylated 4E-BP1 will not be able to bind to eIF-4E, thus enabling the eIF-4E to promote 
the 5’cap-dependent translation initiation78,79. The mTORC1-mediated phosphorylation of p70 
S6 kinase will subsequently activates multiple downstream effectors that involve in 5’cap-
dependent translation initiation and elongation, and ribosome biogenesis80.      
 The mTORC1 complex regulates the lipid biosynthesis by mediating SREBFs 
activation81-83, which is the key regulator of lipid homeostasis pathways. There are three SREBF 
isoforms, the SREBF-1a, SREBF-1c and SREBF2. Inactive form of SREBFs are retained in the 
endoplasmic reticulum membrane. The activation of mTORC1 signalling pathway by the 
corresponding cues will result in the translocation of this inactive SREBF into the Golgi 
apparatus where it will undergo proteolytic cleavage and maturation process84. The activated 
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SREBFs are then translocated into the nucleus where they will bind to the sterol-binding element 
of their target genes that participate in lipid biosynthesis and homeostasis pathways85.  
1.11 Hyper-activation of mTORC1 signalling pathway in ccRCC 
As a central regulator of various key biological processes, deregulations of the mTORC1 
signalling pathway have been implicated in diseases such as cancer, type II diabetes and 
obesity57,61. Aberrant activation by its upstream regulators or genetic alterations that perturb the 
function of this signalling pathway components can contribute to its deregulation, which are 
frequently observed in many cancer types86-88. For example, gene encoding for PI3K, PIK3CA, is 
commonly mutated in the breast cancer luminal A (45%) and luminal B subtype (29%) in the 
TCGA breast cancer cohort89. Furthermore, comprehensive molecular characterisation of 
endometrial cancer revealed that PIK3CA were among the most frequently mutated genes in this 
cancer types90. In addition, mutations in PTEN are also frequently observed in many cancer types 
91. The aberrant activation or deregulation of mTORC1 signalling pathway would thus lead to 
either disruption of cellular homeostasis or upregulation of those biological processes that could 
facilitate uncontrolled cells growth and expansion, thus driving the formation of cancer.  
The mTORC1 signalling pathways is frequently observed to be hyper-activated in ccRCC 
patients92,93. Pantuck et al. performed phosphorylated ribosomal S6 protein (P-S6) 
immunohistochemical staining on 375 ccRCC tissue microarray samples and found that 85% of 
the analysed ccRCC samples were positively stained for this phosphorylated protein92. 
Ribosomal S6 is the substrate of p70 S6 kinase that play a role in ribosomal biogenesis during 
protein biosynthesis. Activated mTORC1 complex phosphorylates the p70 S6 kinase which will 
in turn phosphorylate its substrate, the ribosomal S6 protein94,95. Thus, both phosphorylated p70 
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S6 kinase and phosphorylated S6 proteins are used as the read-out for mTORC1 activity. 
Moreover, the expression of P-S6 positively correlated with the tumour grades and was 
significantly higher in the patients with the metastatic disease92. Nevertheless, the mechanisms 
that drive mTORC1 pathway hyper-activation in ccRCC are yet to be fully elucidated. 
Like many other cancer types, hyper-activation of mTORC1 signalling pathway in 
ccRCC has been associated with genetic alterations in the components of this pathway. The large 
scale sequencing efforts on ccRCC samples conducted by TCGA networks and Sato et al. have 
identified that PIK3CA and PTEN were mutated in approximately 2%-5% of ccRCC cases35,36. 
This mutation fraction, however, was significantly lower when compared to the alterations 
observed in the endometrial cancer cases for instance90. Furthermore, mutations in the mTOR 
gene are found in approximately 6% of ccRCC cases in which the majority of these alterations 
are clustered within the FAT and catalytic kinase domains35,96. A small fraction of mutations is 
also identified in tuberous sclerosis 1 (TSC1) which encodes for the component of the tuberous 
sclerosis complex, the negative regulator of mTORC1 signalling pathway97.    
Collectively, genetic alterations along this signalling axis are thus likely to contribute to 
mTORC1 hyper-activation in ccRCC. However, only a small fraction of ccRCC patients actually 
harboured these mutations which seems to suggest the involvement of another molecular players 
in driving mTORC1 hyper-activation in this cancer type. In fact, a previous study has reported an 
increased in mTORC1 activity in metastatic renal cancer despite the absence of PTEN deletion98, 
indicating that upstream activating signals and/or regulators are still required in some cases. In 
line with this finding, Xu et al. has shown that in HeLa cells that harboured the mTOR-activating 
mutations, the mTORC1 activity in these cells remained dependent on the activation by its 
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upstream regulator RHEB96. Moreover, shRNA-mediated RHEB knockdown significantly 
reduced the mTORC1 activity of all mTOR-activating mutations tested96. 
1.12 Increased mTORC1 activity in ccRCC mouse model  
 There have been plenty of efforts to improve the currently available ccRCC mouse model 
in order to accurately mimic ccRCC pathogenesis in vivo99. Having a robust mouse model for 
ccRCC would give us a valuable experimental tool to better understand this disease and could 
also be used for testing the newly-developed therapies for ccRCC pre-clinically. The early 
approach employed to engineer ccRCC mouse model was based on knocking out the VHL gene 
alone. The rational of this strategy was VHL inactivation is the truncal event of the renal 
tumourigenesis and found in majority of ccRCC sporadic cases. Also, VHL germline mutation is 
observed in the VHL syndrome patients who are predisposed to hereditary ccRCC. Nonetheless, 
the germline homozygous VHL knockout in mice (VHL-/-) led to embryonic lethality, 
demonstrating that VHL functions are essential during embryogenesis100. To circumvent this 
issue, the Cre-lox-based conditional VHL knockout is employed. By using this approach, VHL 
inactivation can be controlled and carried out only in the tissue of interest at a specific time.  
Since ccRCC arises from the epithelium of the proximal tubules, VHL has been 
conditionally inactivated in this tissue as well as in other tissues of the renal tubule system. The 
VHL conditional knockout is achieved by using the renal tubule-specific promoter, such as 
phosphoenolpyruvate carboxykinase (PEPCK)101, cadherin 16 (CDH16)102 and paired box gene 
8 (PAX8)103, to drive the expression of CRE-recombinase and knockout VHL specifically in this 
tissue. Nonetheless, conditional VHL targeting alone was not sufficient to induce tumour 
formation, indicating the requirements of additional genetic/epigenetic alterations or oncogenic 
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drivers to promote tumour formation in this ccRCC mouse model. Hence, the strategy to 
engineer ccRCC mouse model was improvised by conditionally co-inactivating VHL with other 
tumour suppressor genes such as PBRM1 and BAP1. These are the two most recurrently mutated 
genes in ccRCC after VHL, identified in the recent ccRCC molecular characterisation studies35,36. 
Moreover, PBRM1 and BAP1 are located on the chromosome 3p arm in which this region loss of 
heterozygosity was also identified as the truncal event in renal tumourigenesis17. Based on these 
evidences, inactivating either of these genes along with VHL could possibly mimic ccRCC 
pathogenesis and drive the tumour formation in this mouse model.  
 Recent study by Gu et al. generated the VHL-/- ; Bap1-/- double knockout ccRCC mouse 
model using the PAX8-Cre system. Conditional inactivation of these genes in the renal tubules 
was able to initiate ccRCC formation, which recapitulated several important human ccRCC 
features such as the presence of the prominent clear cell cytoplasm and increased in the 
expression of HIFA downstream targets and mTORC1 activity104. In line with the observation in 
ccRCC clinical samples that BAP1 mutations were associated with aggressive phenotype and 
high tumour grade, tumours that arised in this VHL-/- ; BAP1-/- mouse model were found to be the 
high-grade subtype54,104. In parallel, the group also tested the effect of conditionally knocking out 
PBRM1 in combination with VHL using the PAX8-Cre system. The VHL-/- ; PBRM1-/- ccRCC 
mouse model was able to form tumours that exhibited the human ccRCC phenotypes. However, 
the developed tumours were low grade the which were in contrast to the higher grade tumours 
observed in the other VHL-/- ; BAP1-/- ccRCC mouse model104. Nonetheless, these phenotypes 
were in agreement with the prognosis status and tumour grades of the human BAP1-deficient and 
PBRM1-deficient ccRCC samples105.  
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 An independent parallel study conducted by Nargund et al. also developed the VHL-/- ; 
PBRM1-/- ccRCC mouse model. However, in contrast to the Gu et al., this group employed the 
KSP-Cre system instead of the PAX8-Cre system. Regardless, conditional double inactivation of 
VHL and PBRM1 using this KSP-Cre system also led to the tumour development in this mouse 
model. Histologically, the tumours had the distinct human ccRCC clear cell morphology and 
positively stained for carbonic anhydrase 9 (CAIX), a marker of HIFA activity, indicating 
upregulation of HIFA in these tumours106. mTORC1 hyper-activation was also observed in this 
KSP-driven VHL-/- ; PBRM1-/- ccRCC mouse model. The hyper-activation of this mTORC1-
signalling pathway was deemed to be third event that further drove the tumour progression after 
a long latency period106.  
 Increased in mTORC1 activity was consistently observed in the course of tumour 
development in these ccRCC mice models104,106. This observation recapitulated the mTORC1 
hyper-activation that is prevalent in ccRCC clinical samples92,93. Interestingly, the studies 
described above did not report any genetic alterations along the mTORC1 signalling pathway 
that might contribute to the increased in mTORC1 activity in their ccRCC mice models. This 
may suggest that the increased in mTORC1 activity in ccRCC could be the consequence of VHL 
and/or PBRM1 loss-of-function. Further investigations to elucidate the link between VHL and/or 
PBRM1 loss with mTORC1 hyper-activation are thus warranted whereby these mice models 
would be the perfect platform to address this question. Overall, the success in generating novel 
ccRCC mice models that closely mimic the human ccRCC pathogenesis will significantly 
transform the field of renal cancer research. In turn, better insights on renal tumourigenesis can 
be gained in which the ultimate goal is to translate this valuable knowledge clinically for the 
benefit of ccRCC patients.   
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1.13 ccRCC therapeutic strategies  
 Radical or partial nephrectomy is the standard treatment for the early stage or localized 
ccRCC cases which is also depending on the location and size of the effected tissues8,9. Radical 
nephrectomy is the removal of the whole kidney whereas in the partial nephrectomy, only the 
cancerous regions get surgically resected. Overall, the prognosis of patients with stage 1 and 
stage 2 disease, where tumour is only localized to the kidney, is good with five-year survival rate 
of more than 70%. Thus, ccRCC early detection followed by curative surgery could significantly 
improve the overall patients’ survival and also vital in order to prevent the tumour from 
spreading to the distant organs. Nonetheless, disease relapse at the secondary sites have often 
been seen in patients with localized disease who had undergone the curative surgery107.  
ccRCC is classified at the advanced stage (stage III and IV) when the tumours have 
already spread beyond the kidney to the nearby tissues or lymph nodes, or metastasise to the 
distant organs9. As discussed previously, patients with the advanced diseases have poor 
prognosis and are associated with high mortality. Unfortunately one-third of ccRCC patients 
have the metastatic disease in which the five-year survival rate of this stage is less than 10%. It is 
a great challenge to efficiently treat advanced stage ccRCC due to disease aggressiveness and its 
irresponsiveness towards conventional chemo- and radiotherapies. Nevertheless, substantial 
efforts have been put in to improve the current therapeutic strategies especially for the advanced 
stage ccRCC.  
About two decades ago, the cytokines-based immunotherapy was the only viable option 
to treat the metastatic ccRCC. These included administering ccRCC patients with interferon 
alpha (IFN-A) and high dose of interleukin 2 (IL-2). Despite this being the preferred therapeutic 
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strategy back then, the IFN-A and IL2-based therapies had poor overall patients’ response rates, 
which was less than 20%108-110. This treatment strategy was also associated with high toxicity 
and several adverse effects. The inefficiency of this cytokines-based immunotherapy had 
prompted researchers and clinical scientists to come up with novel and more effective strategies 
to treat ccRCC patients. Thus, two novel therapeutic strategies were developed to target the 
receptor tyrosine kinases and mTOR-signalling pathway. These novel treatment options were 
licensed to use in the clinic in mid 2000s to treat advanced stage ccRCC. 
Upregulation of pro-angiogenic factors such as VEGFA which is the downstream target 
of VHL-HIFA contributes to the ccRCC hyper-vascular nature24. Thus, inhibiting angiogenesis 
by targeting RTKs VEGFR and PDGFR was then one of the attractive therapeutic strategies to 
treat ccRCC patients. Sunitinib111, sorafenib112 and pazopanib113 were among the anti-angiogenic 
drugs developed to target the RTKs and clinically approved for treating ccRCC patients. 
Sunitinib is the first-line treatment for metastatic ccRCC and has shown better objective response 
rate and longer progression-free survival as compared to the IFN-A treatment111. In addition to 
targeting the RTKs, treatment option of bevacizumab, a monoclonal antibody against VEGFA, 
plus IFN-A has also been clinically approved as a first-line treatment for metastatic ccRCC114.   
Due to the high prevalence of mTORC1 hyper-activation in ccRCC, inhibitors targeting 
the mTOR have also been developed. These inhibitors such as temsirolimus115 and everolimus116 
have already been approved for use in the clinic for treating advanced ccRCC. Temsirolimus and 
everolimus are the rapamycin derivatives which is also known as rapalogs. Rapalogs forms a 
protein complex with FKB12 that binds to the mTOR FRB domain. The rapalog-FKB12 
complex is an allosteric inhibitor that prevent the substrates recruitment and phosphorylation by 
the mTOR catalytic kinase domain60. Both of these mTOR inhibitors have shown promising 
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effects in the clinic. Temsirolimus, for instance, is among the first-line treatments for metastatic 
ccRCC and has shown better efficacy in term of progression-free survival and overall response 
rates than IFN-a treatment115. However, one limitation with this therapeutic approach is that the 
rapalogs only target the mTORC1 complex. It has been demonstrated that the inhibition of 
mTORC1 complex could result in mTORC2-mediated negative feedback loop of AKT activation 
that would increase cells survival117. In order to address this, there is a second class of mTOR 
inhibitor currently being developed targeting both mTORC1 and mTORC2 complex. The 
mechanism of its inhibition is by competing with ATP for binding site in the mTOR catalytic 
kinase domain118,119.  
Despite the superior efficacy over their predecessors IFN-A and IL2, the overall patients’ 
response rates of these anti-angiogenic agents and mTOR inhibitors are yet to reach the 
satisfactory level120. Importantly, significant fractions of ccRCC patients develop intrinsic 
resistance towards these inhibitors121. In order to improve the treatment strategies for ccRCC 
patients, several clinical trials have been conducted to test the efficacy and safety of 
combinatorially treating ccRCC patients with both anti-angiogenic and mTOR inhibitors. 
Unfortunately, increased in drugs-related adverse effects with no added efficacy was observed in 
some of these trials122,123. However, a phase II randomised clinical trial testing a combined 
treatment of everolimus and lenvantinib on advanced ccRCC patients who have progressed after 
one previous anti-VEGFR treatment showed an improved median progression-free and overall 
survival compared to this drug single treatment124. This promising result indicates that the 
combinatorial targeting approach can still be potentially further developed as the treatment 
option for advanced stage ccRCC patients who have disease progression after the first-line 
treatments.  
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The immune checkpoint inhibitors have recently drawn a great interest to be developed as 
a novel therapeutic strategy for several type of cancers including the renal cancer125. One way 
cancer cells could evade the immune responses is by inhibiting the cytotoxic T-cell function. 
Cancer cells release a protein called program death ligand 1 (PD-L1) that binds to the 
programmed cell death protein (PD-1) on the surface of cytotoxic T-cells that will switch off the 
T-cells, thus preventing these immune cells from attacking the cancer cells126. Targeting either 
PD-1 or PD-L1 would keep the T-cells active and be able to recognise and kill the cancer cells. 
Nivolumab is a monoclonal antibody developed against PD-1 in ccRCC. Several phase III 
clinical trials are currently on going to assess the efficacy of treating advanced ccRCC patients 
with several immune checkpoint inhibitors including nivolumab in combination with the current 
clinically-approved drugs described above120. The primary end point of these clinical trials is to 
determine whether the patients who have received the combo treatment would have a 
significantly improved progression-free and overall survival. 
 Another strategy employed to treat ccRCC patients is by directly inhibiting the pro-
tumourigenic HIF2A. HIF2A is a relevant and attractive target due to VHL-HIF2A axis role as 
the hallmark gatekeeper of renal tumourigenesis. Also, due to ccRCC high intratumour 
heterogeneities, targeting this truncal event of renal tumourigenesis could potentially be a viable 
option and may provide a therapeutic advantage for ccRCC patients. Despite transcription factor 
is typically deemed to be difficult to drug, recent studies have succeeded in developing HIF2A 
small molecule inhibitors, namely the PT2399127 and PT2385128, which bind to a cavity within 
the HIF2a PAS-B domain129. This will consequently prevent HIF2A dimerization with the 
HIF1B to form the functionally active transcription factor. PT2399 has been demonstrated to 
confer anti-tumour activity in both pre-clinical ccRCC models and ccRCC patient-derived 
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xenografts127,130. However, variable degrees of sensitivity towards PT2399 were observed in both 
studies in which PT2399 sensitivity is correlated with HIF2A expression level. Prolong treatment 
resulted in the tumour developing resistance to this HIF2A inhibitor which has always been the 
recurrent problem in ccRCC treatments130. A phase I dose-escalation clincial trial with PT2385 
revealed the safety of the drug with mixed patients’ response131.      
1.14 Transcriptional deregulation in cancer 
 Eukaryotic gene expression programs are tightly controlled by gene regulatory elements 
that consist of promoters, enhancers and insulators132. Promoters are located in the proximity of 
the transcription start site and bound by RNA polymerase II, general transcription factors and co-
factors. These components, known as the basal transcription apparatus, initiate the transcription 
process. Recruitment of the basal transcription apparatus at the promoter region to promote the 
transcription initiation generally depends on the activities or cues from the nearby enhancer 
regions132. Enhancers are stretches of DNA sequences, located either upstream or downstream of 
the transcription start site, which are bound by transcription activators and co-activators that 
function to regulate the expression of a particular gene. The eukaryotic transcriptional processes 
are precisely controlled especially the cell-type-specific transcriptional programs, developmental 
and cell fate determination processes as well as transcriptional programs that response to the 
environmental cues such as hypoxic or stress conditions. In the regulation of cell-type-specific 
transcriptional programs for instance, multiple cell-type-specific TFs co-ordinately binds to these 
enhancer regions, recruit transcription co-factors such as mediator and p300/CBP, and 
subsequently perform a loop to interact with promoter region of the nearby genes133,134. This 
enhancer-promoter/genes looping interaction only occurs within the insulated neighbourhoods, 
which are bound by the CTCF proteins and the cohesin complex135.  
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 The transformation of normal cells into malignant, neoplastic cells is accompanied by the 
acquisition of several capabilities that enable the cells to undergo such transformation process. 
These phenotypic changes are essential in facilitating both tumour formation and its progression 
into the more advanced stages. Hanahan and Weinberg have described these acquired traits as 
the hallmarks of cancer that include; (1) infinite replicative potential, (2) capable of stimulating 
its own proliferation and angiogenesis, (3) irresponsiveness towards growth suppressor signals, 
(4) apoptosis and immune destruction evasiveness, (5) metabolic and energy production 
rewiring, and (6) capable of invading and colonising the distant sites136. The ability of normal 
cells to acquire the cancer-associated traits outlined above could be the consequence of 
transcriptional deregulations that occur within the cells. Aberrant transcriptional networks or 
gene expression programs would result in the cells overexpressing particular pro-tumourigenic 
and/or repressing genes with tumour suppressive function, in which both attributes if not the 
main, is among the important factors that drive tumourigenesis137.  
In general, dysregulated transcriptional regulators due to genetic alterations could 
contribute to the aberrant gene expression programs observed in many cancer types137. In fact, 
several frequently mutated oncogenes and tumour suppressor genes in human cancers are 
transcription factors such as MYC and TP53, respectively, which play vital roles in regulating 
cells growth. For instance, MYC activation is implicated in several cancer types, which is the 
result of amplification or chromosomal translocation138,139. TP53, on the other hand, is a tumour 
suppressor gene and somatic mutations in this gene commonly lead to loss-of-functions. Deemed 
as the guardian of the genome, TP53 have various physiological roles which some of them are 
anti-tumourigenic such as the regulation of cell cycle, DNA repair mechanisms and apoptosis140. 
Moreover, chromosome translocation can result in the formation of fusion transcription factors 
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that would have pro-tumourigenic properties or drive the high expression of this transcription 
factor if it is translocated into the active regulatory region of other genes141. For example, the 
translocation of EWS gene transactivation domain to the FLI1 transcription factor resulted in the 
formation of highly active, pro-tumourigenic chimeric EWS-FLI1 transcription factor that drives 
the tumour formation and progression in Ewing Sarcoma142. Also, translocation of MYC locus to 
the IgH enhancer locus drives the high expression of MYC in Burkitt’s lymphoma143.  
Also, transcription factors are the common terminal effectors of many oncogenic 
signalling pathways such as the PI3K-AKT, RTK-RAS, and WNT signalling pathways144. 
Aberrant activity of these signalling pathways agonists or activating mutations in the components 
of these signalling cascades have frequently been reported in human cancers such as the PIK3CA 
mutations in breast cancer, BRAF mutations in melanoma and KRAS mutations in the colorectal 
and lung cancer144. Since these oncogenic signalling pathways converged on the transcription 
factors, deregulation of these pathways would consequently lead to aberrant gene expression 
programs that confer for tumour growth advantage and promote its progression. In addition, 
dysregulated transcription factors activity could also be contributed by the loss-of-function of 
their upstream regulators. An example of this is the stabilisation and accumulation of HIF2A 
transcription factor and subsequent upregulation of the pro-tumourigenic gene expression 
programs upon VHL inactivation in ccRCC35,36. As a result, the cancer cells would develop 
“addiction” and high dependencies on these transcription factors that drive the gene expression 
programs, which favour the tumour growth and progression137. In addition, aberrant enhancer 
activities have also been demonstrated to play an important role in driving tumour formation and 
progression145. Mutations or the presence of single nucleotide polymorphisms within the 
enhancer sequences would generate a novel binding site for transcription factors that would in 
31 
 
turn drive the aberrant gene expression programs, in which some of these programs could be pro-
tumourigenic. Also, in the case of c-MYC described above, chromosome translocation would 
locate a pro-tumourigenic transcription factor (or other oncogenes) in the vicinity of active 
enhancers which may drive the high expression of these transcription factors and subsequently 
promote tumourigenesis137,145.  
Furthermore, epigenetic regulations such as DNA methylation and histone modifications 
have also been shown to play a critical role in controlling genes activation and expression in 
eukaryotic cells146. DNA hypo- and hyper-methylation at the CpG islands is associated with 
transcriptional activation and silencing, respectively. Abnormal DNA methylation have been 
implicated in several cancer types in which hypo-methylation of an oncogene regulatory region 
would activate and drive its expression whereas tumour suppressor genes hyper-methylation will 
lead to its silencing147. For example, VHL promoter region hyper-methylation been observed in 
ccRCC that result in VHL repression and subsequent HIF2A accumulation37. Moreover, 
dysregulated DNA methylation process is generally due to genetic alterations in the enzymes that 
involve in adding (DNA methyltransferases, DNMT) or removing (ten eleven translocation, 
TET) the methyl group at this CpG islands147.      
DNA is tightly packed and wrapped around core histone octamers called nucleosome. 
Nucleosomes are connected to each other via histone 1 tail (H1) and linker DNA and compacted 
together to form chromatin. Since chromatin is a highly compact structure, chromatin 
“opening/relaxing” so that the DNA regions are accessible by the transcriptional and replication 
machineries as well as “closing/condensing” largely depends on the chemical modifications of 
the core histone octamers residues146. The methylation and acetylation of the histone 3 (H3) 
residues are critical in the gene expression regulation. The acetylation of lysine 27 (H3K27ac) 
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and tri-methylation of lysine 4 (H3K4me1) marks for opened accessible chromatin and 
associated with active transcription148. Also, these chromatin modifications such as the H3K27ac 
for instance is widely used in the ChIP experiments as the surrogate marker for active enhancer 
regions149. On the other hand, methylation of lysine 27 (H3K27me) as well as lysine 9 
(H3K9me) marks for close inactive chromatin and transcription repression146. Epigenetic 
regulation of transcriptional activation/repression via precise histone modifications-mediated 
“opening” and “closing” of the chromatin structures, respectively, are vital to ensure normal 
transcriptional programs and biological processes are taken place. Nevertheless, genes encoding 
for the family members of the histone-modifying enzymes such as the histone acetyltransferases 
(HATs)/deacetylase (HDACs) and histone methyltransferases (HMTs)/demethylases (HDMs) 
are also targets for genetic alterations and in fact, mutations in these genes have been frequently 
observed in several cancer types147. For examples, mutations in SETD2, a H3 lysine 36-specific 
methyltransferases, and KDM5C, a lysine demethylase, were found in a fraction of ccRCC 
patients35,36. Overall, precise regulation of gene expression programs are vital whereby 
perturbations of these finely-tuned transcriptional networks have been demonstrated as one of the 
important factors that drive cancer formation and progression.  
1.15 Super enhancer and cancer 
 As previously described, enhancer is a DNA regulatory element that serves as the binding 
site for transcription factors and co-activators and plays a crucial role in activating the 
transcription process. Recent studies have shown that enhancers could form a large cluster of 
enhancers or commonly known as super enhancer149,150. Unlike typical enhancer, super enhancer 
could span across large DNA region and be bound by several master transcription factors and co-
activators such as the mediators and bromodomain-containing protein 4 (BRD4). Also, super 
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enhancers are enriched with H3K27ac signals, marker for active enhancer region149-152. Super 
enhancer was first identified in murine embryonic stem cells which function was to regulate the 
expression of master transcription factors that involve in maintaining the cells pluripotency153. It 
has then been demonstrated that super enhancer is an important regulator of cell identity, cell fate 
determination and also the lineage- or cell-type-specific gene expression programs149. Super 
enhancer drives the expression of cell-type-specific transcription factors or known as master 
transcription factors. They typically auto-regulate their own expression as well as regulating each 
other expression to form an interconnected auto-regulatory loop. These master transcription 
factors will co-ordinately bind and activate the expression of their downstream targets154. This 
precise and tight regulation of the expression of these master transcription factors as well as their 
downstream targets is vital in defining the “correct” cell identity and fate and also ensuring the 
activation of “necessary” gene expression programs in specific cells at a given time.   
  In addition to driving the expression of critical transcriptional regulators that define cells 
identity, super enhancer have also been implicated in regulating several cancer phenotypes155. In 
multiple myeloma (MM), high densities of mediator and BRD4 binding was found in the super 
enhancer regions that were associated with key genes that promote MM pathogenesis such as 
MYC, XBP1 and PRDM1 as well as other pro-tumourigenic genes such as CCND2 and BCL-
xL151. Mediator, BRD4 and H3K27ac ChIP-Seq was performed to identify super enhancer region 
in glioblastoma multiform (GBM) and small-cell lung cancer (SCLC)151. Super enhancer was 
found to associate with prominent genes in GBM biology such as RUNX1, BHLHE40 and BCL3. 
RUNX1 and BHLHE40 are important transcription factors that mediate the mesenchymal 
transformation of brain tumour. In SCLC, super enhancer was identified in the vicinity of INSM2 
and ID2, two important oncogenes that were highly expressed in this tumour type.  
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Super enhancer profiling in adult T-cell leukaemia (ATL) revealed the presence of super 
enhancer regions at the genes that involve in T-cell activation pathway and known oncogenes156. 
Interestingly, through this profiling study, a novel critical driver of ATL, TIAM2, was discovered 
to be associated with super enhancer and highly expressed in this tumour type. Knocking down 
the expression of this gene in ATL cell lines induced apoptosis whereas overexpression of 
TIAM2 promoted cells growth. Furthermore, super enhancer profiling in several squamous cell 
carcinomas identified the long non-coding RNA CCAT1 to be super enhancer-associated157. The 
expression CCAT1 was co-activated by the super enhancer-regulated master transcription factors, 
TP63 and SOX2. Knocking down either one of CCAT1, TP63 and SOX2 impaired cells growth 
in vitro and in vivo. Further analyses found that CCAT1 forms a complex with TP63 and SOX2 
to activate EGFR expression, which was also associated with super enhancer itself, to promote 
SCC pathogenesis via the activation of MEK/ERK1/2 and PI3K/AKT signalling pathways.   
 Cancer cells could acquire oncogenic super enhancer via several mechanisms. In a 
fraction of T-cell acute lymphoblastic leukaemia (T-ALL) patients, insertion of few nucleotides 
in the regulatory element upstream of oncogene TAL1 generated a de-novo binding site for 
transcription factor MYB158. MYB binding to this region recruited other transcription factors, 
RUNX1, GATA-3 as well as TAL1, which made up the core components of major leukaemogenic 
transcriptional complex. The binding of this core regulatory complex created the super enhancer 
landscape that are important in driving T-ALL pathogenesis. Key oncogenic drivers can acquire 
super enhancer via chromosomal rearrangement that results in the relocation of these oncogenes 
near the super enhancer of other gene, or vice-versa. For example, in adenoid cystic carcinoma, 
the translocation of the TGFB3 super enhancer locus to the proximity of MYB oncogene drove 
the high expression of MYB and subsequent activation of MYB-dependent oncogenic 
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transcriptional program159. In addition, focal amplification of the cis-regulatory element of 
several oncogenes such as MYC can also lead to the formation of super enhancer that drives the 
high expression of these oncogenes and promotes tumourigenesis160. Furthermore, generation of 
novel oncogenic fusion transcription factor could also establish a super enhancer landscape. For 
instance, in alveolar rhabdomyosarcoma, chimeric transcription factor PAX3-FOXO1 generated 
a de novo super enhancer landscape in collaboration with myogenic master transcription factors 
MYOG, MYOD and MYCN in driving this cancer type tumourigenesis161. Furthermore in Ewing 
sarcoma, super enhancer were found within the target genes of EWS-FLI1 chimeric transcription 
factor and several of these super enhancer-driven genes play important role in promoting the 
development and survival of Ewing sarcoma162-164.   
 Due to cancer cells high dependencies or addiction towards these super enhancer-driven 
genes, targeting the super enhancer has become an attractive therapeutic option for cancer. In 
fact, small molecule inhibitors have been developed to perturb the cancer associated-super 
enhancers that include the BRD4 inhibitor JQ1 and THZ1 which is the inhibitor of cyclin-
dependent kinase 7 (CDK7)151,165-170. BRD4 interacts with the Mediator to activate transcription 
process via regulating the RNA polymerase II-mediated transcriptional elongation. CDK7 is a 
component of general transcription factor IIH (TFIIH) that involves in the regulation of RNA 
polymerase II initiation pausing. Treating cancer cells with these small molecules inhibitors led 
to the downregulation of the super enhancer-driven genes prominently the key oncogenic driver 
MYC and also in some cases could affect the general super enhancer landscape155. These data 
demonstrated that cancer-associated super enhancers are sensitive to perturbation, thus making 
them an appealing therapeutic target for cancer.    
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 1.16 Problem statement and objectives 
 Within these past decades, plenty of significant progresses have been made in 
understanding ccRCC pathogenesis. The gained knowledge have been translated into the 
development of diagnostic and therapeutic strategies for ccRCC. This includes the development 
of therapeutic agents targeting angiogenesis and mTOR signalling pathways which are 
frequently upregulated in ccRCC patients. Despite these agents are being widely used in the 
clinic, the overall patients’ objective response rates are yet to reach the satisfactory level and the 
patients often develop resistance towards the administered therapies. Thus, there is a pressing 
need for efficient ccRCC diagnostic and/or therapeutic strategies especially for the advanced 
stage ccRCC patients due to their poor prognosis with the five-year survival rate is less than 
10%. The fact that a significant fraction of ccRCC patients have already exhibited the metastatic 
disease at the time of diagnosis further exacerbating and posing a major challenge to treat this 
disease.  
 One factor that contributes to the lack of efficient therapies developed for ccRCC is the 
incomplete understanding on the underlying mechanisms that support ccRCC progression. 
Tumourigenesis is a complex evolutionary process facilitated by series of genetic and epigenetic 
alterations that confer for selective growth advantage and acquisition of cancer-associated 
traits136,171. Cancer cells have to regularly rewire themselves and are sometimes highly dependent 
on certain genes or pathways in order to maintain the cancer phenotypes as well as adapting to 
various cellular stresses172. In ccRCC, aberrant upregulation of hypoxia-responsive gene 
expression program due to VHL inactivation if not the main is among important drivers of 
ccRCC pathogenesis19. In addition to this, we hypothesised the involvement of other 
transcriptional networks in which ccRCC cells are highly addicted to in order to support its 
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growth and survival.  Hence, the general objective of this present study was to identify novel 
transcriptional dependencies in ccRCC and to interrogate how they support ccRCC 
progression. A better insight into ccRCC transcriptional dependencies could be a promising 
avenue for the development of efficient diagnostic and/or therapeutic strategies for ccRCC. 
 As discussed in the previous section, recent reports have demonstrated that critical 
transcriptional regulators that drive tumourigenesis in many cancer types are regulated by super 
enhancers. Therefore, to identify important ccRCC transcriptional regulators, previous works in 
the lab conducted by Paulo Rodrigues have performed H3K27ac ChIP-Seq in several ccRCC 
cells line to profile the super enhancer regions in ccRCC and look for super enhancer-associated 
transcription factors. The ChIP-Seq data were analysed by Sakari Vanharanta in which Kruppel-
like factor 6 (KLF6) was found to be in the proximity of one of the strongest super enhancer in 
ccRCC, thus could signify its biological relevance in supporting ccRCC pathogenesis. The 
background of this transcription factor KLF6 will be briefly discussed in the Chapter 3 (section 
3.1).  
 Stemming from the previous finding, the specific objective of my PhD project was 
therefore to interrogate the roles of KLF6 and its regulated transcriptional program in 
supporting ccRCC growth. In order to attain this objective, this present study was structured to 
consist of three main aims in which several research questions would be specifically addressed 
under each aims.   
Aim 1: Assessing KLF6 functional relevance in supporting ccRCC growth 
KLF6 was found to be in the proximity of one of the strongest super enhancer in ccRCC. 
It has been widely demonstrated that super enhancer drives the expression of genes that are 
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important in regulating cancer phenotypes in many cancer types150,151. Therefore, the first aim of 
this study was to functionally test whether KLF6 has any biological relevance in supporting 
ccRCC growth. By utilizing the CRISPR-Cas9 and CRISPRi tools to target KLF6 in several 
VHL-deficient ccRCC cell lines, I subsequently investigated specific questions below which 
were important to achieve the main objective of this aim 1:   
a) Does targeting KLF6 affects ccRCC cells proliferation in-vitro? 
b) Would the reintroduction of exogenous KLF6 into the KLF6-targeted ccRCC cells 
rescue the cells growth defect?  
c) Does targeting KLF6 impairs ccRCC cells growth and tumour forming capability in-
vivo?  
d) What is the effect of targeting KLF6 on the ccRCC cells capability to metastasize and 
colonize the lung?    
Aim 2: Investigating the super enhancer role in regulating KLF6 expression  
 Regular enhancer as well as super enhancer can drive the expression of their downstream 
targets that are located thousands of base pairs away. Therefore, one of the questions that would 
be addressed in this aim 2 was (a) whether this large super enhancer spanning the KLF6 
locus actually drives KLF6 expression in ccRCC. In addition, I would also examine (b) 
whether this super enhancer region is sensitive to the perturbation in the activity of its 
constituent enhancers. This is because several studies have demonstrated that cancer-associated 
super enhancers could be sensitive to the perturbation of its constituent enhancers or regulatory 
components that maintain the super enhancer landscape165,169. Both CRISPRi-mediated enhancer 
inactivation and CRISPR-Cas9-mediated super enhancer deletion would be utilized in order to 
address these two important questions.  
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Moreover, multiple transcription factors and co-activators can bind to the large super 
enhancer region and co-regulate the expression of their downstream targets. Therefore, in this 
aim 2, I would also try to identify the KLF6 upstream regulator which I specifically interested in 
investigating (c) whether the transcription factor HIF2A binds to the super enhancer region 
and drives KLF6 expression in ccRCC. 
Aim 3: Dissecting the mechanisms through which KLF6 supports ccRCC growth 
 The KLF6 biological relevance and its upstream regulator were investigated in aim 1 and 
2, respectively. Next, in this aim 3, I tried to elucidate the transcriptional program regulated by 
KLF6 and understand how KLF6 perturbation led to impaired ccRCC cells growth and fitness. 
The following are questions that I would specifically interrogate which would in turn contribute 
to attaining the main objective of this aim 3:  
a) What are the differentially expressed genes between the KLF6-targeted and control 
ccRCC cells? 
b) Are there any significantly deregulated pathways in the KLF6-targeted ccRCC cells?  
c) Does directly perturbing this pathway (identified in b) reduces ccRCC cells growth and 
fitness?  
d) How does KLF6 involve in regulating this deregulated pathway and subsequently 
supports ccRCC cells growth and fitness?   
 
Collectively, the findings and observations obtained from these three main aims would be 
utilised to propose a model of KLF6-mediated transcriptional dependency that supports ccRCC 
cells growth and fitness.     
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2.1 Cell lines, plasmids and reagents 
The human ccRCC cell lines; 786-O, 786-M1A, OS-RC2, OS-LM1 and RCC-MF, were 
obtained from J. Massagué (Memorial Sloan Kettering Cancer Center, NY). The 786-M1A and 
OS-LM1 are the metastatic derivative of 786-O and OS-RC2 cells, respectively, which were 
established and described previously173. The UOK101 cell line was obtained from Marston 
Linehan (National Cancer Institute, MD). The A549 lung cancer cell line was obtained from C. 
Martins (MRC Cancer Unit). The identity of all cell lines used in this study was confirmed by 
STR analysis. Additionally, the identity of ccRCC cell lines were also validated via Sanger 
sequencing-based detection of known VHL mutations that are unique to each of these cell lines. 
MycoAlertTM Mycoplasma Detection Kit (Lonza LT07-318) was used for mycoplasma 
screening. All ccRCC cell lines and the A549 cell line were cultured in RPMI-1640 medium 
(R8758 Sigma) supplemented with 10% FBS, penicillin (100U mL -1) and streptomycin (g mL 
-1). HEK293T cells were used for lentivirus production and cultured in DMEM (Invitrogen), 
supplemented with 10% FBS, penicillin (100U mL -1) and streptomycin (g mL -1).     
The doxycycline-inducible Cas9 plasmid, pCW-Cas9, was a gift from Eric Lander and 
David Sabatini (Addgene plasmid #50661)174. The constitutive Cas9 plasmid, lentiCas9-Blast, 
was a gift from Feng Zhang (Addgene plasmid #52962)175. The constitutive dCas9 plasmid, 
pHR-SFFV-KRAB-dCas9-P2A-mCherry, was a gift from Jonathan Weissman (Addgene plasmid 
#60954)176. The sgRNA expression vector, pKLV-U6-gRNA(BbsI)-PGKpuro2ABFP, was a gift 
from Kosuke Yusa (Addgene plasmid #50946)177. This vector was modified to generate the 
following variants: 1) pKLV-U6-gRNA(BbsI)-PGKhygro2ABFP, 2) pKLV-U6-gRNA(BbsI)-
PGKhygro2AmCherry 3) pKLV-U6-gRNA(BbsI)-PGKhygro2AeGFP. The strategy to generate 
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these mCherry and eGFP variants are described in details in section 2.8 and 2.9 below. The 
pLVX-Puro (Clontech #632164) and pLVX-Hygro (modified by Paulo Rodrigues) were used to 
express the exogenous cDNA constructs. For lentivirus production, the packaging plasmids 
psPAX2 (Addgene plasmid #12260) and pMD2.G (Addgene plasmid #122259) were gifts from 
Didier Trono. The shRNA expression vector, sGEP and LT3-GEPIR, were gifts from Johannes 
Zuber. All sgRNA and shRNA constructs, and primers used in this study were purchased from 
Sigma-Aldrich and these sequences are listed in Table 1 - 3 of this chapter. 
Simvastatin (S6196), fatostatin (F8932), propylene glycol (W294004) and Tween-80 
(P1754) were purchased from Sigma-Aldrich. Everolimus was purchased from APExBIO 
(A8169). The recombinant human PDGF-BB was purchased from Peprotech (#100-14B). D-
Luciferin was purchased from Syd Labs (MB000102-R70170).  
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Table 1. sgRNAs and shRNAs sequence  
  Construct Sequence (5'-3') 
sgNTC GAGTGTCGTCGTTGCTCCTA 
sgKLF6_4 TCGCCAGGGAAGGTGCGCAG 
sgKLF6_5 CCCACTTGAAAGCACACCAG 
Control (Tandem) 
ATCGAAGACAACACCGGAGTGTCGTCGTTGCTCCTAGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGGGATACGGTGCGTCAATCTAGTT
TTACAGTCTTCTCG 
iKLF6_2 
ATCGAAGACAACACCGGCTCGCAGAGACGCCCGGCGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGGGCGAGGCGCGCGGTGGGAGC
GTTTTACAGTCTTCTCG 
iKLF6_3 
ATCGAAGACAACACCGGCTCGCAGAGACGCCCGGCGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGGGTTACGTTTGCAGTCAGTCGTT
TTACAGTCTTCTCG 
iPDGFB_1 CCTCCCCCGCTGCCTCCCTA 
iPDGFB_2 GGAGCCCTAGGGAGGCAGCG 
iSREBF1/2     
combo 1 
ATCGAAGACAACACCGCAGGACACGAACGCGCGGAGGTTTTAGAGCG
CAGGTGTCGCCACCTGCGAAACACCGCGGGCGCAACGCAAACATGGG
TTTTACAGTCTTCTCG 
iSREBF1/2   
combo 2 
ATCGAAGACAACACCGGTGTCCTGCCCTGGCCTCAGGTTTTAGAGCG
CAGGTGTCGCCACCTGCGAAACACCGCGCAACGCAAACATGGCGGCG
TTTTACAGTCTTCTCG 
iSE_1 
ATCGAAGACAACACCGAGAATCGCTGAAGAAACGCGGTTTTAGAGCG
CAGGTGTCGCCACCTGCGAAACACCGTACTGCACTGAAGACTCGGAG
TTTTACAGTCTTCTCG 
iSE_2 
ATCGAAGACAACACCGACCAGCACAATTTGTCACCGGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGTTGAAAAAAAACCTATCACAGTT
TTACAGTCTTCTCG 
iSE_3 
ATCGAAGACAACACCGATGTGGCTCTGAATCACCATGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGAACGGTGAGTTCCCGGTACAGT
TTTACAGTCTTCTCG 
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iSE_4 
ATCGAAGACAACACCGAGTTGGAAAGTTGCATGCTGGTTTTAGAGCG
CAGGTGTCGCCACCTGCGAAACACCGTTACACCAACAGATAAATATGT
TTTACAGTCTTCTCG 
iSE_5 
ATCGAAGACAACACCGATAAAGCCTGTTATTACCAAGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGTTAGCTAATGCTGAACAGAGGTT
TTACAGTCTTCTCG 
 
Del SE_2 
 
ATCGAAGACAACACCGTAGAATGTATTAGTCTTGTGGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGTGGGGTCTTAGGTACCCGAAGT
TTTACAGTCTTCTCG 
Del SE_3 
 
ATCGAAGACAACACCGTGGATCCATGATTGATGCATGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGACAGCTAGTTAGTGACACGAGT
TTTACAGTCTTCTCG 
iHIF2a  
binding site_1 
 
ATCGAAGACAACACCGTCACTCATCTCAGAGAAATGGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGTCTGTGTTGCTAAATCCCGAGTT
TTACAGTCTTCTCG 
 
iHIF2a  
binding site_2 
 
ATCGAAGACAACACCGACTGGATACGTGGAGTTATGGTTTTAGAGCGC
AGGTGTCGCCACCTGCGAAACACCGATTTCAAAACCACATTTCACGTT
TTACAGTCTTCTCG 
 
shREN 713 
TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTATAGTGAA
GCCACAGATGTATAGATAAGCATTATAAT 
TCCTATGCCTACTGCCTCGGA  
shEPAS1_4 
TGCTGTTGACAGTGAGCGACCAGGTGAAAGTCTACAACAATAGTGAA
GCCACAGATGTATTGTTGTAGACTTTCACCTGGCTGCCTACTGCCTCG
GA 
shEPAS1_9 
TGCTGTTGACAGTGAGCGCCCAGCAGATGGACAACTTGTATAGTGAA
GCCACAGATGTATACAAGTTGTCCATCTGCTGGTTGCCTACTGCCTCG
GA 
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Table 2. PCR and ChIP-qPCR primers sequence  
  Construct Sequence (5'-3') 
KLF6 cDNA PCR F ATGGACGTGCTCCCCATGTG 
KLF6 cDNA PCR R ACATGAAGAGGCACCTCTGA 
Flag KLF6 cDNA PCR F 
ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATA
TTGATTACAAAGACGATGACGATAAGGGCTCCGGAGACGTGCT
CCCCATGTGCAG  
Flag eGFP cDNA PCR F 
ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATA
TTGATTACAAAGACGATGACGATAAGGGCTCCGGAGTGAGCAA
GGGCGAGGAGCT 
Flag eGFP cDNA PCR R TTACTTGTACAGCTCGTCCA 
Tandem oligo PCR F TAGACATCGAAGACAACACCG 
Tandem oligo PCR R GCGACGAGAAGACTGTAAAAC 
shRNA PCR F TGAACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG 
shRNA PCR R TCTCGAATTCTAGCCCCTTGAAGTCCGAGGCAGTAGGC 
PGKhygro-2A PCR F ATCGGGATCCAATTCTACCGGGTAGGGGAG 
2A-PCR R TGGGCCAGGATTCTCCTCCACG 
2A-mCherry PCR F 
GTGACGTGGAGGAGAATCCTGGCCCAATGGTGAGCAAGGGCG
AGGAGG 
2A-mCherry PCR R ATCGCGGCCGCTTACTTGTACAGCTCGTCCA 
2A-eGFP PCR F GTGACGTGGAGGAGAATCCTGGCCCAATGGTGAGCAAGGGCG
AGGAGC 
2A-eGFP PCR R CCTAGCGGCCGCTTACTTGTACAGCTCGTCCATGCC 
SE del. PCR screening F CTAGTGGACGAAGGGTTGGA 
SE del. PCR screening R AACAACCGGAATCTCCACTG 
EPAS1 locus PCR F GGATTTTCAGACTGTTGAAT 
EPAS1 locus PCR R CCTACAGAAGAACAGACATG 
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Flag KLF6 ChIP qPCR 
(PDGFB) F 
ATTCCGGGTAGACTTGCCAA 
Flag KLF6 ChIP qPCR 
(PDGFB) R 
GCACGGGAGATGGGGTATAA 
Flag KLF6 ChIP qPCR 
(PDGFB) R 
GCACGGGAGATGGGGTATAA 
ChIP qPCR iSE-1 F GAAGTTGAGTCCCGGTGAAA  
ChIP qPCR iSE-1 R ATACCCGTCCTGGGAAAATC 
ChIP qPCR iSE-2 F TCTGTAGCTGCTGAGGCTGA 
ChIP qPCR iSE-2 R CACGGTGACAAATTGTGCTG  
ChIP qPCR iSE-3 F CAGGGAGTGGAAGCTGATGT  
ChIP qPCR iSE-3 R CACGCTTGCTGATTTCAAAG 
ChIP qPCR iSE-4 F CACAGATTTAAGGTGGCTGTCA  
ChIP qPCR iSE-4 R CAAAAGCCAAAATGATGGA 
ChIP qPCR iSE-5 F GCGCTTTTCCAATCAGAGTC 
ChIP qPCR iSE-5 R CTGAAACCTCCTCTTCAAACAA  
ChIP-qPCR Ctrl 1 F TGCGTATTAATGCTTTTCATTCC 
ChIP-qPCR Ctrl 1 R TCAATTAGTAAAGAATGATGCTTGAAA 
ChIP-qPCR Ctrl 2 F CTGCTGTTTGGGGAGCTTAC 
ChIP-qPCR Ctrl 2  CTGCCTCCTGAATGATGACA 
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Table 3. Sequencing primers  
  Construct Sequence (5'-3') 
sgKLF6_4 targeted region F P5-Read1 sequencing template-TTGCGTGCCCGGGGAGCT 
sgKLF6_4 targeted region R 
P7-Index-Index sequencing template-
CAAGTGGGAGCTTTTGGTGT 
sgKLF6_5 targeted region F P5-Read1 sequencing template-GGAAAGTTTACACCAAAAGCT 
sgKLF6_5 targeted region R 
P7-Index-Index sequencing template-
CTTTGGTGGAAAACATCTGA 
M13 F (TOPO cloning) GTAAAACGACGGCCAGT 
M13 R (TOPO cloning) CAGGAAACAGCTATGAC 
U6 Promoter F                
(single sgRNA cloning) 
GAGGGCCTATTTCCCATGATTCC 
Tandem pKLV F (tandem 
sgRNA cloning) 
AGTACCGGGCCCTACG 
Tandem pKLV R (tandem 
sgRNA cloning) 
GGAAAAGCGCCTCCCCT 
miR-Seq 5 F (shRNA cloning) TGTTTGAATGAGGCTTCAGTAC 
pCEP F (CDNA cloning) AGAGCTCGTTTAGTGAACCG 
786-M1A VHL validation F CTCCCAGGTCATCTTCTGCAA 
786-M1A VHL validation R AGTTCCCCGTCTGCAAAATG 
OS-LM1 VHL validation F AGTACGGCCCTGAAGAAGAC 
OS-LM1 VHL validation R CGTCGAAGTTGAGCCATACG 
RCC-MF VHL validation F AGTACGGCCCTGAAGAAGAC 
RCC-MF VHL validation R AGTTCCCCGTCTGCAAAATG 
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2.2 Genomic DNA and plasmid extraction  
Genomic DNA was extracted by using the QIAamp DNA mini kit (Qiagen #51304) 
according to the manufacturer’s protocol. For the midi and miniprep plasmids extraction, the 
PureYieldTM Plasmid Midiprep System (Promega A2492) and Quick Clean II Plasmid miniprep 
kit (GenScript L00420) were used, respectively, by following the manufacturer’s 
recommendations. The yield and purity of the extracted materials were determined by using 
NanoDropTM 1000 Spectrophotometer (Thermo).  
2.3 Sanger sequencing  
The Mix2Seq Kit (Eurofins Genomics) was used for Sanger sequencing. The samples 
were prepared according to the manufacturers recommendations.  
2.4 Production of chemically competent E.coli 
The NEB5α competent E.coli (NEB C2987H) was cultured in LB broth overnight. On the 
following day, the bacteria culture was diluted 1:100 in fresh LB broth and grown until the 
optical density (600nM) reached between 0.6-0.65. The optical density was measured using the 
Eppendorf Biophotometer plus. The bacteria culture was incubated on ice for 30 minutes, 
followed by spinning down at 3500 rpm for 10 minutes at 4°C. The bacteria pellets were gently 
resuspended in 50mM ice-cold CaCl2 and incubated on ice for another 15 minutes. The bacteria 
suspension was spun down at 3500 rpm at 4°C for 15 minutes. The bacteria pellets were gently 
resuspended in 17mL 50mM ice-cold CaCl2 and 3mL 100% glycerol was added into the solution. 
The chemically competent bacteria were aliquoted and stored in the -80°C freezer.  
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2.5 Bacteria transformation  
The to-be-transformed plasmids were added onto the chemically competent E.coli and 
mixed by gentle flicking. The bacteria-plasmid mix was incubated on ice for 30 minutes, 
followed by heat-shocking at 42°C for 1 minute and incubation on ice for another 5 minutes. 
After adding the SOC recovery media, the bacteria culture was incubated on shaking incubator at 
37°C for an hour. The transformed bacteria were then plated on LB + ampicillin plate and 
incubated at 37°C overnight.   
2.6 Lentiviral production and transduction  
The plasmid of interest (1.5µg) was mixed with the lentiviral packaging plasmids, 
psPAX2 (1.3µg) and pMD2.G (0.5µg), in the Opti-MEMTM I Reduced-Serum Medium (Gibco 
LS31985062). The FuGENE 6 transfection reagent (Promega E269A) was also diluted in the 
Opti-MEMTM I Reduced-Serum Medium and added dropwise onto the plasmids mixture, 
followed by incubation at the room temperature for 30 minutes. The FuGENE 6-plasmids 
mixture was gently added onto the HEK293T cells (seeded onto the 6-wells plate a day prior to 
the transfection). The media containing lentivirus were collected 72-hours post-transfection. 
Briefly, the media containing the lentivirus were spun down at 1000 RPM for 5 minutes to pellet 
any cells or cellular debris. The supernatant was transferred into a syringe and filtered through a 
0.45μM PVDF sterile filter (Elkay Laboratory E25-PV45-50S). The lentivirus containing 
supernatant was either directly used for cells transduction or stored in the -80°C freezer. 
Cells were seeded onto the 6-wells plate at a density of 250000–300000 cells/well 24 
hours before the transduction. The lentivirus supernatant was added onto the cells in the presence 
of 8µg/mL Polybrene (Merck Millipore TR-1003). After overnight incubation, media containing 
50 
 
the lentivirus supernatant was removed, followed by washing the transduced cells with 1x PBS 
twice. Fresh media was added onto the cells. The positively transduced cells were either 
antibiotic selected or sorted by using FACS. The antibiotic selection was started 48-hours post-
transduction whereas the cells sorting was performed by the Flow Cytometry Core Facility, 
Cambridge Institute for Medical Research (CIMR) at least a week post-transduction.  
2.7 Generation of stable Cas9 and dCas9-expressing ccRCC cell lines 
To generate stable Cas9-expressing ccRCC cell lines, the cells were transduced with 
lentivirus carrying either the lentiCas9-Blast or pCW-Cas9 plasmid. The lentiCas9-Blast and 
pCW-Cas9 plasmid encode for constitutive and doxycycline-inducible human codon-optimized 
S. pyogenes Cas9 protein, respectively. The lentiCas9-Blast- and pCW-Cas9-transduced cells 
were selected with 30μg/mL blasticidin (Invivogen ant-bl) and 4μg/mL puromycin (Invivogen 
ant-pr), respectively. Cells were transduced with the pHR-SFFV-KRAB-dCas9-P2A-mCherry 
plasmid to generate stable dCas9-KRAB-expressing cells (CRISPRi cells). The positively 
transduced cells were sorted based on the expression of mCherry fluorescent protein.  
2.8 Construction of the pKLV-U6-gRNA(BbsI)-PGKhygro2AmCherry 
The pKLV-U6-gRNA(BbsI)-PGKhygro2AmCherry sgRNA expression vector was 
constructed by first generating the PGKhygro2AmCherry fragment. The BamHI-PGKhygro2A 
fragment (hereinafter referred to as 5’ fragment) was amplified from the pKLV-U6-
gRNA(BbsI)-PGKhygro2ABFP plasmid. The mCherry-Not1 fragment (hereinafter referred to as 
3’ fragment) was amplified from the pHR-SFFV-KRAB-dCas9-P2A-mCherry plasmid and 
complementary 2A overhang sequences were incorporated into the 5’ end of this mCherry-Not1 
fragment. The PCR amplification was performed using the 2x AccuzymeTM Mix (Bioline Bio-
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25028) according to the manufacturer’s protocols. Gradient temperature PCR was performed to 
determine the optimum annealing temperature to amplify each of these 5’ and 3’ fragments. 
These amplified fragments were purified using the Quick Clean II Gel Extraction Kit (GenScript 
L00418) and fused together via two rounds of PCR amplification.  
Briefly, the first round of PCR was performed without adding the primers. These 5’ and 
3’ fragments annealed to each other at the complementary 2A sequences that resulted in self-
amplification. The self-amplified, fused product was then amplified using the forward and 
reverse primers used to initially amplify the 5’ fragment and 3’ fragment, respectively. The fused 
PGKHygro2AmCherry fragment was double-digested with 10 unit/µg BamHI (NEB R0136) and 
10 unit/µg Not1 (NEB R0189) according to manufacturer’s recommendations and ligated into 
the BamHI and Not1-double digested pKLV-U6-gRNA(BbsI)-PGKhygro2ABFP plasmid. The 
ligation was performed at room temperature for at least 30 minutes using the T4 ligase (Thermo 
EL0011) at a ratio of insert to vector 5:1 (https://nebiocalculator.neb.com), followed by bacteria 
transformation. The strategy to construct the pKLV-U6-gRNA(BbsI)-PGKhygro2AmCherry 
plasmid is illustrated in figure 9.       
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Figure 9: Strategy to construct pKLV-U6-gRNA(BbsI)-PGKhygro2AmCherry sgRNA 
expression vector. 
 
2.9 Construction of the pKLV-U6-gRNA(BbsI)-PGKhygro2AeGFP 
Similar strategy to construct the pKLV-U6-gRNA(BbsI)-PGKhygro2AmCherry was 
employed to generate the pKLV-U6-gRNA(BbsI)-PGKhygro2AeGFP sgRNA expression vector. 
The only modification was the 2AeGFP-Not1 fragment (3’ fragment) was amplified from the 
LT3-GEPIR plasmid.  
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2.10 Cloning single sgRNA construct into the sgRNA expression vector  
The pKLV-U6-gRNA(BbsI)-PGKhygro2ABFP was digested with 10 unit/µg Bbs1 (NEB 
R0539), followed by treatment with 5 unit/µg Antarctic Phosphatase (NEB M0289)  according to 
the manufacturer’s protocol. The sgRNA construct sense and anti-sense strands were purchased 
separately from Sigma-Aldrich. BbsI restriction site overhang was incorporated into the 5’ end of 
these sense and anti-sense strands as exemplified in figure 10. Both strands were annealed 
together and phosphorylated by using T4 Polynucleotide Kinase (NEB M0201) and T4 ligation 
buffer (Thermo EL0011). The reaction was incubated at 37°C for 30 minutes, followed by heat-
inactivation at 95°C for 5 minutes. The annealed sgRNA construct was diluted 1/200 in 
DNAse/RNAse-free water and ligated into the sgRNA expression vector. The ligation was 
performed using the T4 ligase as described previously, followed by transformation into the 
chemically competent E.coli. The presence of the ligated sgRNA construct was confirmed and 
sequence-verified via Sanger sequencing. Cells that were transduced with this sgRNA expression 
vector were either selected with 90µg/mL hygromycin (Invivogen ant-hg) or sorted based on the 
expression of BFP fluorescent protein.  
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Figure 10: Strategy to clone single sgRNA construct into the pKLV-U6-gRNA(BbsI)-
PGKhygro2ABFP. 
 
Different strategy was employed for cloning the single sgRNA construct into the pKLV-
U6-gRNA(BbsI)-PGKhygro2mCherry due to the presence of additional BbsI restriction site 
within the mCherry fluorescent DNA sequence. To overcome this, the sgRNA construct was first 
cloned into the BFP sgRNA expression vector as described previously. This was followed by 
double digesting the sgRNA construct-ligated BFP sgRNA expression vector with 10 unit/µg 
XhoI (NEB R0146) and BamHI to release the U6 promoter-sgRNA construct-sgRNA scaffold 
fragment. The released fragment was gel purified and sub-cloned into the AnP treated, XhoI and 
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BamHI double-digested the pKLV-U6-gRNA(BbsI)-PGKhygro2mCherry. The strategy 
employed to clone single sgRNA construct into the mCherry sgRNA expression vector is 
simplified in figure 11. Cells that were transduced with this mCherry sgRNA expression vector 
were either selected with 90µg/mL hygromycin (Invivogen ant-hg) or sorted based on the 
expression of mCherry fluorescent protein.   
 
Figure 11: Strategy to clone single sgRNA construct into the pKLV-U6-gRNA(BbsI)-
PGKhygro2AmCherry. 
 
2.11 Cloning tandem sgRNAs construct into the sgRNA expression vector  
The tandem sgRNAs construct was designed to express two independent sgRNAs. AarI 
restriction site was incorporated between these sgRNAs sequences with Bbs1 restriction sites 
flanking the constructs. The Bbs1 restriction sites were utilised to clone the tandem sgRNAs 
construct into the sgRNA expression vector. The AaRI restriction site was used to clone an 
additional sgRNA scaffold-U6 promoter fragment into the tandem sgRNAs construct-ligated 
sgRNA expression vector.  
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In brief, the tandem sgRNAs construct was first amplified using the AccuPrimeTM PFX 
supermix (Thermo #12344040) according to the manufacturer’s protocol. The PCR primers and 
conditions used to amplify this tandem sgRNAs construct are listed in table 2 of this chapter and 
supplementary table 1 in the appendices, respectively. The amplified tandem sgRNAs construct 
was gel purified and digested with BbsI restriction enzyme. This was followed by ligation into 
the AnP treated, BbsI-digested sgRNA expression vector and transformation into the chemically 
competent E.coli. The presence of the ligated tandem sgRNAs construct was confirmed and 
sequence-verified via Sanger sequencing. The sequence-verified plasmid was subsequently 
digested with 1 unit/µg AarI restriction enzyme (Thermo ER1581) according to the 
manufacturer’s recommendations and AnP-treated.  
The to-be-cloned additional sgRNA scaffold-U6 promoter fragment was previously 
cloned into the pBigT plasmid. This plasmid was digested with AarI restriction enzyme to 
release the sgRNA scaffold-U6 promoter fragment. This released fragment was gel purified and 
subsequently cloned into the AnP treated, AarI-digested plasmid described above. The ligated 
plasmid was transformed into the chemically competent E.coli and the presence of the ligated 
sgRNA scaffold-U6 promoter fragment was confirmed via Sanger sequencing. Figure 12 shows 
schematic of the tandem sgRNAs construct and strategy to clone this construct into the sgRNA 
expression vector.  
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Figure 12: Strategy to clone tandem sgRNAs construct into the sgRNA expression vector. (Top) 
Schematic of the tandem sgRNAs construct. (Bottom) Diagram simplifying the cloning strategy. 
 
2.12 Cloning shRNA construct into the shRNA expression vector  
 The shRNA constructs were chosen based on the predictions made by Fellmann et al. 
and cloned into the sGEP shRNA expressing vector. Briefly, the shRNA constructs were 
designed to carry the XhoI and EcoRI restriction sites at the 5’and 3’end of these constructs, 
respectively. The shRNA constructs were amplified, gel purified and double-digested with 10 
unit/µg Xho1 and EcoRI (NEB R0146). The PCR primers and conditions used to amplify the 
shRNA constructs are listed in the table 2 of this chapter and supplementary table 2 in the 
appendices, respectively. The digested shRNA constructs were then cloned into the AnP-treated, 
Xho1 and EcoRI-digested sGEP expression vector. The ligated plasmids were transformed into 
the chemically competent E.coli. The presence of the ligated shRNA construct was confirmed 
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and sequence-verified via Sanger sequencing. The shRNA construct cloning strategy into the 
sGEP expression vector is illustrated in figure 13. 
 
Figure 13: Strategy to clone shRNA construct into the sGEP shRNA expression vector. 
 
2.13 Expressing exogenous KLF6   
Either pLVX-Puro of pLVX-Hygro expression vector was used to express the exogenous 
KLF6. The KLF6 coding sequence (CDS) was amplified from cDNA synthesized from the 786-
M1A cells. The EcoRI restriction site was incorporated before the start codon whereas BamHI 
restriction site was incorporated after the stop codon, in which these restriction sites were utilised 
for cloning the KLF6 CDS into the expression vector multiple cloning site. The PCR primers and 
conditions used to amplify KLF6 CDS are listed in table 2 of this chapter and supplementary 
table 3 in the appendices, respectively. The amplified KLF6 CDS was sequence-verified via 
Sanger sequencing, followed by double digestion with EcoRI and BamHI restriction enzymes 
and ligation into the AnP treated, EcoRI and BamHI-digested expression vector. The ligated 
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plasmids were transformed into the chemically competent E.coli. The presence of the ligated 
transgene was confirmed and sequence-verified via Sanger sequencing.   
Prior to reintroducing exogenous KLF6 into the CRISPR-Cas9 sgKLF6_4 786-M1A 
cells, the region targeted by this sgRNA in the exogenous KLF6 CDS was modified using the 
site-directed mutagenesis approach. Briefly, this was performed by amplifying the KLF6 CDS-
ligated expression vector (described above) using primers that bound to the sgKLF6_4 target 
region. These primers harboured the to-be-introduced synonymous mutations. The amplified 
plasmids were subsequently treated with DpnI restriction enzyme (NEB R0176) which would 
only digest the methylated parental plasmid, not the site-directed mutagenised plasmids. After 
the DpnI treatment, the plasmids were transformed into the chemically competent E.coli. Several 
colonies were picked for plasmid extraction, followed by sending these plasmids for Sanger 
sequencing to validate the presence of the reintroduced synonymous mutations.  
For the Flag ChIP experiment, the 5’ end of KLF6 and eGFP CDS was tagged with Flag. 
To generate the Flag-KLF6, 3x Flag sequences were incorporated into the 5’ end of the 
previously used KLF6 CDS forward primer. The constructed pLVX-Puro_KLF6 CDS plasmid 
was used as the template to amplify the Flag-KLF6 CDS in which the cloning was performed as 
described above. The pKLV-U6-gRNA(BbsI)-PGKhygro2AeGFP was used as the template to 
amplify the Flag-eGFP. The forward primer was designed to contain the 3x Flag sequences and 
EcoRI restriction site whereas BamHI restriction site was incorporated into the reverse primer. 
Similar cloning strategy as described above was employed to construct the pLVX-Puro_Flag-
eGFP. Both engineered plasmids were sequence-verified via Sanger sequencing before using 
them in the subsequent ChIP experiments. The primers and PCR conditions used to construct 
these plasmids are listed in table 2 of this chapter and supplementary table 4-5 in the appendices, 
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respectively. Figure 14 shows the cloning strategies to generate the pLVX-Puro_KLF6 CDS and 
pLVX-Puro_Flag-KLF6 CDS plasmids.  
 
Figure 14: Strategy to clone exogenous KLF6 CDS into the expression vector. (Top) pLVX-
Puro-KLF6 CDS and (Bottom) pLVX-Puro_Flag-KLF6 CDS. 
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2.14 TOPO-TA cloning  
Genomic DNA was extracted from the sgKLF6_4-transduced 786-M1A cells. Region 
targeted by the sgKLF6_4 was amplified using the AccuzymeTM Mix (Bioline) according to the 
manufacturer’s recommendations, followed by gel purification. The 3’A overhang was 
incorporated into the gel purified amplicons using the BIOTAQTM DNA polymerase (Bioline 
BIO-21040). The product was cloned into the PCR 4-TOPO vector (Thermo #450071) according 
to the manufacturer’s protocol and subsequently transformed into the chemically competent 
E.coli. The recipes and PCR conditions used for incorporating the 3’ overhang and cloning into 
the TOPO vector are listed in supplementary table 6 in the appendices. Several individual 
colonies were picked for plasmids extraction and sent for Sanger sequencing.  
2.15 RNA extraction and cDNA synthesis  
Total RNA was extracted from the cells using the RNAzol®RT (Sigma-Aldrich R4533) 
by following the manufacturer’s protocols. The concentration and purity of the extracted RNA 
were determined by using the NanoDropTM 1000 Spectrophotometer (Thermo). 1µg of total 
RNA were converted into cDNA using the High-Capacity cDNA Reverse Transcription Kit 
(Thermo #4368814) according to the manufacturer’s protocol.  
2.16 Quantitative real-time PCR (qPCR) 
The gene expression analyses were performed using the 2x Taqman Fast Advanced 
master mix (Thermo #4444557) and 20x pre-designed Taqman gene expression probes (Thermo) 
on the StepOnePlusTM Real Time PCR instrument (Thermo). The default settings for running the 
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Taqman qPCR were used. The TaqMan probes used in this study are listed in table 4 of this 
chapter.  
Table 4. TaqMan probes  
  Probe Assay ID 
KLF6 Hs00810569_m1 
EPAS1 Hs01026149_m1 
PDGFB Hs00966522_m1 
CXCR4 Hs00607978_s1 
CCND1 Hs00765663_m1 
VEGFA Hs00900055_m1 
BHLHE40 Hs01041212_m1 
SREBF1 Hs01088679_g1 
SREBF2 Hs01081784_m1 
SCD Hs01682761_m1 
LSS Hs01552331_m1 
TBP Hs00427620_m1 
 
The gene of interest Ct value were normalised to the Ct value of the housekeeping gene, 
TBP. The gene expression fold change was calculated using the 2-∆∆Ct method as described 
previously178. 
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2.17 RNA-Seq library preparation and analyses 
Total RNA was extracted from the cells in four replicates using the RNeasy Mini Kit 
(Qiagen #74104) according to the manufacturer’s protocols. The quality and concentration of the 
extracted RNA were determined using the Agilent RNA Nano 6000 kit (Agilent #5067-1511) on 
the Agilent Bioanalyzer 2100 instrument. The RNA-Seq libraries were prepared using the 
SENSE mRNA-Seq Library Prep Kit V2 (Lexogen) by following the manufacturer’s 
recommendations with 1μg of total RNA was used as the starting material. The size and quality 
of the final library products were determined using the Agilent High Sensitivity DNA Kit 
(Agilent #5067-4626) on the Agilent Bioanalyzer 2100 instrument. The library concentration 
was determined using the KAPA Library Quantification Kit (KR0405) according to 
manufacturer’s recommendations. The prepped RNA-Seq library from each sample was pooled 
in equimolar concentrations and sent for Illumina high-throughput sequencing. The RNA-Seq 
data were analysed by Sakari Vanharanta. Gene set enrichment analysis and pathway analysis 
were performed by Dora Bihary and Shamith Samarajiwa using the analysed RNA-Seq data. 
2.18 Protein extraction and quantification 
Cells were either trypsinized or scraped on ice, followed by washing the pelleted cells 
with 1x ice-cold PBS once. The cells were lysed on ice for 30 minutes in RIPA buffer (Sigma-
Aldrich R0278) containing 1:100 protease inhibitor cocktail (Sigma-Aldrich) and 1:100 
phosphatase inhibitor cocktail (Sigma-Aldrich). The lysate was vortexed vigorously for 15 
seconds and spun down at 4°C for 20 minutes at 14000 RPM. The protein lysates were 
quantified using the Pierce BCA Protein Assay Kit (Thermo #23225) according to 
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manufacturer’s protocol whereby the absorbance (562nm) was measured by using the Tecan 
infinite M200 pro plate reader. 
2.19 Western blotting 
The protein samples were mixed with 4x TruPAGE LDS sample buffer (Sigma-Aldrich 
PCG3009) and 1:20 B-mercaptoethanol (Sigma M6250), followed by boiling at 95°C for 5 
minutes. The protein samples were separated either using 8% or 10% home-made SDS-PAGE 
gels. The Precision Plus ProteinTM KaleidoscopeTM Pre-Stained Protein Standards (BioRad 
#1610375) was used as the molecular weight marker. The separated proteins were transferred 
onto Immobilon PVDF transfer membrane (Millipore) for 2 hours. The membrane was blocked 
at room temperature for 1 hour with either 5% non-fat dry milk in 0.1% PBS-Tween or 5% BSA 
in 0.1% TBS-Tween. The membrane was incubated with the blocking buffer-diluted primary 
antibody at 4°C overnight. The primary antibodies and respective dilution used in this study are 
listed in table 5. 
On the following day, the membrane was washed three times with either 0.1% PBS-
Tween or 0.1% TBS-Tween (5 minutes/wash), followed by incubation with secondary antibody 
at room temperature for an hour. The secondary antibodies and respective dilution used in this 
study are listed in table 5.  The secondary antibodies used were polyclonal goat anti-mouse 
IgG/HRP (Dako, P0447 1:10000) and polyclonal goat anti-rabbit IgG/HRP conjugated (Dako, 
P0448 1:5000). After washing the membranes three times (5 minutes/wash), the Luminata 
Classico Western HRP substrate (Millipore WBLUC0500) was added onto the membrane, 
followed by incubation at room temperature for 5 minutes. The membrane was exposed onto the 
WB X-ray film (SLS MOL7016) and developed using the film processor machine.  The recipes 
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to prepare the SDS-PAGE gels and buffers for running the Western blotting are listed in 
supplementary table 7-12 in the appendices. 
Table 5. Primary and secondary antibodies 
  Antibodies Catalog number and dilution  
KLF6 Santa Cruz Biotech, sc-7158, 1:1000 
HIF2A Novus Biologicals, NB100-122, 1:1000 
VHL BD Biosciences, #564183, 1:1000 
P-p70 S6-kinase Cell Signaling Technology, #9205, 1:1000 
p70-S6-kinase Cell Signaling Technology, #9292, 1:1000 
P-S6 ribosomal Cell Signaling Technology, #4857, 1:3000 
S6 ribosomal Cell Signaling Technology, #2317, 1:1000 
SREBP1 Santa Cruz Biotech, sc-13551, 1:100 
SREBP2 Santa Cruz Biotech, sc-13552, 1:100 
FLAG Sigma-Aldrich, F1804, 1:500 
B-actin Sigma-Aldrich, A1978, 1:20000 
Polyclonal goat anti-mouse IgG/HRP Dako, P0447 1:10000 
polyclonal goat anti-rabbit IgG/HRP Dako, P0448 1:5000 
 
  2.20 Chromatin Immunoprecipitation (ChIP) 
The trypsinized cells were pelleted and crosslinked with 1% formaldehyde diluted in 1x 
PBS. The crosslinking reaction was performed by incubating the 1% formaldehyde-resuspended 
cells at the room temperature for 10 minutes. The reaction was quenched with 0.125M glycine, 
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followed by incubation at the room temperature for 5 minutes. The crosslinked cells were 
pelleted and washed with 1x PBS twice. After the final wash, the cells were pelleted and then 
either stored at -80oC or directly used for chromatin immunoprecipitation (ChIP) experiment.  
For ChIP, the protein A/G magnetic beads (Thermo #26162) were first equilibrated by 
washing the beads with 0.5% BSA in 1x PBS three times. After the final wash, the beads were 
resuspended with 0.5% BSA in 1x PBS. Antibody was subsequently added and conjugated onto 
the resuspended beads by rotating the tube on a rotating shaker at 4oC for at least 4 hours. The 
antibodies used in the ChIP experiment are listed in table 6 of this chapter: The crosslinked cells 
were resuspended and dounced in lysis buffer (20 mM Tris-HCl pH8.0, 150 mM NaCl, 2mM 
EDTA pH 8.0, 0.1% SDS and 1% Triton X-100), followed by sonication using the Bioruptor 
(Diagenode) for 14 cycles, 30” on / 30” off. The lysates were spun down at 4oC for 20 minutes at 
14000 rpm and the supernatants were collected. The antibody-conjugated beads were washed 
with 0.5% BSA in 1x PBS three times and after the final wash, the beads were resuspended in 
0.5% BSA in 1x PBS. The collected supernatants were added into the antibody-conjugated beads 
and incubated overnight at 4oC on the rotating shaker.  
On the following day, the beads were washed three times with low salt buffer (50 mM 
HEPES pH 7.5, 140 mM NaCl, 1% Triton) and once with high salt buffer (50 mM HEPES pH 
7.5, 500 mM NaCl, 1% Triton). DNA that bound to the antibody-conjugated beads was eluted 
with the elution buffer (50 mM NaHCO3, 1% SDS). De-crosslinking was performed by 
incubating the eluted DNA at 65oC, 1000 rpm for 3 hours. The de-crosslinked DNA was purified 
using the QuickClean II PCR Extraction Kit (Genescript L00419) according to the 
manufacturer’s recommendations and eluted with DNAse/RNAse free water.  
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Table 6. Antibodies used for ChIP experiment 
  Antibodies Catalog number and dilution  
H3K27ac Abcam ab4729 
FLAG Sigma-Aldrich F1804 
Rabbit polyclonal IgG Abcam ab27478 
 
2.21 ChIP-qPCR 
The ChIP-qPCR was performed by adding the purified ChIP DNA into the reaction mix 
that consisted of 2x PowerUp SYBR Green Master Mix (Thermo A25742), 10µM forward and 
10µM reverse primers to amplify the region of interest. The ChIP-qPCR was run on the 
StepOnePlusTM Real Time PCR instrument (Thermo) using the default setting for running SYBR 
green qPCR.  
2.22 ChIP-Seq library preparation 
 The ChIP-Seq library was prepared by Paulo Rodrigues. In brief, the libraries were 
prepared from the purified ChIP DNA using the KAPA Hyper Prep Kit (KR0961) according to 
the manufacturer’s recommendations. The sequencing libraries were ligated with adapter, 
followed by size selection using the Agencourt AmPure XP beads (Beckman Coulter A63880) to 
obtain fragments with the size of 150-350 base pairs. The size-selected fragments were amplified 
using the KAPA HiFi HotStart ReadyMix PCR Kit (KR0370). The amplified libraries were 
pooled in equimolar concentration and sent for Illumina high-throughput sequencing. The ChIP-
Seq data were analysed by Sakari Vanharanta.  
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2.23 In vitro competitive proliferation assay 
For the CRISPR-Cas9 competitive proliferation assay, the Cas9-expressing ccRCC cell 
lines were transduced with either non-targeting control (sgNTC) or sgRNAs targeting the gene of 
interest constructs. The sgNTC and sgRNA constructs were initially cloned into the BFP and 
mCherry variant of the sgRNA expression vector, respectively, or vice versa for the fluorescent-
swapped experiment. The control and targeted cells were mixed at a 1:1 ratio and plated onto 6-
wells plate. The assay was performed for at least 2 weeks or up to 1 month. The percentage of 
each cell population was analysed at the plating day (T=0) and at multiple time points throughout 
the assays by flow cytometry on the LSR Fortessa (BD Biosciences). The following gating 
approaches were used: FSC-A / SSC-A, and FSC-H / SSC-A to select for live and single cells, 
respectively, and then mCherry (561nm/610nm) / BFP (383nm/445nm) channels for 
discriminating these two cells populations. Similar strategy was employed for the CRISPRi 
competitive proliferation assay with slight modification; the BFP+ / mCherry+ sgRNA-expressing 
CRISPRi cells were mixed with the mCherry+ / BFP- parental CRISPRi cells at a 1:1 ratio. Both 
CRISPR-Cas9 and CRISPRi competitive proliferation assay strategies are discussed in details in 
Chapter 3. 
2.24 Drug treatment proliferation assay  
The drug treatment proliferation assay was performed using the IncuCyte® Zoom System 
(Essen Bioscience). The cells were seeded onto 24-wells plate at a density of 8000 cells / well 
and transferred into the Incucyte. After overnight incubation, the media was removed and fresh 
media containing either drug or vehicle was added onto the cells. For the fatostatin treatment 
proliferation assay, the drug was dissolved in DMSO to make a 20mM stock solution, followed 
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by further diluting this stock solution with DMSO to make 10mM, 1mM and 0.5mM working 
solutions. These working solutions were diluted 1:1000 in media to achieve the final 
concentration of 10µM, 1µM and 0.5µM, respectively, and subsequently added onto the cells.  
For the simvastatin treatment proliferation assay, the drug was dissolved and activated 
according to the manufacturer’s protocol. The stock concentration of the activated simvastatin 
was 10mM. This activated simvastatin was diluted in media to achieve the following final 
concentrations; 10µM, 1µM and 0.5µM, and added onto the cells. For the everolimus treatment 
proliferation assay, the drug was dissolved in DMSO to make a 10mM stock solution, followed 
by further diluting this stock solution with DMSO to make 10µM and 1µM working solutions. 
These working solutions were diluted 1:1000 in media to achieve the final concentration of 
10nM and 1nM, respectively, and subsequently added onto the cells  
2.25 Animal studies 
All animal experiments were performed in accordance with protocols approved by the 
Home Office (UK) and the University of Cambridge Animal Welfare and Ethical Review Body 
(PPL 70/7990). For subcutaneous tumour growth assay, cells were pelleted and resuspended in 
PBS/Matrigel Matrix (BD) mix at a 1:1 ratio. 1 x 105 cells in 100µL solution were injected into 
each flank of 5-8 weeks old athymic male nude mice (Charles River Laboratories). The cells 
proliferation rate and tumour growth were assessed by IVIS bioluminescence imaging (Perkin 
Elmer) and calliper measurement, respectively. For the bioluminescence imaging, 100µL 
luciferin was injected intraperitoneally into the mice and the imaging was performed 10 minutes 
post-injection. The cells used in this assay expressed firefly luciferase that catalysed the 
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oxidation of luciferin to oxyluciferin in the reaction that produced bioluminescence as the by-
product.   
The calliper measurement was performed after the subcutaneous tumours became 
palpable. Tumour volume (V) was calculated using the equation V= (length x width2) x 0.5. At 
the end of the assay, the mice were euthanized and the subcutaneous tumours were extracted and 
weighed. For the lung colonisation assay, cells were pelleted and resuspended in 1x sterile PBS. 
3 x 105 cells in 100µL solution were inoculated into the lateral tail vein of 5-8 weeks old 
NOD/SCID mice (Charles River Laboratories) and bioluminescence imaging was performed as 
described above. At the end of the experiment, lungs were extracted from the euthanized mice 
and processed for immunohistochemistry. 
For the in vivo everolimus treatment experiment, everolimus was dissolved in 30% 
propylene glycol and 5% Tween-80 in sterile water. Cells were pelleted and resuspended in 
PBS/Matrigel Matrix (BD) mix at a 1:1 ratio. 5 x 105 cells in 100µL solution were 
subcutaneously injected into each flank of 5-8 weeks old athymic male nude mice (Charles River 
Laboratories). After the tumours became palpable, the mice were separated into two groups with 
equal average tumour size and treated orally with either everolimus (5mg/kg/daily) or vehicle for 
3 weeks. The tumour growth was monitored by calliper measurement.  
2.26 Histology and immunohistochemistry  
The extracted lungs were fixed in 10% formalin in PBS overnight. On the following day, 
the formalin-fixed samples were washed with 1x PBS twice and stored in 70% ethanol. The 
formalin-fixed samples were sent to the Cambridge University Hospital Human Research Tissue 
Bank for paraffin-embedding and sectioning. Human vimentin (Cell Signaling Technology, 
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#5741 1:100) staining was performed on the Bond-Max instrument (Leica) using Bond Polymer 
Refine Detection reagents (Leica) according to the manufacturer’s protocol (IHC Protocol F).  
2.27 Total cholesterol quantification 
Lipids were extracted from the cells using the chloroform-free lipid extraction kit 
(Abcam ab211044) according to the manufacturer’s recommendation. In brief, cells were 
pelleted and washed with 1x PBS once. The cells were resuspended in 1 x PBS, followed by 
adding the lipid extraction buffer onto the cells. The cell suspension was vortexed vigorously for 
1 minute and agitated on see-saw rocker at room temperature for 20 minutes. The cells were 
spun down at 10 000 RPM for 5 minutes. The supernatant was collected and dried overnight at 
37oC. On the following day, the lipid extract was resuspended in suspension buffer and sonicated 
for 20 minutes followed by agitation 37oC for 20 minutes. The total cholesterol was quantified 
using the Amplex Red Cholesterol Assay Kit (Invitrogen A12216) according to the 
manufacturer’s protocol. The quantified total cholesterol was normalised to the total protein 
amount of each samples.   
2.28 Statistical analysis 
Statistical analyses were performed either in R or GraphPad Prism (Version 5). P-values 
lower than 0.05 were considered statistically significant. For competitive proliferation assays, in 
vitro drug treatment proliferation assays and in-vivo subcutaneous tumour formation assays, two-
way ANOVA with Tukey’s range test was used. On the other hand, one-way ANOVA with 
Tukey’s range test was used for in-vivo photon flux analysis, in-vivo tumour weight and lung 
colonization assays, in-vivo everolimus treatment subcutaneous tumour formation assay and in-
vivo total cholesterol quantification assay. For qPCR, three independent experiments are shown 
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unless stated otherwise in the figure legend, each of the experiment is the average of three 
technical replicates. The qPCR statistical significance was determined by using either one-way 
ANOVA with Dunnett’s test or two-tailed unpaired Student’s t-test depending on the assays. 
Boxplots represent median, 25th and 75th percentiles, the whiskers extend to data extremes.  
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Chapter 3 
 
Investigating the functional relevance of 
KLF6 on ccRCC growth  
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3.1 Introduction  
Acetylation of histone H3 at the lysine 27 residue (H3K27ac) is associated with active 
gene regulatory elements. Within some genomic loci, multiple enhancers cluster together to form 
a large enhancer domain, also known as super enhancers, with enriched H3K27ac signals. Super 
enhancers have been widely reported to support the expression of critical transcriptional 
regulators in various biological contexts such as the cell-type-specific gene expression 
programmes. In addition, several lines of evidence have demonstrated that super enhancers play 
an important role in regulating cancer phenotypes which this has been discussed in Chapter 1 
(section 1.16).   
As highlighted in Chapter 1 (section 1.17), H3K27ac ChIP-Seq was previously 
performed on several VHL-deficient ccRCC cell lines by Paulo Rodrigues in order to profile the 
enhancers/super enhancers regions in ccRCC cell lines. The aforementioned work had also 
utilised these H3K27ac ChIP-Seq data to identify transcription factors that were associated or 
located in the vicinity of super enhancer region. It was postulated that these transcription factors 
could potentially have important roles in supporting ccRCC pathogenesis based on the growing 
evidences demonstrating the link between super enhancers and regulation of many critical genes 
that include transcription factors. 
The H3K27ac ChIP-Seq data were analysed by Sakari Vanharanta in which the identified 
enhancers were ranked based on their H3K27ac signals. Kruppel-like factor 6 (KLF6), a zinc 
finger DNA-binding transcription factor, was found to be in the vicinity of one of the strongest 
super enhancers in ccRCC cells (Figure 15A). Figure 15B shows the H3K27ac ChIP-Seq track of 
the ccRCC cells KLF6 locus where there was large cluster of active enhancers with high 
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H3K27ac signals in the proximity of this KLF6 locus. To confirm this observation, previous 
works by Paulo Rodrigues had also performed H3K27ac ChIP-Seq on several human ccRCC 
clinical samples as well as ccRCC xenograft samples. There was also a large cluster of active 
enhancers observed nearby the KLF6 locus in these analysed samples (Figure 15B). 
 
Figure 15: Super enhancer profiling in ccRCC. (A) KLF6 is associated with one of the strongest 
super enhancer in ccRCC. (B) H3K27ac ChIP-Seq signal at the large enhancer cluster in the 
proximity of the KLF6 locus in ccRCC cell lines, ccRCC clinical samples and tumour 
xenografts.  
 
Super enhancers-regulated genes are typically highly expressed and in some cases, the 
expression of these genes can be cell-type-specific. Analysis of the large TCGA RNA-Seq data 
by Sakari Vanharanta revealed high and specific expression of KLF6 in ccRCC compared to 
other tumour types in the large TCGA cohort (Figure 16A). This observation was in line with the 
possibility that KLF6 expression in ccRCC could be super enhancer driven. Furthermore, the 
expression of KLF6 was significantly upregulated in ccRCC samples as compared to the normal 
B A 
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kidney tissues (Figure 16B). This observation seemed to suggest that KLF6 might be pro-
tumourigenic and involved in supporting ccRCC pathogenesis.   
 
 
 
 
 
 
Figure 16: KLF6 is highly expressed in ccRCC clinical samples. (A) KLF6 expression, RSEM 
normalised count, in ccRCC and other tumour types from the TCGA cohort. Mann-Whitney U 
test. (B) KLF6 expression, RSEM normalised count, in ccRCC and normal kidney tissues in the 
TCGA cohort. Mann-Whitney U test.     
 
In brief, KLF6 belongs to the Kruppel-like factors family and to date, there are seventeen 
members of this family discovered. KLFs are the mammalian orthologs of Drosophila 
melanogaster gene, Kruppel, in which mutations in this gene disrupt the fly segmentation pattern 
at the early stage of embryogenesis179. As a zinc finger DNA binding protein, KLFs can either 
function as transcriptional activator or repressor and members of human KLF family have been 
shown to play important roles in various biological processes and also in disease pathogenesis179. 
KLF6 is located on chromosome 10p15 and contains 4 exons. The KLF6 protein consists of 3 
domains; activation domain, serine threonine domain and the DNA binding domain (Figure 
A B 
77 
 
17A). The C-terminal DNA binding domain is composed of three repeats of cysteine2-histidine2 
(cys2-his2) zinc finger and this domain is highly conserved among the 17 members of the KLF 
family180. In addition, there had been reports on the presence of three KLF6 transcript isoforms 
namely KLF6-SV1, KLF6-SV2 and KLF6-SV3. The presence of these isoforms was due to the 
alternative splicing that resulted from germline mutations in the KLF6 exon 2 (Figure 17B). Both 
KLF6-SV1 and KLF6-SV2 isoforms lack the nuclear localization signal sequences whereas the 
KLF6-SV3 isoform does not have exon 3181. 
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Figure 17: KLF6 structure and isoforms. (A) Schematic illustrating the KLF6 genomic DNA, 
mRNA and proteins domains. (B) The presence of KLF6 transcript isoforms due to the 
alternative splicing. Adopted from Andreoli et al180 
 
 There have been contradictory reports on the functions of KLF6 in cancers. Several early 
studies have described KLF6 to have growth suppressive function due to their observations that 
KLF6 was frequently inactivated or downregulated in the analysed cancer types182-184. However, 
recent large-scale genome re-sequencing efforts reveal that KLF6 is rarely inactivated via genetic 
alterations185,186. There were also studies that showed KLF6 supports cancer growth187-189. 
Furthermore, the spliced-variants of KLF6, particularly the KLF6-SV1 isoform, has been 
associated with cancer progression and poor prognosis in prostate, breast and ovarian cancer190-
192. Based on these contradictory reports, I was therefore interested to further understand the role 
B 
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of KLF6 in ccRCC. It was hypothesised that KLF6 could involve in supporting ccRCC 
pathogenesis based on the observation that KLF6 is located in the vicinity of one of the strongest 
super enhancers in ccRCC. This was supported by the fact that super enhancers have been widely 
shown to regulate the expression of important genes in various biological processes as well in 
supporting cancer phenotypes. Also, it was observed that KLF6 expression was higher in ccRCC 
samples as compared to the normal kidney tissues. Thus, the focus of this chapter was to test the 
hypothesis presented above by investigating whether KLF6 plays a role in supporting ccRCC 
growth. To attain this, the state-of-the-art CRISPR-Cas9 and CRISPRi gene editing tools were 
employed to target KLF6 in several VHL-mutant ccRCC cell lines, followed by assessing the 
effect of KLF6 inhibition on ccRCC growth via in vitro and in vivo functional assays.  
 
3.2 Results 
3.2.1 ccRCC cell lines identity validation 
The effect of KLF6 inhibition was tested on several VHL-deficient ccRCC cell lines; 
786-M1A, OS-LM1, RCC-MF and UOK101. Prior to performing the in-vitro functional assays, 
it was crucial to validate the identity of each of these cell lines in order to ensure the cells were 
what they were supposed to be and no cross-contamination had happened. As described in 
Chapter 2 (section 2.1), each of this ccRCC cell line harbours a unique homozygous VHL 
mutations that can be directly detected via Sanger sequencing. Thus, the identity of these cells 
was authenticated by confirming their corresponding VHL mutation. There is a deletion of 
guanine at position 310 and 173 in the VHL exon 1 of the 786-M1A and OS-LM1 cells, 
respectively. In the RCC-MF cell line, there is a cytosine to thymine substitution at position 256 
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in the VHL exon 1 as well. There is a deletion of cytosine in the VHL exon 3 of UOK101 cells. 
PCR primers were designed to amplify region encompassing the mutated site in each of this cell 
line and the amplicons were sent for Sanger sequencing. Figure 18 shows the sequencing 
electropherograms that highlighted the VHL mutation in (A) 786-M1A, (B) OS-LM1, and (C) 
RCC-MF cells. Each of this cell line harboured their respective unique VHL mutations, thus 
validating the identity of these cell lines. The identity of UOK101 cells was successfully 
authenticated by Nazhif Zaini, a member of the lab.  
 
 
 
 
 
 
 
 
 
 
Figure 18: Validation of the ccRCC cell lines identity. (A-C) Sequencing electropherogram 
highlighting the VHL mutation in (A) 786-M1A, (B) OS-LM1 and (C) RCC-MF. 
A 
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3.2.2 KLF6 is expressed in ccRCC cell lines  
Next, the expression of KLF6 protein was assessed in the cell lines described previously 
and in the parental 786-O and OS-RC2 cells as well. For comparison, KLF6 expression was also 
assessed in the A549 lung cancer cell line. The ccRCC cell lines expressed higher level of KLF6 
as compared to the A549 lung cancer cell line (Figure 19A). This was in agreement with the 
analyses of TCGA RNA-Seq data set that revealed higher and specific expression of KLF6 in 
ccRCC clinical samples compared to other tumour types (Figure 16A). As highlighted in the 
introduction section 3.1, several studies have reported the presence of three additional KLF6 
transcript isoforms, KLF6-SV1, SV2 and SV3, due to the alternative splicing. Thus, it was 
important to determine the predominantly expressed KLF6 isoform in our model system. 
Analysis of the previously generated RNA-Seq data from several ccRCC cell lines confirmed 
that the full-length KLF6 was the predominantly expressed isoform in ccRCC cell lines with 
little evidence showing the other transcript isoforms being expressed in these cells (Figure 19B). 
 
 
 
 
 
Figure 19: Characterisation of KLF6 expression in ccRCC cell lines. (A) KLF6 protein 
expression in a panel of ccRCC cell lines and A549, a lung cancer cell line. (B) Transcript reads 
of the full length and alternatively spliced KLF6 variants as measured by RNA-Seq in ccRCC 
cell lines.  
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3.2.3 High efficiency of CRISPR-Cas9-mediated KLF6 targeting   
As described previously, the CRISPR-Cas9 gene editing tool was employed to perturb 
KLF6 function in the ccRCC cell lines. The KLF6-targeting sgRNAs were designed using the 
Broad Institute sgRNA design tool. Based on the prediction algorithm, two sgRNAs were 
chosen, sgKLF6_4 and sgKLF6_5, in which each of this sgRNA targeted two independent 
regions within the KLF6 exon 2 (Figure 20A). The Cas9 protein would be recruited and cleaved 
these sgRNAs-targeted sites where in the absence of repair template, the error-prone NHEJ 
would take place that subsequently resulted in the introduction of mutations193. In addition, the 
non-targeting control construct, sgNTC, was also designed. The sgKLF6 and sgNTC constructs 
were cloned into the pKLV-U6-gRNA(BbsI)-PGKhygro2ABFP sgRNA expression vector, 
followed by transduction into the 786-M1A cells expressing the doxycycline-inducible Cas9. 
The targeting efficiency of these sgKLF6 constructs was assessed by performing genetic analysis 
on their respective targeted regions and checking the KLF6 expression level in these cells. The 
workflow for assessing the sgKLF6 targeting efficiency is exemplified in figure 20B. 
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Figure 20: CRISPR-Cas9-mediated KLF6 targeting. (A) Regions targeted by sgKLF6_4 and 
sgKLF6_5 constructs within the KLF6 exon 2. (B) Experimental workflow to assess the sgKLF6 
constructs targeting efficiency.  
 
The most common type of mutations induced by the CRISPR-Cas9 gene editing tool are 
insertions and/or deletions (INDELS). INDELS result in either frameshift or introduction of 
nonsense mutations, which could be deleterious194. However, there is a possibility that the 
induced mutations are synonymous or in-frame mutations, which could retain the KLF6 wild-
type functions. To examine the targeting efficiency of both sgKLF6 constructs, the sgKLF6_4 
and sgKLF6_5-targeted regions were amplified from the transduced 786-M1A cells and the 
amplicons were sent for Illumina high throughput sequencing. About 98% of the sequencing 
B 
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reads analysed from both sgKLF6-targeted sites were mutated sequences (Figure 21A). In 
addition, the TOPO-TA cloning was also performed on the sgKLF6_4-targeted site. Out of 
fifteen TOPO-TA clones sent for Sanger sequencing, ten clones had six different types of 
deletion, all resulting in frameshift mutation. Two clones had same one nucleotide insertion; also 
resulting in frameshift mutation, while three other clones had failed sequencing reads (Figure 
21B). Importantly, there was no wild-type sequence detected. Next, the KLF6 protein level in the 
sgKLF6_4 and sgKLF6_5-transduced 786-M1A cells was assessed and it was observed that 
KLF6 expression was significantly depleted in these cells (Figure 21C). Collectively, these 
finding confirmed the high efficiency of sgKLF6_4 and sgKLF6_5 constructs in targeting KLF6 
and be used in the subsequent functional assays. 
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Figure 21: High efficiency of the sgKLF6 constructs in targeting KLF6. (A) Fraction of wild 
type and mutant KLF6 genomic DNA in cells targeted by sgKLF6_4 and sgKLF6_5 constructs. 
(B) Genetic analysis of the sgKLF6_4-targeted region TOPO-TA clones. (C) KLF6 expression 
in 786-M1A cells transduced with sgKLF6_4, sgKLF6_5 and non-targeting control constructs.   
 
3.2.4 Development of competitive proliferation assay    
The phenotypic effect upon KLF6 inhibition in the ccRCC cell lines was assessed using 
the competitive proliferation assay which I developed in the lab. The basis of this assay was to 
mix the KLF6-targeted and control cells at a 1:1 ratio, followed by assessing the percentage of 
each cells population over time using FACS. By employing this strategy, the cells growth was 
able to be assessed for an extended period of time, thus ensuring a small or delayed effect in cell 
proliferation could be observed. As discussed in Chapter 2, several variants of the sgRNA 
expression vector were generated and one of them was the pKLV-U6-gRNA(BbsI)-
PGKhygro2AmCherry. These BFP and mCherry variant of the sgRNA expression vectors were 
utilised to distinguish between the pooled KLF6-targeted and control cell populations. In brief, 
the sgKLF6 and sgNTC constructs were cloned into the BFP and mCherry sgRNA expression 
vectors, respectively, followed by transducing the cells with either of these constructs. As a 
result, the sgKLF6-transduced cells population would be BFP+ whereas the control cell 
population would be mCherry+. These BFP+ KLF6-targeted and mCherry+ control cells were co-
cultured according to the condition described above.  
If KLF6 does play a role in supporting ccRCC pathogenesis, targeting KLF6 would 
impair ccRCC cells growth. Therefore, in the competitive proliferation assay, the BFP+ KLF6-
targeted cell population would be depleted from the assay and outgrown by the mCherry+ control 
86 
 
cells population. However, if the KLF6 role in ccRCC is dispensable, it was predicted that this 
BFP+ cell population would proliferate at the same rate as the mCherry+ control cell population. 
Thus, the percentage of each cell population at the end of the assay would be similar to their 
respective percentage on the plating day, T=0. Figure 22 simplifies the competitive proliferation 
assay strategy along with the expected observations for the control and experimental conditions. 
The experimental condition consisted of a mixture of BFP+ KLF6-targeted and mCherry+ control 
cell population. In addition, BFP+ control cells were also generated in which this cell population 
was co-cultured with the mCherry+ control cell population that served as the control condition for 
this competitive proliferation assay.     
 
 
 
 
 
 
 
 
 
 
Figure 22: The in-vitro competitive proliferation assay. (Top) A Simplified diagram of the 
competitive proliferation assay strategy. (Bottom) The observations in the control and 
experimental conditions of the competitive proliferation assay.  
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3.2.5 Competitive proliferation assay (CRISPR-Cas9-mediated KLF6 inhibition) 
3.2.5.1 786-M1A cells   
The 786-M1A cells expressing the doxycycline-inducible Cas9 were first transduced with 
either sgKLF6-BFP or sgNTC-mCherry constructs. Three different conditions were set up in this 
competitive proliferation assay. The first condition was the control condition which has been 
described previously. The second and third conditions were the mCherry+ control cells mixed 
with the BFP+ sgKLF6_4 and sgKLF6_5 cells, respectively. The assay was performed for 28 
days where the percentage of BFP+ and mCherry+ cell populations in each condition was assessed 
weekly by FACS.  
Figure 23A shows the percentage of BFP+ and mCherry+ cell populations in each 
condition at the beginning and end of the assay. The x-axis and y-axis show the 
excitation/detection wavelength used to detect the BFP and mCherry fluorescents, respectively. 
For the control condition (top panel), as compared to day 0, there was no significant change in 
the percentage of BFP+ and mCherry+ cell populations at the end of the assay. For example, the 
percentage of BFP+ control cell population at the start and end of the assay was 42.9% and 
43.1%, respectively. This was in line with the initial expected result for this control condition. 
This was due to both cell populations were transduced with non-targeting control construct 
which in theory should not have any effect the cells growth.      
The middle panel shows the condition of the mixed BFP+ sgKLF6_4/mCherry+ control 
cell populations. The percentage of BFP+ KLF6 targeted-cells was 38.2% at the start of the assay 
and significantly decreased to 17.6% after 28 days in culture. In contrast, the percentage of the 
mCherry+ control cell population increased from 56.1% to 76.4% at the end of the assay. Similar 
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result was observed when I mixed the BFP+ sgKLF6_5 cells with the mCherry+ control cells (last 
panel). The population of BFP+ KLF6-targeted cells decreased from 45.8% to 23.2% whereas the 
mCherry+ cell population increased from 52.1% to 74% at the end of the assay.  
These competitive proliferation assay data were analysed by normalising the percentage 
of cell populations in each week to their respective percentage at the beginning of the assay. 
After normalising the percentage of each week to the plating day, the relative fraction of BFP+ 
KLF6-targeted and mCherry+ control cells was determined. The graph in figure 23B shows the 
analysed data for all three set-up conditions for this assay. The relative fraction of BFP+ and 
mCherry+ cells populations in the control condition remained unchanged throughout the assay. 
However, in both KLF6 targeting conditions, the relative fraction of BFP+ KLF6 targeted-cell 
and mCherry+ control cell populations continuously decreased throughout the assay where at the 
end of the assay, the ratio between BFP+ and mCherry+ cells was about 0.3. 
To confirm that the observed phenotype was not confounded by the fluorescent proteins, 
the sgRNA expressing vectors were swapped by cloning the sgKLF6 and sgNTC constructs into 
mCherry and BFP backbones, respectively. It was then observed that the KLF6-targeted cells 
which in this “fluorescent markers-swapped” experiment expressed the mCherry fluorescent 
protein got depleted from the assay and outgrown by the BFP+ control cells population (Figure 
23C). The relative fraction of mCherry+ KLF6-targeted and BFP+ control cell populations was 
0.44 for the sgKLF6_4 construct and 0.29 for the sgKLF6_5 (Figure 23D). Collectively, the 
observations from these competitive proliferation assays suggested that KLF6 plays a role in 
supporting ccRCC growth, at least in the 786-M1A cell line. The KLF6-targeted 786-M1A cells 
grew slower that resulted in the depletion of this cell population in the competitive proliferation 
assay.  
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Figure 23: Competitive proliferation assay of the CRISPR-Cas9 KLF6-targeted 786-M1A cells. 
(A) FACS plots of each of the set-up condition at the start and end of the assay. (B) Analysis of 
the experiment shown in A. Graph shows the relative fraction of BFP+ KLF6-targeted and 
mCherry+ control cells, normalised to day 0. Two-way ANOVA with Tukey’s range test. (C) 
FACS plot of the swapped fluorescent markers experiment. (D) Analysis of the experiment 
D 
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shown in C. Graph shows the relative fraction of mCherry+ KLF6-targeted and BFP+ control 
cells, normalised to day 0. Two-way ANOVA with Tukey’s range test.      
 
3.2.5.2 Rescuing the KLF6-targeted 786-M1A cells with exogenous KLF6   
In order to validate the previous findings, a rescue experiment was performed by 
reintroducing exogenous KLF6 into the KLF6-targeted 786-M1A cells, followed by assessing 
the effect of this KLF6 reintroduction on cells growth. This rescue experiment would confirm 
that the observed growth defect was actually the result of KLF6 inhibition, not due to unexpected 
off-target effect. KLF6 coding sequence (CDS) was amplified from the cDNA of 786-M1A cells 
and the amplified KLF6 CDS was sequence-verified via Sanger sequencing. The sequence-
verified KLF6 CDS was cloned into the pLVX-Hygro expression vector which was modified by 
Paulo Rodrigues from the commercially available pLVX-Puro expression vector. Since the 
rescue experiment was performed in the sgKLF6_4-transduced cells, several synonymous 
mutations were reintroduced within the sgKLF6_4 target site of the exogenous KLF6 using the 
site-directed mutagenesis tool. This was to prevent the reintroduced exogenous KLF6 from being 
targeted by the sgKLF6_4 construct. 
Next, the 786-M1A cells expressing the doxycycline-inducible Cas9 were transduced 
with either pLVX-Hygro empty vector (hereinafter referred to as EV cells) or pLVX-Hygro 
KLF6 CDS (hereinafter referred to as KLF6 CDS cells). These EV and KLF6 CDS cells were 
subsequently transduced with either sgKLF6_4-mCherry or sgNTC-BFP constructs depending 
on the competitive proliferation assay conditions. Figure 24A shows the KLF6 immunoblot of 
the sgNTC + EV cells, sgKLF6_4 + EV cells and sgKLF6_4 + KLF6 CDS cells. KLF6 protein 
expression was significantly depleted in the sgKLF6_4 transduced-EV cells (lane 2). KLF6 
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expression was detected in the sgKLF6_4-transduced KLF6 CDS cells; this supposed to be from 
the reintroduced exogenous KLF6 since the endogenous KLF6 was targeted by sgKLF6_4 (lane 
3).  
Three different conditions were set up for this rescue competitive proliferation assay 
where in the first condition, the mCherry+ sgNTC + EV and BFP+ sgNTC + EV cells were 
competed against each other. This served as the control condition. The second condition was the 
mixture of mCherry+ sgKLF6_4 + EV and BFP+ sgNTC + EV cells and this condition mimicked 
the experimental conditions of the previous competitive proliferation assay. The last condition 
was the rescue condition that consisted of a mixture of mCherry+ sgKLF6_4 + KLF6 CDS and 
BFP+ sgNTC + EV cell populations.  
The results of this rescue competitive proliferation assay are shown in figure 24B. The 
relative fraction of the mCherry+ and BFP+ sgNTC + EV cell populations in the control condition 
remained unchanged throughout the assay. This was expected because both of these cell 
populations proliferated normally at a similar rate. The relative fraction of the mCherry+ 
sgKLF6_4 + EV and BFP+ sgNTC + EV cells decreased over time due to KLF6 inhibition in 
these mCherry+ sgKLF6_4 + EV cells. This result was consistent with the previous competitive 
proliferation assay observations that targeting KLF6 led to impaired cells growth. However, in 
the rescue condition, the reintroduction of exogenous KLF6 into the sgKLF6_4-targeted cells 
(mCherry+ sgKLF6_4 + KLF6 CDS) alleviated the proliferative defect. It can be observed from 
the graph that these cells (orange line) grew better compared to the KLF6-targeted cells that did 
not carry the exogenous KLF6 (red line). The findings of this rescue competitive proliferation 
assay confirmed that the previously observed growth defect in KLF6-targeted 786-M1A cells 
was indeed due to KLF6 inhibition. 
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Figure 24: Exogenous KLF6 rescue competitive proliferation assay of the CRISPR-Cas9 KLF6-
targeted 786-M1A cells. (A) KLF6 expression in the cells used in the KLF6 CRISRPR-Cas9 
rescue competitive proliferation assay. (B) Analysis of the rescue competitive proliferation 
assay. Graph shows the relative fraction of mCherry+ sgKLF6_4 + EV cells and mCherry+ 
sgKLF6_4 cells reintroduced with exogenous KLF6 compared to BFP+ control cells. Two-way 
ANOVA with Tukey’s range test. 
 
3.2.5.3 Targeting KLF6 in other ccRCC cell lines 
Next was to investigate whether KLF6 inhibition would also affect the growth of several 
other VHL-deficient ccRCC cell lines. To test this, the constitutively-expressing Cas9 OS-LM1, 
RCC-MF and UOK101 cells were generated, followed by transducing these cells with either 
sgKLF6_4, sgKLF6_5 or sgNTC constructs. As expected, a reduction in the KLF6 protein level 
was observed in the cells that were transduced with the sgKLF6_4 and sgKLF6_5 constructs 
(Figure 25A). The previously described competitive proliferation assay was employed to assess 
the effect of KLF6 inhibition in these OS-LM1, RCC-MF and UOK101 cells. Results of the 
competitive proliferation assay are shown in figure 25B where in this experiment, the BFP+ 
A B 
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KLF6-targeted cells were competed against the mCherry+ control cells. The CRISPR-Cas9-
mediated KLF6 targeting in these cells resulted in impaired cells growth, indicated by the 
decreased relative fraction of the BFP+ KLF6 targeted and mCherry+ control cell populations 
over times. This was due to the depletion of these BFP+ cells from the assay and consequent 
increased in the population of mCherry+ cells.  
The sgRNA expression vectors were also swapped in order to ensure the observed growth 
defect was not confounded by the fluorescent proteins. Consistent results were observed where 
the swapped mCherry+ KLF6-targeted cells grew slower compared to the BFP+ control cells that 
resulted in the depletion of these mCherry+ cells from the assay. This was reflected by the 
decreased relative fraction of the mCherry+ KLF6 targeted and BFP+ control cell populations 
over times (Figure 25C). Collectively, these observations corroborated the hypothesis that KLF6 
plays important role in supporting ccRCC cells growth. 
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Figure 25: Competitive proliferation assay of the CRISPR-Cas9 KLF6-targeted OS-LM1, 
UOK101 and RCC-MF cells. (A) KLF6 expression in the KLF6-targeted OS-LM1, UOK101 and 
RCC-MF cells. (B) Graph shows the relative fraction of BFP+ KLF6-targeted and mCherry+ 
control cells, normalised to day 0. Two-way ANOVA with Tukey’s range test. (C) Graph shows 
the relative fraction of mCherry+ KLF6-targeted and BFP+ control cells, normalised to day 0. 
Two-way ANOVA with Tukey’s range test. 
A 
B 
C 
96 
 
3.2.6 Competitive proliferation assay (CRISPRi-mediated KLF6 inhibition) 
The induction of double-strand break by the CRISPR-Cas9 mutagenesis tool could put 
the cells under stress and consequently reduced the cells fitness. Hence, it was also important to 
confirm that the previously observed impaired cells growth was not contributed by the CRISPR-
Cas9-mediated double-strand break. To address this, CRISPRi approach was employed to inhibit 
KLF6 in ccRCC cell line and the cells proliferation rate upon CRISPRi-mediated KLF6 depletion 
was assessed. CRISPRi is a non-mutational approach to target protein that employs catalytically-
inactivated Cas9 (dCas9) fused with transcriptional repressor domain KRAB195. Unlike the wild-
type Cas9 that induces the double-strand break and INDELS, the catalytically-inactivated dCas9 
will only sit at the targeted site whereby the fused KRAB domain will repress the expression of 
gene encoding the protein of interest.      
3.2.6.1 CRISPRi-mediated KLF6 depletion in 786-M1A cells   
In the CRISPR-Cas9 system, the sgRNAs are designed to target the protein coding 
sequences, normally the early exons. This is because INDELS and frameshift mutations in these 
early exons would be deleterious and result in non-functional protein. In the case of KLF6, the 
sgRNAs targeted regions were in exon 2. In contrast, there is a difference in the CRISPRi system 
where the targeted region is within -300 to +50 base pairs of the transcription start site. In order 
to increase the CRISPRi inhibition efficiency, the tandem sgRNAs approach was utilised which 
has been described in Chapter 2 (section 2.11). Two independent constructs, iKLF6_2 and 
iKLF6_3, were designed based on the prediction made in Gilbert et al176. These iKLF6 
constructs targeted the KLF6 5’ untranslated region. The regions targeted by iKLF6_2 and 
iKLF6_3 within the KLF6 5’ untranslated region are shown in figure 26.  
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Figure 26: Regions targeted by the CRISPRi iKLF6 tandem constructs.   
 
The 786-M1A cells were transduced with KRAB-dCas9-mCherry plasmid, hereinafter 
referred to as 786-M1A CRISPRi cells. These mCherry+ 786-M1A CRISPRi cells were then 
transduced with either iKLF6 or non-targeting control tandem constructs. These constructs were 
previously cloned into the BFP sgRNA expression vector. The KLF6 repressing efficiency of 
this CRISPRi approach was assessed at both mRNA and protein level. As compared to the 
control cells, there was about 90% reduction in KLF6 mRNA level in the iKLF6-transduced cells 
(Figure 27A). In agreement with the qPCR data, the expression of KLF6 protein was 
significantly depleted in these cells (Figure 27B). These observations confirmed the high 
efficiency of this CRISPRi tool along with the utilisation of the tandem sgRNAs targeting 
approach in knocking down KLF6 expression in these 786-M1A cells. 
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Figure 27: High efficiency of the CRISPRi approach in repressing KLF6 expression. (A) KLF6 
mRNA expression in the KLF6-targeted 786-M1A CRISPRi cells. Average of three experiments. 
Error bars, SEM. One-way ANOVA with Dunnett’s test. * P < 0.05, ** P < 0.005 and *** P < 
0.0005. (B) KLF6 protein expression in the KLF6-targeted and control 786-M1A CRISPRi cells.    
 
The phenotypic effect of CRISPRi-mediated KLF6 inhibition was assessed using the 
competitive proliferation assay with slight modification. The double mCherry+/ BFP+ iKLF6 or 
control 786-M1A CRISPRi cells were competed against the mCherry+/BFP- 786-M1A CRISPRi 
parental cells. Similar to the previous assay, three conditions were set up. The first condition was 
the competition between the mCherry+/BFP+ control 786-M1A CRISPRi cells and 
mCherry+/BFP- 786-M1A CRISPRi parental cells. This condition served as control condition. 
The second and third condition were the mixture of mCherry+/BFP- 786-M1A CRISPRi parental 
with either mCherry+/BFP+ iKLF6_2 or iKLF6_3 786-M1A CRISPRi cells, respectively. The 
FACS plots in figure 28A show the percentage cell populations in each condition at the start and 
end of the competitive proliferation assay.    
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In the control condition (top panel), there was no significant difference in the percentage 
of both cell populations at the beginning and end of the assay. However, for the iKLF6_2 and 
iKLF6_3 conditions (middle and bottom panel), both mCherry+/BFP+ iKLF6_2 and iKLF6_3 
786-M1A CRISPRi cells grew slower compared to the mCherry+/BFP- 786-M1A CRISPRi 
parental cells that resulted in the depletion of these double positive cells at the end of the assay. 
For instance, the population of mCherry+/BFP+ iKLF6_2 cells decreased from 50.8% to 20.3% 
whereas the mCherry+/BFP- cell population increased from 47.2% to 78.1% at the end of the 
assay. These competitive proliferation assay results were analysed by normalising the percentage 
of each cell populations in each week to their respective percentage at the beginning of the assay. 
Then, the relative fraction of the mCherry+/BFP+ (iKLF6_2, iKLF6_3 or control) 786-M1A 
CRISPRi cells and mCherry+/BFP- 786-M1A CRISPRi parental cells was determined and the 
analysed data are shown in figure 28B.  
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Figure 28: Competitive proliferation assay of the KLF6-depleted 786-M1A CRISPRi cells. (A) 
FACS plot of the CRISPRi KLF6 targeting competitive proliferation assay. (B) Analysis of the 
experiment shown in A. Relative fraction of the KLF6-targeted and control 786-M1A CRISPRi 
cells, normalised to day 0, compared to 786-M1A CRISPRi parental cells. Two-way ANOVA 
with Tukey’s range test.     
 
3.2.6.2 KLF6 CRISPRi rescue competitive proliferation assay   
KLF6 CRISPRi rescue experiment was also performed by reintroducing exogenous KLF6 
into the KLF6-depleted 786-M1A CRISPRi cells. In contrast to the KLF6 CRISPR-Cas9 rescue 
experiment (section 3.2.6.2), the exogenous KLF6 CDS was not subjected to any nucleotides 
substitution because the iKLF6 tandem constructs target sites resided outside this transgene. The 
KLF6 CDS was cloned into the pLVX-Puro expression vector. The 786-M1A CRISPRi cells 
were transduced with either pLVX-Puro empty vector (hereinafter referred to as EV cells) or 
pLVX-Puro KLF6 CDS (hereinafter referred to as KLF6 CDS cells). This was followed by 
transducing these EV and KLF6 CDS cells with either the non-targeting control or iKLF6_2 
construct to generate the following cell lines; 1) non-targeting control + EV cells, 2) iKLF6_2 + 
EV cells and 3) iKLF6_2 + KLF6 CDS cells. 
The non-targeting control + EV cells were used in the control condition. The iKLF6_2 + 
EV cells and iKFL6_2 + KLF6 CDS cells were used in the KLF6 inhibition and rescue 
conditions, respectively. KLF6 expression in these cells were confirmed by Western blotting 
(Figure 29A). In each condition, the mCherry+/BFP+ cells were competed against the 
mCherry+/BFP- 786-M1A CRISPRi parental cells. Figure 29B shows the result of the KLF6 
CRISPRi rescue experiment, represented by the relative fraction of the mCherry+/BFP+ cells and 
the mCherry+/BFP- cell populations. Consistent with the previous findings, KLF6 inhibition 
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resulted in impaired cells growth (red line). However, the presence of exogenous KLF6 in the 
KLF6-targeted cells was able to mitigate the proliferative defect caused by the KLF6 inhibition 
(orange line). Collectively, using two independent approaches to target KLF6 (CRISPR-Cas9 
and CRISPRi), I have robustly demonstrated that KLF6 involved in supporting ccRCC cells 
growth in vitro. KLF6 inhibition reduced ccRCC cells growth in vitro whilst the reintroduction 
of exogenous KLF6 was able to alleviate this proliferative defect.  
 
 
Figure 29: Exogenous KLF6 rescue competitive proliferation assay of the CRISPRi KLF6-
depleted 786-M1A cells. (A) KLF6 expression in the cells used in the KLF6 CRISPRi rescue 
competitive proliferation assay. (B) Analysis of the rescue competitive proliferation assay. Graph 
shows the relative fraction of the KLF6-targeted, KLF6-targeted with the reintroduction of 
exogenous KLF6 and control 786-M1A CRISPRi cells, normalised to day 0, compared to 786-
M1A CRISPRi parental cells. Two-way ANOVA with Tukey’s range test.     
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3.2.7 Investigating the effect of KLF6 inhibition in vivo 
Next, I investigated the effect of targeting KLF6 on ccRCC cells growth and tumour-
forming capability in vivo. To test this, CRISPR-Cas9 KLF6-targeted and control 786-M1A as 
well as the OS-LM1 cells were subcutaneously injected into the athymic nude mice by Sakari 
Vanharanta. As an additional information, Sakari Vanharanta performed the cells injection for all 
in vivo experiments in the lab to ensure consistencies across the experiments. The cells growth 
was assessed by measuring the bioluminescence signals weekly until the signals had saturated. 
Both 786-M1A and OS-LM1 cells harboured the TGL reporter transgene that encodes for 
luciferase, an enzyme that catalyses the oxidization of D-Luciferin in a reaction that produces 
bioluminescence as by-product. Hence, to perform the bioluminescence imaging experiment, D-
luciferin was injected into the mice intraperitoneally. The bioluminescence signals positively 
correlate with the cells abundance. For instance, cells that are rapidly growing would have high 
bioluminescence signals due to the presence of more cells whereas the slow proliferating cells 
would have lower bioluminescence signals. Once the subcutaneous tumours were palpable, the 
tumour volume was calliper measured until the end of the assay.   
3.2.7.1 KLF6-targeted 786-M1A cells tumour formation assay  
Figure 30A illustrates the experimental set-up for the CRISPR-Cas9 KLF6-targeted 786-
M1A in vivo tumour formation assay. Three animal groups were set up in which each group 
consisted of five mice. The mice in each group were fed with doxycycline-supplemented food to 
induce the Cas9 expression. After the cells inoculation, the bioluminescence signals in each mice 
were measured which are shown in figure 30B. The average bioluminescence signals in each 
group were relatively similar, demonstrating consistencies in cells preparation and injection.  
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The bioluminescence imaging was performed for three weeks before the signals had 
saturated. Figure 30C shows the bioluminescence signals in each mice three weeks post-
inoculation. Overall, the mice in control group had higher bioluminescence signals than the mice 
in sgKLF6_4 and sgKLF6_5 groups, indicating that the KLF6-targeted 786-M1A cells grew 
slower than the control cells. To ensure that the difference between these KLF6-targeted and 
control groups was not due to variation in the initially inoculated cells, I normalised the week 3 
bioluminescence reads of each mice to their corresponding inoculation day signals. The relative 
to day 0 photon flux of the mice in control group was significantly higher compared to the mice 
in both KLF6-targeted groups (Figure 30D). This data demonstrated that KLF6 perturbation 
reduced the 786-M1A cells proliferation in vivo, which was in concordant with the in vitro 
observations.   
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Figure 30: Bioluminescence reads of the CRISPR-Cas9 KLF6-targeted 786-M1A cells in vivo. 
(A) Schematic illustrating the experimental design for KLF6-targeted 786-M1A cells tumour 
formation assay. (B) Bioluminescence reads of the KLF6-targeted and control cells at the 
inoculation day. N=10 injection sites / group. One-way ANOVA with Tukey’s range test. (C) 
Bioluminescence images of mice in the KLF6-targeted and control groups three weeks post-
inoculation. (D) Normalised to day 0 bioluminescence reads in week 3 of each animal group. 
One-way ANOVA with Tukey’s range test. 
 
The tumour volume was determined by calliper measurement after the tumours became 
palpable. It was observed that the KLF6-targeted 786-M1A cells were still able to form tumours. 
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Nevertheless, due to these cells impaired growth, the formed tumours were much smaller 
compared to the tumours of the control cells. At the end of the experiment, the average tumour 
volume in the control group was 480 mm3 whereas the average tumours volume of the sgKLF6_4 
and sgKLF6_5 groups were 155 mm3 and 177 mm3, respectively (Figure 31A). The 
subcutaneous tumours were extracted and weighed in order to validate these observations. In line 
with the tumour volume data, the average control group tumour weight was about 300 mg 
whereas the average tumour weight of the KLF6-targeted groups was around 100 mg (Figure 
31B).  
 
 
Figure 31: Tumours size of the CRISPR-Cas9 KLF6-targeted 786-M1A cells. (A) The average 
tumours volume of the KLF6-targeted and control groups at the indicated time points. N=10 
tumours /group. Error bars, SEM. Two-way ANOVA with Tukey’s range test. (B) The weight of 
tumours in each group at the end of the experiment shown in A. One-way ANOVA with Tukey’s 
range test. 
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3.2.7.2 KLF6-targeted OS-LM1 tumour formation assay  
The tumour formation assay was also performed on the CRISPR-Cas9 KLF6-targeted 
OS-LM1 cells. There were 6 mice in the control group whereas the sgKLF6_4 and sgKLF6_5 
group consisted of 7 mice / group. Figure 32A shows the bioluminescence read of the inoculated 
cells in each group at day 0. The bioluminescence reads of each mice at day 21 were normalised 
to their respective day 0 signals. These normalised bioluminescence reads are shown in figure 
32B. The sgKLF6_4 and sgKLF6_5 groups had lower normalised to day 0 bioluminescence 
reads than the control group, consistent with the observations that targeting KLF6 in ccRCC cells 
resulted in impaired cells proliferation. This consequently led to the formation of smaller 
tumours compared to tumours of the control cells (Figure 32C). The average tumour volume of 
the control group was 472.5 mm3 whereas the average tumour volume of the sgKL6_4 and 
sgKLF6_5 group was 194.3 mm3 and 235.5 mm3, respectively.  
In sum, targeting KLF6 in the 786-M1A and OS-LM1 cells reduced the cells growth in 
vivo. Both of these KLF6-targeted cells were still capable to form tumours. Nonetheless, in line 
with these cells impaired growth, the formed tumours were smaller compared to the tumours of 
the control cells. For instance, in the 786-M1A experiment, there was about three-fold difference 
between the average tumour size of the control and KLF6-targeted groups. These findings further 
corroborated the role of KLF6 in supporting ccRCC cells growth both in vitro and in vivo.  
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Figure 32: Tumour formation assay of the CRISPR-Cas9 KLF6-targeted OS-LM1 cells. (A) 
Bioluminescence reads of the KLF6-targeted and control OS-LM1 cells at the inoculation day. 
N=12 injection sites for control group. N = 14 injection sites for sgKLF6_4 and sgKLF6_5 
groups. One-way ANOVA with Tukey’s range test. (B) Normalised to day 0 bioluminescence 
reads in week 3 of each animal group. One-way ANOVA with Tukey’s range test. (C) The 
average tumours volume of the KLF6-targeted and control groups at the indicated time points. 
N= 10 tumours for the control group. N = 14 tumours for the sgKLF6_4 and sgKLF6_5 groups. 
Error bars, SEM. Two-way ANOVA with Tukey’s range test. 
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3.2.7.3 Genetic analysis of the KLF6-targeted 786-M1A tumours 
As demonstrated in the previous sections, the CRISPR-Cas9 KLF6-targeted cells were 
still capable to form tumours. Since the mutations induced by the CRISPR-Cas9 approach were 
random, it was postulated that these KLF6-targeted 786-M1A and OS-LM1 cell populations 
might consist of cells that retained the KLF6 activity as well as wild-type escaper cells. 
Furthermore, there might be selective growth advantage on the escaper clones especially since 
the subcutaneous tumour formation assays were performed for an extended period of time. Thus, 
to directly test this possibility, genetic analysis was performed on the KLF6-targeted 786-M1A 
subcutaneous tumours. These tumours were harvested at the end of the assay which was 84 days 
(12 weeks) post-cells inoculation.  
Genomic DNA was extracted from tumours of the sgKLF6_4 (n=2) and control group 
(n=1). The sgKLF6_4 targeted region was amplified and the amplicons were sent for Illumina 
high-throughput sequencing in order to assess the percentage of mutated and wild-type KLF6 
alleles in these extracted tumours. As expected, it was found that 99.6% of reads in the control 
tumour were wild-type KLF6. However, in the two tumours targeted by sgKLF6_4, I found that 
the wild-type KLF6 alleles in each of this tumour were 18% and 66%, respectively (Figure 33). 
The fraction of KLF6 wild-type allele in these sgKLF6_4 targeted tumours was significantly 
higher compared to the KLF6-targeted 786-M1A cells in vitro, in which < 3% of the KLF6 
alleles were wild-type (Figure 21A). This finding confirmed the speculation that due to the 
selective growth advantage, at least a fraction of tumours formed by the KLF6-targeted cells 
contained the wild-type escaper clones.  
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Figure 33: Genetic analysis of the KLF6-targeted 786-M1A tumours. Fraction of wild-type and 
mutant KLF6 allele at the sgKLF6_4 target region in the control and KLF6-targeted 
subcutaneous tumours harvested 84 days (12 weeks) post-cell inoculation. 
 
3.2.7.4 KLF6-targeted 786-M1A lung colonisation assay  
Advanced stage ccRCC is highly aggressive which predominantly metastasises to the 
lung or liver. The main ccRCC cell line used in this study was the 786-M1A, a metastatic 
derivative of 786-O cells. Vanharanta et al. have demonstrated that these 786-M1A cells are 
aggressive and have a significantly higher lung colonisation capability as compared to its 
parental 786-O cell line. Thus, I next sought to investigate whether KLF6 inhibition would have 
any effect on the 786-M1A cells lung colonisation capability.  
To perform the lung colonisation assay, the CRISPRi KLF6-targeted 786-M1A cells were 
used. KLF6 expression in these cells was first assessed prior to using them in the in vivo lung 
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colonisation assay. Strong and stable KLF6 repression was observed in these KLF6-targeted cells 
as compared to the control cells (Figure 34A). The KLF6-depleted and control 786-M1A 
CRISPRi cells were inoculated into the lateral tail vein of the NOD/SCID mice (N=5 
mice/group). The lung bioluminescence signals were measured right after the cells inoculation 
(day 0 measurement), followed by performing the bioluminescence imaging weekly until the end 
of the assay. The mice lung bioluminescence signals in each week were normalised to their 
respective signals at the day 0. The average normalised to day 0 bioluminescence signals for 
each animal group is shown in figure 34B. It was observed that the KLF6-deficient cells had a 
profound reduced lung colonisation capacity compared to the control 786-M1A CRISPRi cells, 
which was in line with the previous observations that KLF6 inhibition led to reduced ccRCC 
growth in vitro and in vivo. Nonetheless, the difference in the average normalised photon flux 
between these groups did not reach statistical significance. This was possibly due to the high 
variability in the bioluminescence signals of the mice in the control group.  
The lungs were extracted at the end of the assay and processed for human vimentin IHC 
staining. This was to confirm that the lung metastatic foci were formed by the inoculated ccRCC 
cells which were of human origin. Figure 34C shows the representative mice lung 
bioluminescence images from each group along with their respective human vimentin-stained 
histological lung sections. The vimentin-stained lung metastatic foci of the animal in each group 
were quantified in which the quantification data are shown in figure 34D. Four out of five mice 
in the control group had significantly higher overall tumour load in their lungs compared to the 
mice in the KLF6-targeted groups.  
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Figure 34: Lung colonisation assay of the CRISPRi KLF6-depleted 786-M1A cells. (A) KLF6 
expression in KLF6-targeted and control 786-M1A CRISPRi cells prior to tail vein inoculation. 
(B) Average normalised to day 0 lung photon flux of the KLF6-targeted and control 786-M1A 
CRISPRi cells at the indicated time points. N=5 mice/group. Error bars, SEM. Two-way 
ANOVA with Tukey’s range test. (C) Representative bioluminescence images and the respective 
lung sections stained with human vimentin. Scale bar, 5mm. (D) Quantification of vimentin-
stained lung metastatic foci of each animal group. N= 5 lung sections for control and iKLF6_2 
groups. N= 4 lung sections for iKLF6_3 group. One-way ANOVA with Tukey’s range test.  
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3.3 Summary 
Through active chromatin profiling, KLF6 was identified in a previous study in the lab to 
be in the vicinity of one of the strongest super enhancer in ccRCC. In line with the possibility 
that KLF6 expression in ccRCC could be super enhancer-driven, KLF6 expression was found to 
be high and relatively specific to ccRCC as compared to other tumour types. Importantly, in 
comparison to normal kidney tissues, KLF6 expression was significantly upregulated in ccRCC 
clinical samples, suggesting the pro-tumourigenic role of this transcription factor KLF6 in 
supporting ccRCC pathogenesis.  
In contrast to several studies that have suggested the growth suppressive function of 
KLF6, KLF6 was found to have a growth promoting role in ccRCC. CRISPR-Cas9 and 
CRISPRi-mediated KLF6 targeting in ccRCC cell lines resulted in impaired cells growth in vitro. 
This was demonstrated through the competitive proliferation assay where the KLF6-targeted cell 
population was depleted from the assay and outgrown by the control cell population. The 
reduced rate of proliferation was confirmed to be the consequence of KLF6 inhibition in these 
cells because the reintroduction of exogenous KLF6 into the KLF6-targeted cells was able to 
alleviate this proliferative defect. Consistent with the phenotypic effect in vitro, CRISPR-Cas9-
mediated KLF6 inhibition reduced the ccRCC cells growth in vivo which subsequently resulted 
in the formation of smaller subcutaneous tumours compared to tumours of the control cells. 
Furthermore, targeting KLF6 using the CRISPRi approach in the 786-M1A cells, which had 
enhanced metastatic capabilities, significantly reduced the cells lung colonisation capability. 
Overall, these data indeed supported the hypothesis that this super enhancer-associated 
transcription factor KLF6 plays an important role in supporting ccRCC pathogenesis.  
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Chapter 4 
 
Interrogating the role of super enhancer in 
driving KLF6 expression  
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4.1 Introduction  
In the previous chapter 3, it was demonstrated that KLF6 was an important transcriptional 
regulator that involved in supporting ccRCC growth both in vitro and in vivo. This was well-
aligned with its high expression and association with one of the strongest super enhancer in 
ccRCC. Whether this adjacent super enhancer locus actually drove KLF6 expression in ccRCC 
remained to be investigated. Enhancer/super enhancer can activate the expression of distant 
genes that are located thousands of base pairs away. Therefore, it was crucial to test and confirm 
whether this super enhancer region plays a role in supporting KLF6 expression in ccRCC which 
was the main focus of this chapter. To functionally investigate the link between this super 
enhancer and regulation of KLF6 expression in ccRCC, CRISPRi tool was employed to 
inactivate several constituent enhancers within the super enhancer locus. This was followed by 
assessing the KLF6 expression level upon repressing the activity of these enhancers. In addition, 
the CRISPR-Cas9 mediated deletion of large segment of the super enhancer region was also 
performed in order to test the role of this super enhancer in driving KLF6 expression.  
As discussed in Chapter 1 (section 1.16), cancer-associated super enhancers can be 
sensitive to perturbation of its constituent enhancers or regulatory components that maintain the 
super enhancer landscape such as the BRD4 and CDK7. Repressing the activity of the 
constituent enhancers can disrupt the super enhancer and in some cases, even would result in the 
super enhancer complete inactivation. Thus, targeting super enhancer has been widely explored 
as an alternative treatment option for cancer due to its sensitivity to perturbation as well as the 
cancer cells high dependency towards the super enhancer-driven genes. Therefore, it was 
interesting to examine whether this KLF6-associated super enhancer would also be sensitive to 
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perturbation in the activity of its constituent enhancers, or perhaps this super enhancer locus acts 
in a robust fashion to drive KLF6 expression in ccRCC.   
Multiple transcription factors can bind the super enhancer region to co-regulate the 
expression of their downstream targets. Given the prominent role of the transcription factor 
HIF2A in driving ccRCC pathogenesis, works in this chapter also focused on investigating 
whether there was any link between the ccRCC-initiating VHL-HIF2A pathway and the 
modulation of KLF6 expression in ccRCC. This was initially done by examining the correlation 
between the EPAS1-encoded HIF2A and KLF6 expression in the ccRCC RNA-Seq TCGA data 
set which will be discussed in further details in the results section below.  
 
4.2 Results 
4.2.1 CRISPRi-mediated super enhancer inactivation  
The CRISPRi and tandem sgRNAs approaches were employed to inactivate several 
distinct enhancers within the KLF6 super enhancer locus in the 786-M1A cells. Previous study in 
the lab has demonstrated that these strategies were highly efficient and specific in targeting the 
distal enhancer regions196. The H3K27ac ChIP-Seq track in figure 35A shows the targeted 
regions in which these regions were named as iSE-1 – iSE-5. In order to design the sgRNAs 
targeting these regions, the p300 ChIP-Seq data, previously generated by Paulo Rodrigues, were 
used as a guide196. As a transcriptional co-factor, p300 is a marker for enhancer region. p300 
peaks are found in the valley of H3K27ac signals in which this region is considered to be the 
transcription factors binding site148. In total, five independent tandem sgRNAs targeting the iSE-
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1 – iSE-5 regions were designed. Figure 35B exemplified the tandem sgRNAs construct 
targeting the p300 peak in the valley of H3K27ac iSE-2 region. Also shown is the dCas9-KRAB 
protein recruitment to the p300 region bound by the two sgRNAs construct.   
 
 
 
 
 
 
 
 
 
 
Figure 35: Strategy for the CRISPRi-mediated inactivation of the KLF6-associated super 
enhancer. (A) Several constituent enhancer regions, iSE-1 – iSE-5, targeted by CRISPRi. (B) 
Tandem sgRNAs approach targeting the p300 peak in the valley of H3K27ac iSE-2 region.    
 
The 786-M1A CRISPRi cells were transduced with either one of the iSE-1–iSE-5 tandem 
sgRNAs construct. For control, the 786-M1A CRISPRi cells were transduced with the tandem 
non-targeting control construct. I subsequently performed the H3K27ac chromatin 
immunoprecipitation on each of these cells. The ChIP-Seq libraries were prepared by Paulo 
A 
B 
118 
 
Rodrigues whereby the sequencing data were subsequently analysed by Sakari Vanharanta. In 
agreement with previous study in the lab, the combination of CRISPRi and tandem sgRNAs 
targeting approaches were efficient in specifically repressing the activity of their respective 
targeted region. This was marked by a complete loss of H3K27ac signals, marker for an active 
enhancer, at each of this targeted region (Figure 36A). In parallel, I also performed ChIP-qPCR 
on the purified H3K27ac ChIP DNA above and found profound reduction in H3K27ac 
occupancy at each of the inactivated enhancer region, thus validating the ChIP-Seq data (Figure 
36B).  
 
 
 
 
 
 
Figure 36: CRISPRi high efficiency in repressing the activity of constituent enhancers. (A) 
H3K27ac ChIP-Seq signal in the KLF6 locus. The CRISPRi-targeted enhancer regions, iSE-1 –
iSE-5, are indicated by the boxes. (B) H3K27ac ChIP-qPCR of the CRISPRi-inactivated iSE-1 – 
iSE-5 enhancers regions.   
 
In contrast to the previous reports that cancer-associated super enhancers can be sensitive 
to perturbation of their constituent enhancers, there was no interdependency observed between 
individual enhancers within this KLF6-associated super enhancer locus (Figure 36A). Rather, 
B A 
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this super enhancer remained strongly active, demonstrating the robustness of this KLF6-
associated super enhancer landscape. Next was to examine whether inactivating these enhancer 
regions would have any effect on the expression of nearby KLF6. There was no massive KLF6 
downregulation by the repression each of this constituent enhancer individually (Figure 37). For 
instance, there was only about 25% and 10% reduction in the KLF6 mRNA level upon 
inactivating the iSE-2 and iSE-3 enhancer region, respectively. Furthermore, inhibiting the iSE-
1, iSE-4 and iSE-5 enhancer regions did not result in KLF6 downregulation, yet the KLF6 
expression level remained similar to the level seen in control cells. These observations seemed to 
suggest that this super enhancer locus operated in a modular fashion to drive KLF6 expression in 
ccRCC. This could possibly explain why inactivating one individual enhancer within this super 
enhancer locus was not sufficient to significantly reduce KLF6 expression in these cells.  
 
 
 
 
 
 
 
Figure 37: KLF6 expression in the individually inactivated iSE-1 – iSE-5 region in 786-M1A 
CRISPRi cells. Average of three experiments. Error bars, SEM. One-way ANOVA with 
Dunnett’s test. * P < 0.05, ** P < 0.005 and *** P < 0.0005. 
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 4.2.2 Combinatorial enhancers targeting 
It was speculated in the previous section that this super enhancer locus acted in a modular 
manner in driving the expression of KLF6 in these cells. Thus, to test this possibility, I attempted 
to inactivate two constituent enhancer regions simultaneously and assessed whether this 
combinatorial targeting approach would lead to further reduction in the KLF6 mRNA level. As 
demonstrated in figure 37, targeting of these enhancers individually did not affect the KLF6 
mRNA level apart from the iSE-2 inactivation where 25% reduction in KLF6 expression level 
was observed. Hence, I chose to inactivate the iSE-2 region in combination with either iSE-3 or 
iSE-4 region. The combinatorial enhancers targeting strategy is illustrated in figure 38A. 
In brief, the 786-M1A CRISPRi cells were first transduced with the iSE-2-BFP-
hygromycin vector. The positive cells were hygromycin-selected, followed by second round of 
transduction with either iSE-3 or iSE-4-eGFP-hygromycin vector. Then, I sorted for the double 
BFP+ and eGFP+ cell populations and subsequently assessed the expression of KLF6 in these 
cells. In line with the hypothesis, combinatorial iSE-2 and iSE-3 inactivation resulted in 40% 
reduction in the KLF6 mRNA level, indicating that there was some additive effect when these 
two enhancers were targeted simultaneously (Figure 38B). Moreover, compared to the effect of 
individual iSE-2 and iSE-4 targeting, simultaneous iSE-2 and iSE-4 inactivation also resulted in 
a slightly better reduction in the expression of KLF6 (Figure 38B). Despite the observed additive 
effect upon combinatorial enhancer targeting, KLF6 expression in these cells remained fairly 
strong.  
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Figure 38: Combinatorial enhancers targeting. (A) Schematic illustrating the combinatorial 
enhancer targeting strategy. (B) KLF6 expression in the 786-M1A cells with combinatorial 
enhancer targeting. Average of three experiments. Error bars, SEM. One-way ANOVA with 
Dunnett’s test. * P < 0.05, ** P < 0.005 and *** P < 0.0005. 
   
The additive effect observed when two enhancers were simultaneously inactivated had 
prompted me to test the effect of targeting all five enhancers at once. The following strategy was 
employed where the 786-M1A CRISPRi cells were lentivirally-transduced with iSE-1, iSE-2, 
iSE-3, iSE-4, and iSE-5-targeting constructs simultaneously, followed by sorting for the top 5% 
BFP+ cell population. The rational of sorting the population of cells with the brightest BFP 
expression was that these cells could express all five tandem sgRNAs constructs (hereinafter 
referred to as iSE combo-expressing 786-M1A cells). Figure 39A shows the FACS gating 
strategy used to sort for these iSE combo-expressing cells. It was observed that concurrent 
inactivation of these five enhancers resulted in about 60% reduction in the KLF6 mRNA level 
B 
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(Figure 39B), further corroborating the hypothesis that this super enhancer region operates in a 
modular fashion to drive KLF6 expression in ccRCC.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Simultaneous inactivation of all five enhancer regions. (A) The gating strategy to sort 
for the iSE combo-expressing 786-M1A cells. (B) KLF6 mRNA expression in the 786-M1A 
cells that had simultaneous inactivation of all five enhancer regions. Average of four 
experiments. Error bars, SEM. Two-tailed Student’s t-test. * P < 0.05, ** P < 0.005 and *** P < 
0.0005.  
A 
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4.2.3 CRISPR-Cas9 mediated deletion of the super enhancer region 
By employing the CRISPRi-based enhancer inactivation, I have demonstrated that this 
super enhancer functions in a modular fashion to drive KLF6 expression. Inactivating individual 
enhancer did not significantly affect the expression of KLF6. However, there was a progressive 
depletion in the KLF6 expression level upon repressing several enhancers simultaneously. To 
further consolidate these findings, I next attempted to delete the entire enhancers cluster 
upstream of KLF6 locus using the CRISPR-Cas9 approach and assessed the KLF6 expression 
level. In order to delete this 113Kb large enhancer region, two independent tandem sgRNAs 
constructs were designed, namely the Del_SE_2 and Del_SE_3. Each of this tandem sgRNAs 
construct expressed two sgRNAs; the first sgRNA was designed to target the 5’ end whereas the 
second sgRNA targeted the 3’ end of this large enhancers cluster. Simultaneous Cas9 recruitment 
and cleavage of its targeted sites could potentially result in large deletion of this enhancers 
cluster. Figure 40A illustrates the strategy employed to delete this enhancer cluster as well as the 
Del_SE_2 tandem sgRNAs construct. .  
The Cas9-expressing 786-M1A and OS-LM1 cells were transduced with either Del_SE_2 
or Del_SE_3 tandem sgRNAs construct. For control, these cells were transduced with the 
tandem non-targeting control construct. This was then followed by assessing the expression of 
KLF6 in all of the cells generated above. However, only relatively modest downregulation of 
KLF6 was observed in the population of these Del_SE_2 and Del_SE_3-transduced 786-M1A 
(Figure 40B) and OS-LM1 cells (Figure 40C). For instance, I observed about 20% and 40% 
reduction in the expression of KLF6 in the Del_SE_2 and Del_SE_3-transduced 786-M1A cells, 
respectively. In addition, the level of KLF6 downregulation in the Del_SE_3-transduced cells 
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was similar to the effect seen when I concurrently inactivated the iSE-2 and iSE-3 enhancer 
regions in the 786-M1A cells (Figure 38B). 
  
 
 
 
 
 
 
 
 
 
 
Figure 40: CRISPR-Cas9-mediated deletion of the large enhancers cluster in the population of 
786-M1A and OS-LM1 cells. (A) Schematic of the tandem sgRNAs construct and strategy used 
for the CRISPR-Cas9-mediated deletion of the large enhancers cluster upstream of KLF6. (B 
and C) KLF6 mRNA expression in the enhancers-deleted (B) 786-M1A and (C) OS-LM1 cells. 
Average of three experiments. Error bars, SEM. One-way ANOVA with Dunnett’s test. * P < 
0.05, ** P < 0.005 and *** P < 0.0005. 
A 
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      The modest reduction in the KLF6 expression level observed in figure 40B-C could 
possibly due to the heterogeneity in the CRISPR-Cas9 targeting efficiency in these cells. It was 
speculated that there were the presence of wild-type cell population as well as population of cells 
that did not harbour the desired homozygous large deletion of this targeted region. Also, it was 
important to point out that deleting such a large segment of DNA on both alleles was inefficient. 
Nonetheless, I decided to pursue this super enhancer deletion experiment in more detail by 
performing single-cell sorting of the Del_SE_3-transduced 786-M1A cells in order to identify 
clones that had a homozygous deletion of the region. The reason for using these Del_SE_3-
transduced 786-M1A cells for single-cell sorting was that these cells had a better KLF6 
downregulation. Then I performed a PCR-based screening strategy to identify single cell-derived 
clones that would harbour a homozygous large deletion of this region. The basis of screening 
strategy was to amplify a small region in the middle of the deleted enhancers cluster (Figure 
41A). In theory, there should not be any amplified product in the clones that harboured a 
homozygous large deletion of this region.   
Several single cell-derived clones were screened using this approach. I identified clones 
with putative homozygous deletion (Del_SE_3_19), heterozygous deletion (Del_SE_3_15) as 
well as wild-type clone with no deletion (Del_SE_3_9) (Figure 41A). The Del_SE_3_19 clone 
could potentially possess the homozygous deletion of the entire enhancers region due to the 
absence of any amplified product. In contrast, the Del_SE_3_9 clone had a strong amplified 
product band, indicating that the targeted enhancers cluster was still intact. The Del_SE_3_15 
clone, on the other hand, could possibly harboured the heterozygous deletion because the 
intensity of the amplified product band appeared to be the intermediate of Del_SE_3_9 and 
Del_SE_3_19 clones. As a positive control, I performed PCR amplification of a region within 
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the EPAS1 locus using the same genomic DNA used in this deletion screening experiment. The 
respective EPAS1 region was able to be amplified in all of the screened clones, thus validating 
the quality of the genomic DNA templates.  
Next, I performed H3K27ac ChIP-Seq on these Del_SE_3_9, Del_SE_3_15 and 
Del_SE_3_19 clones in order to assess the targeted region H3K27ac signals in each of this clone. 
Like the previous ChIP-Seq experiments, the sequencing libraries were prepared by Paulo 
Rodrigues whereby the ChIP-Seq data were analysed by Sakari Vanharanta. In agreement with 
the PCR screening data, there was no H3K27ac signal detected in the Del_SE_3_19 clone, thus 
confirming that this clone indeed harboured a homozygous large deletion of the enhancers 
cluster. There were reduction in H3K27ac signals in the Del_SE_3_15 clone and this was in line 
with the prediction that this clone might carry a heterozygous deletion. Moreover, there were 
high H3K27ac signals observed in the Del_SE_3_9 clone targeted region, consistent with the 
PCR screening data that suggested the enhancers cluster in this clone was still intact (Figure 
41B). Next was to determine whether the KLF6 expression level in these clones correlated with 
their enhancers cluster deletion status. In agreement, there was about 65% reduction in the 
expression of KLF6 in the Del_SE_3_19 clone which carried the homozygous large deletion 
(Figure 41C). The magnitude of KLF6 downregulation in this clone was similar to the effect of 
inhibiting all five enhancer regions simultaneously using the CRISPRi approach (Figure 39B). 
Moreover, there was ~50% reduction in the KLF6 mRNA level in the Del_SE_3_15 clone. As 
expected, the KLF6 expression level in the Del_SE_3_9 wild-type clone was similar to the level 
of the control clone (Figure 41C).  
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Figure 41: Large enhancers cluster deletion in the single cell-derived clones of the Del_SE_3-
transduced 786-M1A cells. (A) PCR-based screening for single cell-derived clones that 
harboured deletion of the large enhancers cluster. Clones shown in red, Del_SE_3_9, 
Del_SE_3_15 and Del_SE_3_10, were selected for further analysis. Green bar shows the 
amplified region for the PCR screening strategy. The EPAS1 locus was used as genomic control 
region. (B) H3K27ac ChIP-Seq signals of the KLF6 locus in clones with no deletion 
(Del_SE_3_9), heterozygous deletion (Del_SE_3_15) and homozygous deletion (Del_SE_3_19). 
(C) Corresponding KLF6 expression in the single cell-derived clones shown in B. Average of 
three experiments. Error bars, SEM. One-way ANOVA with Dunnett’s test. * P < 0.05, ** P < 
0.005 and *** P < 0.0005. 
A 
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Collectively, these data demonstrated that KLF6 expression in ccRCC was indeed 
supported by this nearby super enhancer in a modular fashion. As briefly highlighted in the 
previous introduction section, enhancers or super enhancer can drive the expression of distant 
genes that are located thousands base pairs away. Therefore, I was interested to check whether 
this super enhancer region also drives the expression of other genes along this chromosome 10 
arm. To address this, I performed RNA-Seq on the wild-type Del_SE_3_9 clone that had no 
deletion and the enhancer cluster-deleted Del_SE_3_19 clone. The RNA-Seq data were analysed 
by Sakari Vanharanta in which he compared the expression level of genes that are located within 
the 5Mb window flanking the deleted enhancers cluster in these two clones. The RNA-Seq 
analysis revealed that KLF6 was the most significantly downregulated gene within the 5Mb 
genomic region flanking the 113kb deleted region, further corroborating the previous 
observations that KLF6 was the main target of this super enhancer (Figure 42). 
 
Figure 42: The expression level of genes that are located within a 5Mb window flanking the 
113kb deletion of the super enhancer region. Del_SE_3_19 clone compared to Del_SE_3_9 
clone by RNA-Seq. N=4 for both samples. Blue bar indicates the location of the 113kb deletion.  
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4.2.4 HIF2A modulates KLF6 expression in ccRCC 
Several transcription factors could bind to this super enhancer locus and co-regulate the 
expression of KLF6 in ccRCC. Since the transcription factor HIF2A is a well-established 
oncogenic driver of ccRCC pathogenesis, Sakari Vanharanta and I were prompted to directly 
investigate whether there was any link between HIF2A and KLF6 expression in ccRCC. We first 
began by utilising the publicly available ccRCC TCGA RNA-Seq data and examined whether 
there was any correlation between the expression of EPAS1-encoded HIF2A and KLF6 in the 
ccRCC clinical samples. Interestingly, there was a positive correlation between EPAS1 and 
KLF6 expression in the ccRCC clinical samples in which the correlation value between these 
genes was fairly similar to the correlation value seen between EPAS1 and its well characterised 
downstream target CCND1 (Figure 43). The positive correlation observed between the 
expression of EPAS1 and KLF6 in ccRCC clinical samples might suggest that HIF2A could 
potentially play a role in modulating KLF6 expression in ccRCC.       
 
 
 
 
 
 
Figure 43: Positive correlation between the expressions of EPAS1 with either KLF6 (red) or 
CCND1 (blue) in the clinical TCGA ccRCC data set.  
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To functionally test the link between HIF2A and KLF6, I checked the expression of 
KLF6 in the HA-VHL reintroduced-786-M1A and OS-LM1 cells. In parallel, the expression of 
two well-characterised HIF2A downstream targets CXCR4 and CCND1 were also assessed in 
these HA-VHL reintroduced cells. VHL reintroduction will result in the proteosomal degradation 
of HIF2A that will consequently downregulate the expression of its downstream targets. As 
expected, CXCR4 and CCNDI expressions were significantly attenuated in the HA- VHL 
reintroduced-786-M1A and OS-LM1 cells. There was about 50% reduction in the KLF6 mRNA 
level in both HA-VHL reintroduced-786-M1A and OS-LM1 cells (Figure 44A). In addition, I 
also checked the KLF6 protein expression level in the HA-VHL-reintroduced 786-M1A cells by 
Western blotting. Firstly, the expression of reintroduced exogenous HA-VHL and consequent 
loss of HIF2A expression were confirmed in these cells. Then, in line with the qPCR results, I 
observed KLF6 protein depletion in these HA-VHL reintroduced-786-M1A cells (Figure 44B).   
 
 
 
 
 
 
 
 
 
 
Figure 44: Expression of HIF2A downstream targets in HA-VHL reintroduced cells. (A) The 
expression of KLF6, CXCR4 and CCND1, in the HA-VHL reintroduced-786-M1A and OS-LM1 
cells. Average of three experiments. Error bars, SEM. Two-tailed Student’s t-test. * P < 0.05, ** 
P < 0.005 and *** P < 0.0005. (B) KLF6, HIF2A and VHL immunoblot of 786-M1A cells 
transduced with either HA-VHL or empty vector. 
B A 
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To corroborate these findings, the RNAi approach as described by Fellmann et al197was 
additionally employed to knockdown EPAS1 expression in the 786-M1A cells. The expression of 
CCND1, KLF6 as well as the EPAS1 itself were assessed in these cells. The shRNA-mediated 
EPAS1 inhibition in these 786-M1A cells resulted in the downregulation of CCND1 and KLF6 
expression by about 50% and 30%, respectively (Figure 45). However, the level of CCND1 and 
KLF6 downregulation in this EPAS1 shRNA experiment was not as profound as compared to the 
effect of reintroducing VHL into this 786-M1A cell line (Figure 44A). This could be due to the 
magnitude of EPAS1 knockdown in this RNAi experiment which was downregulated by only 
60%. Hence, it was postulated that a much stronger EPAS1 knockdown in these cells would 
result in more profound CCND1 and KLF6 downregulation. Nevertheless, the findings of HA-
VHL reintroduced and RNAi experiments demonstrated that HIF2A does play a role in 
modulating KLF6 expression in ccRCC.  
 
 
 
 
 
 
Figure 45: shRNA-mediated EPAS1 inhibition. The expression of EPAS1, CCND1 and KLF6 in 
the EPAS1 knockdown 786-M1A cells. Average of two experiments. Error bars, SEM. 
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4.2.5 HIF2A acts through the super enhancer to support KLF6 expression  
A recent study has linked HIF2A with the maintenance of super enhancer in ccRCC198. In 
relation to this, I have demonstrated that KLF6 expression in ccRCC was super enhancer-driven 
and modulated by HIF2A. Thus, to test whether these present findings were in line with the 
aforementioned study above, Sakari Vanharanta and I re-examined the H3K27ac ChIP-Seq data 
of the HA-VHL-reintroduced 786-M1A and OS-LM1 cells, previously generated in the lab by 
Paulo Rodrigues. We assessed the effect of VHL reintroduction and consequent HIF2A loss to 
the H3K27ac patterns of the KLF6 super enhancer locus. There was a reduction in H3K27ac 
signal at one of the enhancer regions downstream of KLF6 locus in both HA-VHL reintroduced-
786-M1A and OS-LM1 cells (Figure 46A). Apart from this, there was no significant difference 
in the general H3K27ac signals pattern of this KLF6 super enhancer locus between the control 
and VHL-reintroduced cells. This was consistent with the previous findings that demonstrated 
the robustness of this particular KLF6-associated super enhancer region (Figure 36A).  
Moreover, examination of the previously generated and analysed 786-M1A and OS-LM1 
HIF2A ChIP-Seq data revealed that HIF2A bound the same enhancer region that had the 
H3K27ac signal reduced upon VHL reintroduction (Figure 46B-C). Based on these HIF2A 
ChIP-Seq data, HIF2A might modulate KLF6 expression in ccRCC by acting through the KLF6 
super enhancer locus. In order to test this possibility, the HIF2A binding site, shown in figure 
46B, was CRISPRi-inactivated in combination with another enhancer region putatively bound by 
HIF2A in the 786-M1A cells. The combinatorial enhancers targeting strategy as described in 
section 4.2.2 above was employed to perform this iHIF2A binding site experiment. The 
CRISPRi-mediated inactivation of these HIF2A binding sites reduced the KLF6 expression level 
by 40% (Figure 46D). This finding was relatively similar to the effect of reintroducing HA-VHL 
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into these 786-M1A cells (Figure 44A). Overall, these findings confirmed that HIF2A binds to 
this super enhancer locus to modulate the expression of KLF6 in ccRCC.   
Figure 46: HIF2A binds the KLF6 super enhancer locus. (A) H3K27ac ChIP-Seq signal of 786-
M1A and OS-LM1 cells transduced with either empty vector or HA-VHL. A region significantly 
altered in both HA-VHL reintroduced cells when compared to the empty vector control 
highlighted by grey box. (B and C) A close up of the region highlighted in panel A together with 
HIF2a ChIP-Seq signals in (B) 786-M1A and (C) OS-LM1 cells. (D) KLF6 expression in the 
786-M1A cells in which two putative HIF2a binding sites were inactivated using CRISPRi. 
Average of three experiments. Error bars, SEM. Two-tailed Student’s t-test. * P < 0.05, ** P < 
0.005 and *** P < 0.0005. 
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4.3 Summary 
One of the primary focus of this chapter was to investigate whether KLF6 expression in 
ccRCC was supported by this nearby super enhancer locus. Using the CRISPRi-based enhancer 
inactivation approach, it was discovered that this super enhancer region drove the expression of 
KLF6. In addition, this super enhancer acted in a modular fashion to drive KLF6 expression in 
ccRCC. Significant reduction in the expression of KLF6 mRNA level was only achieved when 
either several constituent enhancers were inactivated concurrently or by genetic deletion of the 
large enhancers cluster, in which in this present study the CRISPR-Cas9 approach was used to 
delete 113Kb of the enhancers cluster upstream of KLF6 locus.  
Moreover, it was observed that this KLF6 super enhancer was robust and insensitive to 
the perturbations in the activity of its constituent enhancers. There was no interdependency 
between these constituent enhancers. Inactivating one individual enhancer only resulted in the 
loss of H3K27ac signals at the specific targeted region without affecting the general H3K27ac 
signals pattern or the whole super enhancer landscape. This was in contrast to several recent 
studies that have demonstrated the cancer-associated super enhancers are sensitive to 
perturbation of its constituent enhancers or regulatory components that establish or maintain the 
super enhancer landscape. However, such redundancy and robustness are well-aligned with the 
fact that most critical biological processes and developmental transcriptional programmes are 
insensitive to environmental and other incoming variations.  
Last but not least, the works in this chapter also revealed a link between the ccRCC-
initiating VHL-HIF2A pathway and KLF6 expression modulation in ccRCC. Through the 
previously generated VHL reintroduced-cells H3K27ac ChIP-Seq as well as the HIF2A ChIP-
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Seq data, HIF2A was discovered to bind this KLF6 super enhancer locus, in which the HIF2A 
binding sites were identified downstream of the KLF6 locus. Collectively, these data suggested 
that HIF2A supports KLF6 expression by acting through the large KLF6 super enhancer, 
potentially explaining the relatively high KLF6 levels in ccRCC when compared to other tumour 
types (Chapter 3, figure 16).   
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Chapter 5 
Dissecting the transcriptional network 
regulated by KLF6 that supports  
ccRCC growth 
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5.1 Introduction  
 It has been demonstrated in previous chapter that KLF6 expression in ccRCC is 
supported by a robust super enhancer that is partially activated by the ccRCC-initiating VHL-
HIF2a axis. Consistent with the observation that KLF6 is highly expressed in ccRCC clinical 
samples, which reflects its relevance in ccRCC pathogenesis, CRISPR-Cas9 and CRISPRi-
mediated KLF6 perturbation impaired ccRCC cells growth both in-vitro and in-vivo. Therefore, 
as an important transcriptional regulator, inhibition of KLF6 could affect pro-tumourigenic 
transcriptional programs that are involved in supporting ccRCC growth and progression. Hence, 
the works described in this chapter primarily focus on further understanding how KLF6 
supported ccRCC pathogenesis and unravelling the transcriptional programmes regulated by this 
super enhancer-associated transcription factor. Understanding the functions of KLF6 as well as 
its downstream targets/regulated transcriptional networks could be useful in further 
understanding ccRCC pathogenesis and paving the way for the development of better diagnostic 
and/or therapeutic strategies for ccRCC.    
 
5.2 Results 
5.2.1 Assessing the global effect of KLF6 inhibition  
 In order to identify the KLF6 downstream targets, I performed RNA-Seq on the KLF6-
targeted and control 786-M1A CRISPRi cells and assessed the differentially expressed genes 
between these two cell populations at the genome wide level. Sequencing libraries were prepared 
from the total RNA of each cell line (four replicates/cell line) and subjected to Illumina high-
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throughput sequencing. The RNA-Seq data were analysed by Sakari Vanharanta where he 
performed the differential gene expression analysis. The volcano plot in figure 47 shows the 
differentially expressed genes in the KLF6-targeted versus control 786-M1A CRISPRi cells. 
Genes that were significantly downregulated upon KLF6 inhibition are represented in red circles 
whereas the blue circles represent genes that were significantly upregulated in the KLF6-targeted 
cells. As expected, KLF6 was the top most significantly downregulated gene in the KLF6-
targeted cells, thus validating the robustness of the CRISPRi KLF6 targeting approach and most 
importantly the validity of the RNA-Seq data.     
 
 
 
 
 
 
 
 
Figure 47: Volcano plot of the differentially expressed genes in KLF6-targeted versus control 
786-M1A CRISPRi cells. Blue and red circles represent genes that were significantly 
upregulated and downregulated, respectively, in KLF6-targeted cells.  
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5.2.2 KLF6 modulates a part of HIF2A-driven transcriptional program   
 Our collaborator, Dora Bihary and Shamith Samarajiwa, assisted us in further analysing 
the RNA-Seq data where they performed the gene set enrichment (GSEA) and pathway analyses. 
The gene set enrichment analysis revealed a highly significant association between KLF6 
inhibition and downregulation of the canonical hypoxia-response gene set (Figure 48A). It has 
been previously demonstrated that HIF2A acted through the super enhancer region to partially 
activate KLF6 expression in ccRCC. Thus, I hypothesised that some of these HIF2A downstream 
targets might be secondary targets activated by KLF6. To test this hypothesis, I reintroduced 
exogenous KLF6 into the VHL-expressing 786-M1A cells, followed by assessing the expression 
of several known HIF2A downstream targets CCND1, VEGFA and BHLHE40 in these cells. 
Based on the hypothesis, reintroducing exogenous KLF6 into these cells might be able to rescue 
the expression of some of these genes. As expected, proteosomal degradation of HIF2A led to 
reduced expression of CCND1, VEGFA and BHLHE40 in the VHL-reintroduced cells (Figure 
48B). Interestingly, reintroduction of exogenous KLF6 into these cells completely restored 
BHLHE40 expression to the level similar to the control cells. Moreover, there was also slight 
upregulation in the expression of CCND1 and VEGFA, but overall the expression of these genes 
remained low.  
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Figure 48: Significant association between KLF6 depletion and the hypoxia-response gene 
signature. (A) Gene set enrichment analyses shows downregulation of the canonical hypoxia-
response gene set in the KLF6-depleted 786-M1A cells. (B-D) Expression of HIF2A downstream 
targets, (B) CCND1, (C) VEGFA and (D) BHLHE40, in the VHL-expressing 786-M1A cells, 
reintroduced with either empty vector or exogenous KLF6. Average of three experiments. Error 
bars, SEM. One-way ANOVA with Tukey’s range test. * P < 0.05, ** P < 0.005 and *** P < 
0.0005. 
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The reintroduction of exogenous KLF6 was only able to completely restore BHLHE40 
expression in the VHL-expressing cells. Hence, I focused on further investigating KLF6 
involvement in regulating the expression of this gene. I first checked the expression of 
BHLHE40 in the KLF6-depleted 786-M1A CRISPRi using qPCR. It was observed that the 
expression of this gene was downregulated in these cells, consistent with the KLF6 possible role 
in modulating BHLHE40 expression in ccRCC. Moreover, reintroduction of exogenous KLF6 
into these KLF6-depleted 786-M1A CRISPRi cells was able to restore BHLHE40 expression to 
the level seen in the control cells (Figure 49A-B), thus confirming that KLF6 operates upstream 
of BHLHE40. Taken these data together, a part of HIF2A downstream targets are secondary 
targets whose expression are regulated by the HIF2A transcriptional effector KLF6.    
 
 
 
 
 
 
 
 
Figure 49: KLF6 modulates the expression of BHLHE40. (A) Expression of KLF6 and 
BHLHE40 in the KLF6-depleted 786-M1A cells. Average of three experiments. Error bars, SEM. 
One-way ANOVA with Dunnett’s test. * P < 0.05, ** P < 0.005 and *** P < 0.0005. (B) 
BHLHE40 expression in the KLF6-depleted 786-M1A cells reintroduced with either empty 
A B 
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vector or exogenous KLF6. Average of three experiments. Error bars, SEM. One-way ANOVA 
with Tukey’s range test. * P < 0.05, ** P < 0.005 and *** P < 0.0005. 
 
5.2.3 Deregulation of lipid homeostasis pathways in KLF6-targeted cells   
Despite being a part of the VHL-HIF2a pathway, it was worth to note that the phenotype 
of KLF6-targeted cells differed from the VHL-reintroduced cells in vitro19. As demonstrated in 
Chapter 3, KLF6 inhibition resulted in impaired cells growth whereas the VHL-reintroduced 
cells, which have the HIF2A degraded, do not exhibit a proliferative defect under standard tissue 
culture conditions. Hence, it was postulated that the observed growth defect of the KLF6-
inhibited cells could be due to the perturbation of “unknown” transcriptional programs that are 
directly regulated by the KLF6. To identify potential KLF6 downstream effectors that could 
explain the observed phenotypic effect, unbiased pathway analysis was performed on the RNA-
Seq data by our collaborator in order to look for pathways that were significantly deregulated 
upon KLF6 inhibition. Pathways related to lipid homeostasis that include cholesterol, 
triacylglycerol and oleate biosynthesis were among the top most significantly deregulated 
pathways in these KLF6-depleted 786-M1A cells (Figure 50A). In addition, the heatmap in 
figure 50A highlights downregulation of several key genes that involve in the cholesterol 
biosynthesis pathway in these cells.    
In agreement, the gene set enrichment analysis revealed a highly significant association 
between genes that were downregulated upon KLF6 depletion and those participated in 
cholesterol homeostasis (Figure 50B). I also checked the expression level of genes that 
participate in each intermediate steps of the triacylglycerol and cholesterol biosynthesis 
pathways in which these pathways are illustrated in figure 50C. This targeted analysis revealed 
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that most of these genes were downregulated in the KLF6-depleted cells. The fold change 
downregulation of these genes was represented in different shade of blue. Downregulation of 
SREBF1 and SREBF2, two critical transcription factors that support the expression of many lipid 
homeostasis-associated genes, were also observed in the cells that had KLF6 knockdown. 
Analysis of publicly available SREBF1 and SREBF2 ChIP-Seq datasets, as well as literatures 
search, by our collaborator Dora Bihary and Shamith Samarajiwa revealed that the regulatory 
region of these downregulated genes were bound by the transcription factor SREBF1 and/or 
SREBF2 (Figure 50C).  
To validate these RNA-Seq findings, qPCR was performed in order to assess the 
expression level of SREBF1 and SREBF2 as well as SCD and LSS in these KLF6-targeted 786-
M1A CRISPRi cells. SCD and LSS are among the key enzymes that are involved in the 
intermediate steps of triacylglycerol and cholesterol biosynthesis pathways, respectively. qPCR 
analysis confirmed the downregulation of these genes upon KLF6 inhibition in these 786-M1A 
cells (Figure 50D). To determine whether these transcriptional changes were translated 
phenotypically, I quantified the total cholesterol level of the KLF6-depleted and control 786-
M1A CRISPRi cells. Indeed, a significant reduction in the total cholesterol level was observed in 
the KLF6-depleted cells as compared to the control cells (Figure 50E). Collectively, these 
findings demonstrated that KLF6 plays a role in modulating lipid homeostasis in ccRCC.  
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Figure 50: Deregulation of lipid homeostasis pathway in the KLF6-depleted 786-M1A cells. (A) 
Most significantly deregulated pathways upon KLF6 depletion as determined by Ingenuity 
Pathway Analysis. Highlighted in red are pathways involved in lipid homeostasis. Heatmap 
(right) shows significant downregulation of several key genes in the cholesterol biosynthesis 
pathway. (B) Gene set enrichment analysis shows downregulation of cholesterol homeostasis-
related genes in KLF6-depleted cells. (C) A simplified schematic of triacylglycerol and 
cholesterol biosynthesis pathways. Different shade of blue represents expression level fold 
change in the KLF6-targeted cells. SREBF1 and SREBF2 target genes determined by systematic 
literature analysis (red triangles and circles) and publicly available ChIP-Seq datasets analysis 
(green triangles and circles). (D) Validation of SREBF1, SCD, SREBF2 and LSS expression 
using qPCR. Average of three experiments. Error bars, SEM. One-way ANOVA with Dunnett’s 
test. * P < 0.05, ** P < 0.005 and *** P < 0.0005. (E) Total cholesterol level in the KLF6-
targeted 786-M1A cells. Average of three experiments. Error bars, SEM. One-way ANOVA with 
Tukey’s range test. 
 
5.2.4 Lipid homeostasis perturbation impairs ccRCC cells growth   
 Lipid metabolism has been shown to play a role in promoting tumourigenesis of various 
cancer types199. Hence, I next examined the effect of perturbing the lipid homeostasis pathways 
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on ccRCC cells growth. To test this, the CRISPRi combinatorial targeting approach was 
employed to simultaneously inhibit SREBF1 and SREBF2 expression in the 786-M1A cells. Two 
tandem sgRNAs constructs were designed, namely the iSREBF1/2 combo 1 and combo2. Each 
of these constructs expressed two independent sgRNAs, one targeting SREBF1 while the other 
targeting SREBF2. There was downregulation in the expression of both SREBF1 and SREBF2 in 
these iSREBF1/2–transduced 786-M1A CRISPRi cells (Figure 51A). Then the total cholesterol 
level of these cells was determined. I found that there was a significant reduction in the total 
cholesterol level in these SREBF1/2-targeted 786-M1A cells (Figure 51B). This was indeed in 
line with the central role of transcription factor SREBF1 and SREBF2 in regulating the lipid 
homeostasis pathways. Next, the proliferation rate of these SREBF1 and SREBF2-targeted cells 
was assessed using the previously described competitive proliferation assay. Simultaneous 
SREBF1 and SREBF2 targeting in the 786-M1A cells reduced the cells growth, which was in line 
with the phenotype of inhibiting KLF6 in these cells (Figure 51C).   
 
 
 
 
 
 
 
 
 
 
Figure 51: Targeting SREBF1 and SREBF2 reduced ccRCC cells growth. (A) (Top) Illustration 
of the tandem sgRNAs construct used for combinatorial targeting of SREBF1 and SREBF2 by 
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CRISPRi approach. (Bottom) SREBF1 and SREBF2 expression in SREBF1 and SREBF2-targeted 
786-M1A cells. Average of two experiments. Error bars, SEM. (B) Total cholesterol level in the 
SREBF1 and SREBF2-targeted 786-M1A cells. Average of three experiments. Error bars, SEM. 
One-way ANOVA with Tukey’s range test. (C) Competitive proliferation assay of the SREBF1 
and SREBF2-targeted 786-M1A cells. Relative fraction of iSREBF1/2 combo and NTC-
transduced cells, normalised to day 0, compared to untransduced cells. Average of three 
replicates. Two-way ANOVA with Tukey’s range test.  
 
In addition to targeting SREBF1 and SREBF2 genetically, I also investigated the effect of 
treating ccRCC cells with fatostatin, a small molecule that inhibits SREBF1 and SREBF2 
activation200, on the cells growth. Downregulation of SCD and LSS, downstream targets of 
SREBF1 and SREBF2, respectively, were observed after 48 hours of fatostatin treatment, 
indicating the inhibition of SREBF1 and SREBF2 activation in these fatostatin-treated cells 
(Figure 52A). The cells treated with fatostatin had slower growth compared to the vehicle-treated 
cells in a dose-dependent manner (Figure 52B). To consolidate these findings, I also examined 
the effect of treating 786-M1A cells with simvastatin which is the HMG-CoA reductase 
inhibitor. HMG-CoA reductase is one of the key enzymes that involve in the cholesterol 
biosynthesis pathway. Simvastatin-mediated inhibition of the cholesterol biosynthesis pathway 
impaired the cells growth (Figure 52C). It was also observed that treating the cells with higher 
concentration of simvastatin resulted in cell death. Collectively, these findings demonstrated the 
role of lipid metabolism in supporting ccRCC pathogenesis and revealed a link between KLF6, 
lipid homeostasis pathways and ccRCC cell growth. Inhibition of KLF6 led to the deregulation 
of lipid homeostasis pathways that consequently reduced the ccRCC cells rate of proliferation. 
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Figure 52: Chemical inhibition of the lipid homeostasis pathway impaired ccRCC cells growth. 
(A) Expression of SCD and LSS in 786-M1A cells treated with fatostatin for 48 hours as 
measured by qPCR. Average of two experiments. Error bars, SEM. (B) Proliferation of 786-
M1A cells treated with either vehicle or indicated concentrations of fatostatin. Average of six 
technical replicates. Two-way ANOVA with Tukey’s range test. (C) Proliferation of 786-M1A 
cells treated with either vehicle or indicated concentrations of simvastatin. Average of four 
technical replicates. Two-way ANOVA with Tukey’s range test. 
 
5.2.5 Co-regulation of lipid homeostasis by KLF6 and mTORC1 
 Next, I wanted to investigate the mechanism on how KLF6 would involve in modulating 
the lipid homeostasis pathways in ccRCC. The mTORC1 complex has been shown to modulate 
lipid metabolism by regulating the expression and activity of SREBF1 and SREBF281,82. Thus, I 
hypothesised that the coordinated downregulation of lipid homeostasis genes upon KLF6 
inhibition could be the consequence of perturbed mTORC1 activity in these cells. In addition to 
this speculation, the previous findings also seemed to suggest that KLF6 could operate upstream 
and positively regulate the expression of these genes. 
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In order to distinguish between these two possibilities, I first tested whether the mTORC1 
complex regulates SREBF1 and SREBF2 activity in ccRCC. The 786-M1A cells were treated 
with Torin1, a potent mTOR antagonist, followed by checking the expression of SREBF1 and 
SREBF2 matured form. As expected, Torin1 strongly inhibited mTORC1 activity that was 
demonstrated by the absence of phosphorylated p70 S6 kinase (P-p70 S6 kinase) and consequent 
loss of ribosomal S6 phosphorylation (P-S6), a substrate of the P-p70 S6 kinase (Figure 53A). As 
described in the Chapter 1 (section 1.11), P-p70 S6 kinase and P-S6 were used as the read-out for 
mTORC1 activity. I also observed the decreased expression of SREBF1 and SREBF2 active 
form in the Torin1-treated cells (Figure 53A), which was in line with the previous reports that 
have demonstrated mTORC1 role in regulating SREBF1 and SREBF2 activation. Additionally, 
inhibition of SREBF1 and SREBF2 activation was translated into a reduction in total cholesterol 
level in the Torin1-treated 786-M1A cells (Figure 53B).  
I also assessed the SREBF1, SREBF2, SCD and LSS mRNA level in the Torin1-treated 
786-M1A cells using qPCR. In line with the reduced SREBF1 and SREBF2 activity observed in 
figure 53A, the expression of their downstream targets SCD and LSS was also downregulated in 
a dose-dependent manner. In addition, I found that the Torin1 treatment also resulted in the 
downregulation of SREBF1 expression (Figure 53C). However, an increase in the SREBF2 
expression level was observed, which was in contrast to the effect seen upon KLF6 inhibition 
where the SREBF2 expression was downregulated in the KLF6-targeted cells (Figure 50D). 
Thus, while this data demonstrated that mTORC1 inhibition indeed phenocopied the effects of 
KLF6 depletion at the level SREBF1 and SREBF2 downstream targets, an increase in the 
SREBF2 mRNA level possibly suggested that KLF6 directly regulates the expression of this 
gene. 
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Figure 53: The mTORC1 complex regulates SREBF1 and SREBF2 activity in ccRCC. (A) 
mTORC1, SREBF1 and SREBF2 activity in the 786-M1A cells as determined by 
immunoblotting after Torin1 treatment for 48 hours. (B) Total cholesterol level in the 786-M1A 
cells treated with Torin1 for 48 hours. Average of three experiments. Error bars, SEM. One-way 
ANOVA with Tukey’s range test. (C) Expression of SREBF1, SCD, SREBF2 and LSS in 786-
M1A cells treated with Torin1 for 48 hours as measured by qPCR. Average of three experiments. 
Error bars, SEM. One-way ANOVA with Dunnett’s test. * P < 0.05, ** P < 0.005 and *** P < 
0.0005. 
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To test whether KLF6 directly regulates the expression of these lipid homeostasis genes, I 
reintroduced exogenous flag-KLF6 and flag-eGFP into the KLF6-depleted 786-M1A CRISPRi 
cells. This was followed by performing flag ChIP-Seq in order to identify regions that are bound 
by KLF6. This flag-KLF6 ChIP-Seq strategy was employed because there was no suitable KLF6 
antibody for performing the KLF6 ChIP experiment. The expression of the reintroduced flag-
KLF6 and flag-eGFP were confirmed in the respective cells by immunoblotting (Figure 54A). 
Then, I assessed the expression of LSS in these cells in order to test whether the exogenous flag-
KLF6 construct was functional. Indeed, downregulation of LSS was observed in the KLF6-
depleted cells that were reintroduced with flag-eGFP, which was consistent with both RNA-Seq 
and qPCR validation data. The reintroduction of flag-KLF6 into these KLF6-depleted cells was 
able to restore LSS expression to the level similar to flag-eGFP-transduced control cells, thus 
confirming the functionality of this exogenous flag-KLF6 construct (Figure 54B). 
 
Figure 54: Reintroduction of flag-KLF6 and flag-eGFP into the KLF6-depleted cells. (A) 
Expression of flag-KLF6 and flag-eGFP in the respective cells. (B) LSS expression in the KLF6-
depleted 786-M1A cells, transduced with either flag-KLF6 or flag-eGFP. Average of three 
technical replicates is shown. Error bars, SEM. 
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Analysis of the flag ChIP-Seq data by Sakari Vanharanta revealed about 11,000 KLF6 
peaks in which these peaks were distributed across different genomic regions. The most 
prominent region was the promoter with an enrichment for a motif known to be bound by the 
members of KLF family (Figure 55A). In concordant with the RNA-Seq and qPCR validation 
data, the proximal regulatory regions of SREBF1, SREBF2, SCD and LSS were found to be 
bound by KLF6, which was indicated by the presence of KLF6 peaks at these regions (Figure 
55B –E). Thus, these ChIP-Seq data confirmed the hypothesis that KLF6 directly regulates the 
expression of these genes in ccRCC. 
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Figure 55: Genomic regions bound by the flag-KLF6. (A) (Left) Genomic distribution of the 
11487 KLF6 peaks relative to known transcripts. (Right) The most significant DNA motif 
detected using MEME de novo motif discovery on the 500 most significant KLF6 peaks. (B-E) 
Enrichment of flag-KLF6 signal in the genomic regions of (B) SREBF1, (C) SCD, (D) SREBF2 
(E) and LSS. Arrows indicate the direction of transcription.  
 
5.2.6 Impaired mTORC1 activity in the KLF6-targeted ccRCC cell lines  
 I have demonstrated that KLF6 directly regulates the expression of lipid metabolism 
genes as well as possible involvement of the mTORC1 complex in modulating the lipid 
homeostasis pathways in ccRCC. To further investigate the contributing role of mTORC1 
complex to the observed phenotypes, the level of mTORC1 activity in the KLF6-depleted and 
control 786-M1A cells was assessed. I hypothesised that KLF6 inhibition could have an effect on 
the cells mTORC1 activity that would consequently lead to the deregulation of lipid homeostasis 
pathways. Hence, to test this hypothesis, the expression level of P-p70 S6 kinase and P-S6, read-
out for mTORC1 activity, were assessed in the KLF6-depleted and control cells upon serum 
starvation overnight. 
 In line with the hypothesis, I found that the mTORC1 activity of the KLF6-depleted cells 
was attenuated after an overnight serum starvation, demonstrated by significant reduction in the 
expression of P-p70 S6 kinase and P-S6. In contrast, the control cells were able to sustain the 
expression of these phosphorylated proteins even under the serum-starved condition (Figure 
56A). This could possibly be due to either the higher basal level of mTORC1 activity or the 
presence of unknown factor that was able to sustain the mTORC1 activity in these 786-M1A 
control cells. I further validated this finding by examining the effect of KLF6 inhibition on the 
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mTORC1 activity of other VHL-mutant ccRCC cell lines, the OS-LM1 and UOK101. I observed 
that the KLF6-depleted OS-LM1 and UOK101 cells also had reduced expression of P-S6 (Figure 
56B-C), thus confirming the hypothesis that KLF6 inhibition in ccRCC cells led to mTORC1 
activity impairment in these cells. Collectively, these findings revealed KLF6 dual roles in 
modulating lipid homeostasis in ccRCC; 1) KLF6 directly regulates the expression of lipid 
homeostasis genes and 2) KLF6 modulates mTORC1 activity in ccRCC in which the mTORC1 
complex plays a role in SREBF1 and SREBF2 activation and subsequent regulation of the lipid 
homeostasis pathway.  
 
 
Figure 56: Impaired mTORC1 activity in KLF6-depleted ccRCC cell lines. (A-C) mTORC1 
activity in KLF6-depleted (A) 786-M1A, (B) OS-LM1 and (C) UOK101 cells.   
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5.2.7 mTORC1 activity supports ccRCC growth in vitro and in vivo.  
 Impaired mTORC1 activity was possibly another contributing factors that led to the 
reduced proliferation rate of these KLF6-targeted cells. To further validate the role of mTORC1 
complex in supporting ccRCC growth, the effect of treating the 786-M1A cells with everolimus, 
a mTORC1 complex inhibitor, on the cells growth was assessed. I first checked the expression of 
P-p70 S6 kinase and P-S6 in the 786-M1A cells 48 hours post-everolimus treatment. The 
mTORC1 activity was attenuated in the everolimus-treated 786-M1A cells in a dose-dependent 
manner (Figure 57A). It was observed that the everolimus-treated 786-M1A cells grew slower 
compared to the cells treated with the vehicle control (Figure 57B), thus validating the role of 
mTORC1 complex in supporting the growth of these cells in vitro.  
I also investigated the effect of everolimus treatment on the ccRCC tumour growth in 
vivo. The 786-M1A cells were subcutaneously injected into each flank of athymic nude mice as 
previously described in Chapter 3. After the tumours had become palpable, the mice were 
separated into two groups; the experimental and control groups. Mice in the experimental group 
were orally treated with everolimus (5mg/kg) while the control group mice were administered 
with vehicle control. The assay was performed daily for 21 days where the tumours growth were 
monitored via calliper measurement. At the end of the assay, I found that the tumours of the 
everolimus-treated mice were smaller compared to tumours of vehicle-treated mice, indicating 
the tumours impaired growth upon the treatment with everolimus (Figure 57C). Collectively, 
these findings confirmed the role of mTORC1 complex in supporting the 786-M1A cells growth 
both in vitro and in vivo.  
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Figure 57: mTORC1 complex perturbation impairs ccRCC cells growth in vitro and in vivo. (A) 
mTORC1 activity in the everolimus-treated 786-M1A cells. (B) Proliferation of 786-M1A cells 
treated with either vehicle or indicated concentrations of everolimus. Average of four technical 
replicates. Two-way ANOVA with Tukey’s range test. (C) Tumours volume from 786-M1A 
cells in mice fed with everolimus or vehicle pre- and 21 days post treatment. N=12 
tumours/group. One-way ANOVA with Tukey’s range test.  
 
5.2.8 KLF6 modulates mTORC1 activity via transcriptional regulation of PDGFB  
 Next, I sought to investigate how KLF6 would involve in promoting mTORC1 activity in 
ccRCC. As previously speculated, there might be the presence of unknown factors that would 
contribute to the sustained mTORC1 activity in the 786-M1A control cells under the serum-
starved condition. This could possibly explain the difference in the level of mTORC1 activity 
between the control and KLF6-depleted cells. However, to our knowledge, there has been no 
report linking KLF6 and the mTORC1 signalling pathway. Thus, in order to identify the 
potential mediator between KLF6 and mTORC1 signalling pathway, I re-examined the RNA-Seq 
data of the KLF6-depleted 786-M1A cells. I specifically looked for the downregulated genes that 
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were either known mTORC1 agonist or have been linked with mTORC1 signalling pathway in 
general. From the RNA-Seq data, there was a significant downregulation of PDGFB expression, 
a known activator of the mTORC1 signalling pathway, in the KLF6-depleted cells. Moreover, 
previous report has shown that PDGFB was able to modulate the SREBF1 and SREBF2 
expression and activity201. Based on these evidences, I hypothesised that KLF6 potentially 
modulates mTORC1 activity in ccRCC by transcriptionally regulating the expression of its 
agonist PDGFB.   
I then validated this RNA-Seq finding by checking the expression of PDGFB in the 
independent set of KLF6-depleted 786-M1A cells. On top of this, I also assessed PDGFB 
expression level in the KLF6 knockdown OS-LM1 and UOK101 cells. In line with the RNA-Seq 
data, the qPCR analysis confirmed that there was downregulation in the expression of PDGFB in 
the KLF6-depleted 786-M1A, OS-LM1 and UOK101 cells (Figure 58A-C). Importantly, the 
reintroduction of either exogenous KLF6 or flag-KLF6 into the KLF6-depleted 786-M1A cells 
was able to rescue the PDGFB expression (Figure 58D and 59A). This data seemed to suggest 
that the impaired mTORC1 activity upon KLF6 inhibition in ccRCC cells was potentially due to 
the downregulation of PDGFB expression in these cells. 
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Figure 58: Downregulation of mTORC1 agonist PDGFB in the KLF6-depleted ccRCC cell 
lines. (A) PDGFB expression in KLF6-depleted 786-M1A cells as measured by qPCR. Average 
of three experiments. Error bars, SEM. One-way ANOVA with Dunnett’s test. (B-C) PDGFB 
expression in KLF6-depleted (B) OS-LM1 and (C) UOK101 cells. Average of three technical 
replicates. Error bars, SEM. (D) PDGFB expression in the KLF6-depleted 786-M1A cells, with 
the reintroduction of either empty vector or exogenous KLF6. Average of four experiments. 
Error bars, SEM. One-way ANOVA with Tukey’s range test. * P < 0.05, ** P < 0.005 and *** P 
< 0.0005 
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The RNA-Seq and qPCR data as well as the exogenous KLF6 rescue experiment 
indicated that KLF6 potentially operated upstream of PDGFB in ccRCC. I next wanted to 
determine whether PDGFB was a direct KLF6 downstream target. To investigate this, I 
examined the previously generated flag-KLF6 ChIP-Seq data and found that the PDGFB 
proximal regulatory region contained KLF6 peaks, signifying KLF6 binding at this region 
(Figure 59B). The corresponding ChIP-qPCR analysis showed the enrichment of flag-KLF6 at 
the PDGFB proximal regulatory region, thus validating the ChIP-Seq finding (Figure 59C). In 
sum, the PDGFB qPCR as well as the flag-KLF6 ChIP-Seq and ChIP-qPCR data strongly 
demonstrated that KLF6 directly regulates the expression of mTORC1 signalling agonist 
PDGFB in ccRCC cells. Sakari Vanharanta and I subsequently tested whether these in vitro 
findings were clinically relevance and reflected in the actual ccRCC clinical samples. Analysis of 
the ccRCC TCGA RNA-Seq data revealed that ccRCC patients with high level of KLF6 
expression also expressed higher levels of PDGFB (Figure 59D), which was aligned with our in 
vitro findings that KLF6 transcriptionally regulated PDGFB expression in ccRCC.   
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Figure 59: KLF6 directly regulates the expression of PDGFB in ccRCC. (A) PDGFB expression 
in KLF6-depleted 786-M1A cells, reintroduced with either exogenous flag-KLF6 or flag eGFP. 
Average of three technical replicates. Error bars, SEM. (B) Flag ChIP-Seq signal at the PDGFB 
proximal regulatory region. (C) Flag ChIP-qPCR of the PDGFB proximal regulatory region. 
Average of two of experiments. Error bars, SEM (D) PDGFB expression (RSEM normalised 
counts) in clinical ccRCC samples with either high (top 50%) or low (bottom 50%) KLF6 
expression. Mann Whitney U test.  
 
5.2.9. PDGFB activates mTORC1 signalling pathway in ccRCC 
I have thus far provided evidences that 1) KLF6 directly regulates PDGFB expression 
and 2) the impaired mTORC1 activity in the KLF6-targeted cells was the consequence of 
PDGFB downregulation in these cells. Nonetheless, to further consolidate these findings, the 
role of PDGFB in regulating the mTORC1 signalling pathway in ccRCC was directly tested. To 
address this, PDGFB was targeted in the 786-M1A cells using the CRISPRi approach, followed 
C D 
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by checking the expression of mTORC1 activity surrogate markers in these cells. PDGFB was 
targeted using the single sgRNA targeting approach where two sgRNA constructs were designed, 
iPDGFB_1 and iPDGFB_2. Downregulation of PDGFB was confirmed in the iPDGFB-
transduced 786-M1A cells (Figure 60A). The mTORC1 activity of these cells were assessed after 
an overnight serum starvation. It was found that PDGFB inhibition impaired the mTORC1 
activity of these cells (Figure 60B), phenocopying the effect of KLF6 inhibition in ccRCC cell 
lines (Figure 56A-C). This finding validated the role of PDGFB in regulating the mTORC1 
signalling pathway in ccRCC. 
 
 
 
 
 
 
 
Figure 60: PDGFB regulates mTORC1 signalling pathway in ccRCC. (A) PDGFB expression in 
PDGFB-depleted 786-M1A cells. Average of three experiments. Error bars, SEM. One-way 
ANOVA with Dunnett’s test. (B) mTORC1 activity in PDGFB-depleted 786-M1A cells. 
 
Finally, I tested the effect of supplementing the KLF6-targeted 786-M1A cells with 
human recombinant PDGFB. Based on the previous findings, I postulated that the recombinant 
PDGFB supplementation would be able to re-stimulate the mTORC1 signalling pathway in these 
A B 
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KLF6-targeted cells under the serum-starved condition. Hence, the KLF6-targeted and control 
786-M1A CRISPRi cells were serum-starved overnight and treated with 10ng/mL human 
recombinant PDGFB for an hour on the following day. Then, I assessed these cells mTORC1 
activity. In line with the hypothesis, supplementation with recombinant PDGFB was able to re-
stimulate the mTORC1 signalling pathway in these KLF6-targeted cells, demonstrated by an 
increased expression of  P-p70 S6 kinase and P-S6 in these cells as compared to the vehicle-
treated cells (Figure 61A-B). This validated the role of KLF6-PDGFB axis in supporting the 
mTORC1 activity in ccRCC.  
A 
B 
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Figure 61: Recombinant PDGFB supplementation re-stimulates mTORC1 activity in the KLF6-
depleted cells. (A and B) Expression of (A) P-p70 S6 kinase and (B) P-S6 in the KLF6-depleted 
786-M1A cells supplemented with either human recombinant PDGFB or vehicle control for 1 
hour. Graph on the right shows quantification of the immunoblot bands. 
 
5.3 Summary 
 Through transcriptomic profiling and subsequent functional assays, I unraveled a network 
of transcriptional programs linking the super enhancer-regulated transcription factor KLF6 with 
the modulation of lipid homeostasis and mTORC1 signalling pathways in ccRCC. These data 
suggested that the proliferative defect observed upon KLF6 inhibition was the consequence of 
impaired lipid homeostasis and mTORC1 signalling pathways in these cells. This was supported 
by the findings that direct perturbation of lipid homeostasis as well as the mTORC1 signalling 
pathways reduced ccRCC cells growth, phenocopied the effect of targeting KLF6 in ccRCC cells 
(discussed in Chapter 3).  
 Further investigations into the mechanism on how KLF6 could be involved in modulating 
the lipid homeostasis pathways in ccRCC revealed that KLF6 regulates the expression of some 
lipid homeostasis genes that include the SREBF1 and SREBF2, two critical transcriptional 
regulators of lipid metabolism. Then I discovered that the mTORC1 signalling pathway also 
contributed to the deregulation of lipid homeostasis pathways in the KLF6-targeted cells. I had 
first prompted to check the involvement of the mTORC1 signalling pathway based on previous 
reports81,82 that have demonstrated the role of mTORC1 complex in modulating lipid metabolism 
via the regulation of SREBF1 and SREBF2 activity. In line with the previous reports81,82, 
impaired mTORC1 activity was observed in the KLF6-targeted cells in which these cells were 
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more sensitive to serum-starvation as compared to the control cells. Taken these observations 
together, deregulation of lipid homeostasis pathways in the KLF6-targeted cells were due to 
downregulation of some lipid homeostasis genes, whose expression were directly regulated by 
KLF6, as well as impaired mTORC1 signalling pathway.  
  In this chapter, the question on how KLF6 was linked to the mTORC1 signalling 
pathway was also investigated. I found that KLF6 inhibition led to the downregulation of 
PDGFB which is a known activator of the mTORC1 signalling pathway. Via exogenous KLF6 
rescue and flag-KLF6 ChIP-Seq and ChIP-qPCR experiments, PDGFB was demonstrated to be a 
direct KLF6 downstream target. Reintroduction of exogenous KLF6 into the KLF6-targeted cells 
was able to restore PDGFB expression in these cells. The flag-KLF6 ChIP-Seq and ChIP-qPCR 
experiments revealed that KLF6 bound to the proximal regulatory region of PDGFB. 
Importantly, supplementing the overnight serum-starved, KLF6-depleted cells with human 
recombinant PDGFB was able to re-activate the mTORC1 signalling pathway in these cells. In 
sum, KLF6 promotes the mTORC1 signalling pathway in ccRCC by transcriptionally regulating 
the expression of one of its agonist PDGFB.      
 In addition to the transcriptional networks described above, the gene set enrichment 
analysis performed by our collaborator found a significant association between KLF6 inhibition 
and downregulation of the canonical hypoxia-response gene signature. This data suggested that 
KLF6 was involved in regulating the expression of some of the known HIF2A downstream 
targets. I tested this by checking whether KLF6 reintroduction into the VHL-expressing ccRCC 
cells was able to restore the expression of several HIF2A downstream targets. It was observed 
that KLF6 reintroduction was able to restore the expression of BHLHE40 to the level seen in the 
control cells. Slight upregulation in the expression of VEGFA and CCND1 was also observed, 
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but the expression level of these genes was still fairly low. Interestingly, it has been shown 
previously that HIF2A drove the expression of KLF6 in ccRCC by acting through the KLF6 
super enhancer locus. Hence, these findings further indicated that some of the HIF2A 
downstream targets are secondary targets that were activated by KLF6. Collectively, through the 
works presented in this chapter, I discovered several transcriptional networks that were regulated 
by KLF6 of which some of these transcriptional programs were essential in supporting ccRCC 
pathogenesis 
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Chapter 6 
Discussion 
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6.1 Introduction  
 The purpose of this study was to identify a novel transcriptional network that plays a role 
in supporting ccRCC pathogenesis with the hope that the gained knowledge could potentially be 
useful for diagnostic and/or therapeutic development. As discussed in Chapter 1, the current 
clinically-approved therapeutic strategies for ccRCC have been those targeting the angiogenesis 
and the frequently hyper-activated mTOR signalling pathways. Nevertheless, objective patients’ 
response rates especially in patients with advanced stage ccRCC towards these treatment options 
are still low. One factor that contributes to the lack of efficient therapies developed for ccRCC is 
the incomplete understanding on ccRCC cellular dependencies or the underlying mechanisms 
that support its progression. Therefore, to address this problem, a better understanding on ccRCC 
pathogenesis is urgently needed given the high mortality and poor prognosis of the advanced 
stage ccRCC. 
6.2 KLF6 expression regulation by a robust super enhancer  
By utilising previously generated active chromatin ChIP-Seq data, a large enhancer 
cluster with enriched H3K27ac signal was identified encompassing the KLF6 locus. As 
demonstrated in Chapter 4, KLF6 expression in ccRCC was found to be regulated by this nearby 
super enhancer. Comprehensive in vitro and in vivo functional assays showed that this super 
enhancer-regulated transcription factor KLF6 was functionally important in supporting ccRCC 
growth. KLF6 inhibition resulted in reduced ccRCC cells proliferation rate both in vitro and in 
vivo. This was in line with reports linking super enhancers and the regulation of critical genes 
including those that support cancer phenotypes149,150.  
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Targeting cancer-associated super enhancers is actively being explored as a potential 
therapeutic strategy in several different cancer types due to reports demonstrating that they may 
be particularly sensitive to perturbations165-167. However, in contrast to what others have 
suggested, I found that this KLF6 super enhancer tolerated the perturbations in the activity of its 
constituent enhancers fairly well. These findings seemed to imply that targeting KLF6 super 
enhancer and its subsequent development as an alternative approach for treating ccRCC could 
potentially be challenging. Yet, this speculation was solely based on several CRISPRi enhancer 
inactivation experiments, thus I cannot eliminate the possibility that this KLF6 super enhancer 
could still remain an attractive therapeutic target for ccRCC. Further interrogation into this super 
enhancer region could possibly lead to the identification of machineries or co-factors that upon 
its targeting would perturb this KLF6 super enhancer landscape and therefore would constitute a 
potential therapeutic avenue. Also, it is appealing to test in the future study whether this KLF6 
super enhancer locus is sensitive to BRD4 or CDK7 inhibition by JQ1 or THZ1, respectively. 
Furthermore, I discovered that this super enhancer locus functions in a modular fashion to 
drive KLF6 expression in ccRCC. Significant reduction in the KLF6 mRNA level was only 
achieved when several constituent enhancers were simultaneously inactivated or large segment 
of this enhancers cluster was deleted. The tight regulation of KLF6 expression by the super 
enhancer was in line with KLF6 high expression in ccRCC clinical samples and its important 
role in supporting ccRCC growth. Moreover, the redundancy and robustness in the regulation of 
KLF6 expression in ccRCC are well-aligned with the fact that most critical biological processes 
and developmental transcriptional programmes are insensitive to environmental and other 
incoming variations133,202. 
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6.3 Identification of KLF6 upstream transcriptional regulators  
   Interestingly, HIF2A was discovered to act through this KLF6 enhancers cluster in 
modulating KLF6 expression in ccRCC. Thus, it is plausible that the accumulation of HIF2A due 
to VHL inactivation in ccRCC consequently contributes to the relatively high expression of 
KLF6 in ccRCC clinical samples as compared to other tumour types. This might also explain the 
observed upregulation of KLF6 expression in ccRCC as compared to normal kidney tissues. 
Through previously generated p300 ChIP-Seq data, several distinct p300 peaks were identified at 
the valley of this super enhancer H3K27ac signals. This region is known to be the transcription 
factor binding site. Thus, in addition to HIF2A, there could be several other important 
transcription factors that bind to this super enhancer region and drive the expression of KLF6 in 
ccRCC. The identification of these transcription factors would give us better insight on how 
KLF6 expression is regulated as well as explaining its upregulation in ccRCC samples as 
compared to the normal kidney tissues. This could also possibly lead to the discovery of factors 
that support the formation and maintenance of this KLF6 super enhancer landscape. The 
discovery of such factor might be beneficial if targeting this KLF6 super enhancer to be further 
explored and developed as an alternative treatment strategy for ccRCC.      
One approach to identify these transcription factors is by performing DNA motif 
discovery within this KLF6 super enhancer locus using the available online tools such as MEME 
and FIMO. These putative transcription factors role in driving KLF6 expression can be assessed 
by perturbing the function of these transcription factors by either CRISPR-Cas9 or CRISPRi, 
followed by assessing the KLF6 mRNA level. Luciferase reporter assay can subsequently be 
employed to confirm the binding of these putative transcription factors to the super enhancer 
locus if they are found to drive KLF6 expression. A very preliminary DNA motif discovery 
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analysis was performed on the iSE-2 revealed a DNA motif known to be bound by the 
transcription factor FOXJ3 at this enhancer region (Figure 62). Also, the FOXJ3 expression was 
found to be highly expressed in ccRCC as compared to other tumour types in the TCGA RNA-
Seq data set. Thus, it is worth to follow-up on this finding in the future as well as identifying 
other transcription factors that bind to this KLF6 super enhancer using the DNA motif discovery 
approach described previously.   
Figure 62: FOXJ3 DNA binding motif at the iSE-2 enhancer region. 
 
In addition to the DNA motif discovery analysis, the candidate transcription factors can 
also be shortlisted by looking into previous studies that have reported or identified any upstream 
regulators of KLF6. For instance, there were studies that demonstrated the role MEF2 family 
transcription factor in regulating KLF6 expression in which this MEF2-KLF6 axis acted as a pro-
survival factor in hippocampal neurons and cardiomyocytes203,204. Therefore, it is interesting to 
test whether this family of MEF2 transcription factors are also involved in regulating KLF6 
expression and functionally relevance in supporting ccRCC pathogenesis.      
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6.4 The pro-tumourigenic role of KLF6 in ccRCC   
There have been opposing reports on the role of KLF6 in different type of 
cancers183,187,189,205. In this present study, KLF6 was discovered to have a pro-tumourigenic role 
in ccRCC. KLF6 inhibition in several VHL-deficient ccRCC cell lines impaired cell growth 
which resulted in the formation of smaller tumours in vivo. Also, the KLF6-targeted 786-M1A 
cells had reduced metastatic lung colonisation capability, which could be the consequence of 
impaired cells growth. Overall, this was an interesting finding because the 786-M1A cells are the 
metastatic sub-population of the 786-O cells, which are aggressive and characterised by a 
significantly enhanced lung colonisation capability173. Nonetheless, these present findings 
contradicted those of Gao et al, who have reported that KLF6 possesses a growth suppressive 
function in ccRCC206. We are not certain of the reasons behind this discrepancy. Technical-wise, 
KLF6 was targeted in this study by utilising both CRISPR-Cas9 and CRISPRi approaches in 
which two independent sgRNA constructs were designed for each targeting approach. I also 
demonstrated that the reintroduction of exogenous KLF6 into these CRISPR-Cas9 and CRISPRi 
KLF6-targeted cells was able to alleviate the cells proliferative defect. These comprehensive 
interrogations on KLF6 function in our model system were to ensure the robustness and 
reliability of our findings. On the other hand, the study that has demonstrated the growth 
suppressive function of KLF6 rely solely on a single siRNA construct206, thus making it difficult 
to exclude any possible off-target effects.  
Also, due to KLF6 high expression and regulation by one of the strongest super enhancer 
in ccRCC, it may possibly be difficult to target and achieve significant reduction in the KLF6 
expression level. Nonetheless, by employing the state-of-the-art CRISPRi in conjunction with 
tandem sgRNAs targeting approaches, I was able to obtain 95% reduction in the KLF6 
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expression level. Thus, I believe that our CRISPR-Cas9 and CRISPRi-based gene inactivation 
strategies might be more efficient and robust in targeting KLF6 compared to the RNAi approach 
employed by Gao et al206. I also attempted to reproduce one of their main findings which has 
suggested that KLF6 suppressed ccRCC cells growth by repressing the expression of E2F1206. I 
first examined the KLF6-depleted 786-M1A cells RNA-Seq data to check the E2F1 expression 
level in these cells. In contrast to the effect seen by Gao et al206, KLF6 inhibition led to the 
downregulation of E2F1 expression in these cells. This RNA-Seq finding was validated by 
performing E2F1 qPCR analysis on two independent KLF6-depleted 786-M1A cells validation 
sets (Figure 63). 
 
 
 
 
 
Figure 63: KLF6 and E2F1 expression in KLF6-targeted 786-M1A CRISPRi cells. Average of 
two experiments. Error bars, SEM. 
 
The same group who had initially discovered the KLF6 inactivation and its tumour 
suppressive function in prostate cancer subsequently reported about the presence of several 
KLF6 transcript isoforms in this tumour type181,183. The presence of these isoforms, KLF6-SV1, -
SV2 and SV3, are the consequence of alternative splicing that occurs due to a germ line single 
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nucleotide polymorphism (SNP) in the KLF6 intron 1 (IVS1 -27 G/A). The KLF6-SV1 in 
particular has been linked to tumour progression and poor prognosis in breast and ovarian 
cancer190,191. However, it has been confirmed that the observed phenotypic defect in this present 
study was due to the inhibition of full length KLF6, not the presumably “oncogenic” KLF6-SV1. 
This was because these ccRCC cell lines predominantly expressed the full length KLF6, with 
little evidence showing these KLF6 transcript isoforms were being expressed in these cells 
(Figure 19). Furthermore, to my knowledge, there has been no report describing the presence of 
the aforementioned KLF6 intronic polymorphism in ccRCC.   
Despite the discrepancy between my findings and those reported by Gao et al, as well as 
the possible contribution of KLF6-SV1 isoform, I am convinced that KLF6 is a pro-tumourigenic 
transcription factor that supports ccRCC pathogenesis. This was because KLF6 expression was 
high in ccRCC clinical samples as compared to normal kidney tissues. In theory, I would not 
have expected the expression of KLF6 to become upregulated in ccRCC samples if it possesses a 
tumour suppressive function. Moreover, KLF6 expression was robustly regulated by one of the 
strongest super enhancers in ccRCC, signifying the KLF6 functional relevance in ccRCC 
pathogenesis. Last but not least, I also discovered that KLF6 was partially activated by the 
ccRCC-initiating VHL-HIFA pathway, which has been widely-established as the hallmark 
gatekeeper of renal tumourigenesis. These evidences were indeed well-aligned and supportive of 
a pro-tumourigenic role for KLF6 in ccRCC.   
6.5 Dual KLF6 roles in modulating lipid homeostasis pathways in ccRCC 
It was discovered that KLF6 inhibition in ccRCC cell lines led to the deregulation of lipid 
homeostasis pathways. Direct genetic and pharmacological perturbations of lipid homeostasis 
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pathways impaired ccRCC cells growth in vitro, thus implying that the reduction in the KLF6-
targeted cells proliferation rate was due to the deregulation of the lipid homeostasis pathways in 
these cells. Mechanistically, I identified a dual role for KLF6 in modulating lipid homeostasis 
pathways in ccRCC. First, KLF6 was discovered to directly regulate the expression of several 
lipid homeostasis genes in ccRCC, which include the lipid metabolism master transcriptional 
regulator SREBF1 and SREBF2. Through flag-KLF6 ChIP-Seq experiment, we provided a clear 
evidence that KLF6 binds at the proximal regulatory region and drive the expression of these 
lipid homeostasis genes. Secondly, KLF6 was found to modulate the lipid homeostasis pathways 
in ccRCC by supporting the activity of mTORC1 complex. Evidences from the literatures have 
demonstrated that mTORC1 complex is a critical regulator of lipid homeostasis pathways in 
which it involves in regulating SREBF1 and SREBF2 activation81,82. In line with the previous 
reports, I found that the inhibition of mTORC1 complex impaired SREBF1 and SREBF2 
activation in our model system. Taken these together, these data revealed that impaired 
mTORC1 activity in the KLF6-targeted cells also contributed to the observed lipid homeostasis 
pathways deregulation in these cells.   
Metabolic rewiring that includes alterations in the lipid metabolism has been described as 
the emerging hallmarks of cancer136,207. Increased lipid biosynthesis is frequently observed in 
different cancer types as rapidly proliferating cancer cells require lipids for the synthesis of new 
cell membrane199. Lipids are the cells membrane main building block in which the fatty acid 
forms the membrane phospholipid bilayer whereas the membrane lipid rafts are enriched with 
cholesterol and sphingolipids. Lipid rafts play important roles in modulating the membrane 
fluidity and molecules trafficking as well as providing the structural base for the assembly of 
receptor signalling complex. In addition to its structural role, lipids could serve as source of 
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energy as well as functioning as signalling molecules199. A known example of lipid signalling 
molecule is phosphoinositide, a second messenger, which upon phosphorylation relays the 
transduced cellular signals. Despite the established roles of lipid metabolism in promoting 
tumourigenesis, it is of interest to investigate in future studies on how the deregulation of lipid 
homeostasis pathways would specifically contribute to the impaired ccRCC growth.  
6.6 Cholesterol biosynthesis role in supporting cells fitness and survival 
The cholesterol biosynthesis pathway was among the top most significantly 
downregulated pathways upon KLF6 inhibition in ccRCC cells. On top of this, there was a 
highly significant association between genes that were downregulated upon KLF6 depletion and 
those participated in cholesterol homeostasis pathways. In line with these findings, I observed a 
reduction in total cholesterol level in the KLF6-targeted cells. Furthermore, inhibiting the 
activity of mTORC1 complex in ccRCC cell line phenocopied the effect of KLF6 inhibition on 
the total cholesterol level in these cells. Therefore, these data corroborated the KLF6 dual roles 
in modulating the lipid homeostasis pathway, which in this case I provided the evidence of KLF6 
involvement in regulating the cholesterol biosynthesis pathway in ccRCC. 
Also, it is important to highlight that one of ccRCC prominent features are the 
accumulation of glycogen and cytoplasmic lipid, predominantly in the form of cholesteryl ester, 
which give the ccRCC distinct clear cell morphology. Recent studies have performed lipidomic 
profiling and found high level of cholesteryl ester and triacylglycerol in ccRCC tissues, 
suggesting lipid biosynthesis rewiring in ccRCC in order to support its growth and 
progression208,209. In line with this observation, cholesterol accumulation has been shown to drive 
tumourigenesis in prostate cancer whereby targeting the cholesterol pathway in this cancer 
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impairs the cells growth210,211. Several studies have shown statins efficiency in inhibiting the 
growth of several different cancer cells212-214, an effect that I also observed upon treating the 786-
M1A cells with fatostatin and simvastatin (Figure 52). In addition, I also found that the treatment 
with high concentration of simvastatin led to complete cells death. Based on these observations 
and reports demonstrating the importance of cholesterol in driving tumourigenesis, the 
cholesterol-lowering drug statins are currently being explored for use as cancer therapeutic 
agent215.  
As suggested by others, cholesterol could involve in increasing the cancer cells fitness as 
well as protecting the cells from apoptosis210,212,216. In line with this, I have a very preliminary 
data showing that the KLF6-targeted cells were more sensitive towards camptothecin-induced 
apoptosis (Figure 64). This observation was consistent with several studies that demonstrated the 
role of KLF6 as a pro-survival factor that protect podocytes217, hippocampal neuronal204 and 
hepatocellular carcinoma cells187 from apoptosis and stress. However, it remains unknown 
whether the increased in KLF6-targeted ccRCC cells sensitivity to induced apoptosis was due to 
downregulation of cholesterol biosynthesis in these cells in which this could potentially be tested 
in future studies. 
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Figure 64: Increased KLF6-depleted 786-M1A CRISPRi cells sensitivity towards camptothecin-
induced apoptosis. Relative bioluminescence reads of caspase 3/7 in the KLF6-targeted and 
control 786-M1A cells treated with indicated concentration of camptothecin. Average of three 
experiments. Error bars, SEM. Two-tailed Student’s t-test. P values were calculated comparing 
the bioluminescence reads of the KLF6-targeted cells and control cells of the same condition.                  
* P < 0.05, ** P < 0.005 and *** P < 0.0005. 
 
6.7 Cytoplasmic lipid accumulation and ccRCC clear cell phenotype 
As discussed previously, abundant accumulation of cytoplasmic lipid is a distinctive 
feature of ccRCC. However, the molecular mechanism that leads to this phenotype remains 
elusive. Also, it has not yet been fully elucidated how this accumulation of lipid contributes to 
ccRCC growth and progression. Therefore, these have been among the areas of active 
investigation in the field of kidney cancer. In ccRCC, the accumulated cholesteryl ester and 
triacylgerides are stored in the form of lipid droplets in which these lipid droplets serve as source 
of energy as well as lipid species for membrane synthesis and signal transduction. A study found 
an overexpression of HIF2A-regulated PLIN2 (Adipophilin/Adipose Differentiation Related 
Protein) in ccRCC clinical samples in which PLIN2 encodes for lipid droplet coat protein and 
involves in mediating the lipid storage in ccRCC218. In addition, the HIF2A-PLIN2-modulated 
lipid storage plays a role in supporting ccRCC fitness by maintaining the integrity of 
endoplasmic reticulum.  
To check whether the findings of this present study have any relevance or link to this 
existing data, I re-examined the KLF6-depleted 786-M1A cells RNA-Seq data and found that 
PLIN2 was downregulated in these cells. This suggested that KLF6 could possibly modulate 
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PLIN2 expression in ccRCC, based on the evidences shown that a part of HIF2A downstream 
genes are secondary targets activated by KLF6. However, further investigation to address the 
functional links between KLF6, PLIN2 and regulation of lipid accumulation and storage in 
ccRCC are necessary.  
Furthermore, another study has demonstrated that lipid accumulation in ccRCC could be 
mediated by HIF1A regulation of very low-density lipoprotein receptor gene in which 
upregulation of this gene would increase the extracellular lipid uptake219. In addition, study by 
Tun et al. has shown that renal cancer cells may exhibit a mesenchymal-like stem cell state and 
can undergo adipogenic transdifferentiation upon supplementation with the adipocyte 
differentiation cocktail220. In general, adipocyte differentiation is marked by the formation of 
lipid droplet as well as an increase in the expression of adipogenic differentiation markers such 
as PPARG. Consistent with this, gene expression analyses conducted by Tun et al. have found 
that PPARG was upregulated in early stage ccRCC, suggesting its potential role in mediating 
lipid accumulation in ccRCC. Nevertheless, recent study by Sanchez et al. has performed 
PPARG loss-of-function analyses and found that PPARG perturbation neither effect the lipid 
accumulation nor ccRCC progression in vitro and in vivo221. Overall, it still remains an open yet 
interesting to-be-solved puzzles on the molecular determinants that facilitate the ccRCC 
cytoplasmic lipid accumulation and the rise of “clear cell” phenotype. Also, it is encouraging to 
test in the future studies whether KLF6 could directly involve in contributing to the lipid 
accumulation in ccRCC.    
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6.8 KLF6 and the mTORC1 signalling pathway in ccRCC 
The mTOR signalling pathway is frequently hyper-activated in ccRCC92,93. However, the 
molecular mechanisms leading to its hyper activation is less understood. Others have suggested 
genetic alterations in the components of this signalling pathway such as PTEN and mTOR gene 
contributed to this phenotype, however, there is only a fraction of ccRCC patients who actually 
harbour these mutations35,36, suggesting the involvement of additional molecular players. Indeed, 
recent studies on generating novel ccRCC mouse model demonstrated that concomitant loss of 
VHL and either PBRM1 or BAP1 could directly lead to increased mTORC1 activity in the course 
of ccRCC development104,106. KLF6 was found in this present study to promote mTORC1 
activity in ccRCC which could lead to the speculation that the high expression of this super 
enhancer-driven transcription factor KLF6 may contribute to mTORC1 signalling pathway 
hyperactivation observed in ccRCC patients. In my point of view, this is interesting as I 
unravelled a link between one of the strongest super enhancers and the regulation of frequently 
hyper-activated mTORC1 signalling pathway in ccRCC. Since KLF6 is also partially regulated 
by HIF2A, these data established a novel link between the ccRCC-initiating VHL-HIF axis and 
the modulation of mTORC1 signalling pathway. 
It was discovered in this study that KLF6 supported the mTORC1 signalling pathway by 
directly regulating the expression of its activator PDGFB. It is important to point out that the 
786-M1A cells used in this study carry a homozygous truncating PTEN mutation222, which 
would contribute to the mTORC1 activation in these cells. However, my findings seemed to 
suggest that despite this mutation, the KLF6-regulated PDGFB activating signal was still 
required. CRISPRi-mediated PDGFB targeting impaired the mTORC1 activity in 786-M1A cells 
upon overnight serum starvation, which phenocopied the effect of targeting KLF6 in these cells. I 
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observed that the KLF6-depleted cells had more profound reduction in their mTORC1 activity 
after an overnight serum starvation compared to control cells, whereby recombinant human 
PDGFB supplementation reactivated the mTORC1 signalling pathway in these cells. Thus, cues 
to activate this signalling pathway are still required and this was in line with study by Xu et al. 
who have reported that mTOR-activating mutated HeLa cells remained dependent on the 
activation by its upstream regulators RHEB96. Also, a previous report has shown an increased in 
the mTORC1 activity of the metastatic renal cancer in the absence of PTEN deletion98, thus 
further highlighting the important role of upstream activating signals such to stimulate the 
mTORC1 signalling pathway in ccRCC.  
Since PDGFB is a secreted factor, it can then act in both autocrine and paracrine manners 
to activate the PDGF receptor and its downstream effectors. Autocrine signalling is defined by 
the activation of hormones or growth factors on the same cells that secrete them. The paracrine 
signalling, on the other hand, is denoted by the binding and acting of these secreted factors on 
the neighbouring cells. As described in chapter 3, competitive proliferation assay was employed 
to assess the proliferation rate of the KLF6-targeted ccRCC cells. In this approach, the KLF6-
targeted cells were pooled and competed either against the control cells (CRISPR-Cas9 
approach) or untransduced parental cells (CRISPRi approach). Therefore, one limitation with 
this strategy was the control/parental cells or maybe the KLF6-targeted cells could secrete 
factors that might affect their counterpart growth in a paracrine manner. Despite of this 
possibility, the findings of the in-vivo assays, where the KLF6-targeted and control cells were 
individually inoculated into the mice, were in line with the competitive proliferation assays 
observations. The KLF6-targeted cells grew slower that resulted in the formation of smaller 
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subcutaneous tumours compared to the control cells. Also, targeting KLF6 reduced the cells 
capability to metastasize and colonize the lungs. 
Moreover, it still remains to be investigated whether ccRCC cells actually secrete 
PDGFB into the extracellular environment. This could hence be another potential follow-up 
experiment in the future, testing whether ccRCC cells could secrete PDGFB extracellularly and 
activate the mTORC1 signalling pathway in the autocrine or paracrine manner. If ccRCC cells 
do secreting PDGFB, there was possibility during the competitive proliferation assay that the 
PDGFB secreted by the control cells could activate the mTORC1 signalling pathway in the 
KLF6-targeted cells. To investigate this possibility in the future study, the KLF6-targeted ccRCC 
cells can be supplemented with conditioned media from the control or parental ccRCC cells, 
followed by assessing the mTORC1 activity of these supplemented cells. Even if PDGFB acts in 
the paracrine manner, the KLF6-targeted cells were still depleted from the competitive 
proliferation assay, which seemed to suggest that the “secreted PDGFB” might not be sufficient 
to promote the growth of the KLF6-targeted cells. One explanation to this observation was KLF6 
depletion also resulted in the downregulation of genes that were associated with lipid 
homeostasis pathways and hypoxia responsive transcriptional program in which these pathways 
were also important in supporting ccRCC cells growth. 
PDGFB is also a known pro-angiogenic factor and therefore, it is also appealing to 
examine in a follow-up study whether PDGFB perturbation would affect ccRCC growth both in 
vitro and in vivo and importantly the ccRCC tumours “hyper-vascular” morphology. In addition 
to several molecular signalling loops that I have discussed previously, the findings of this study 
also revealed a functional link between the pro-angiogenic PDGFR and mTORC1 signalling 
pathways, which are the two main clinically-approved therapeutic targets for ccRCC111,116. I have 
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highlighted in the Chapter 1 that targeting this pathway individually did not particularly result in 
a satisfactory overall patients’ response rate120. However, a recent clinical trial testing the 
combinatorial treatment approach using mTOR inhibitor everolimus and lenvantinib (a multi-
target RTKs inhibitor that include PDGFRA and PDGFRB223) demonstrated that the combined 
therapies resulted in  a superior median progression-free survival and overall survival as 
compared to treatment with each of these drugs alone124. Therefore, the functional link that I 
discovered between these two molecular pathways could explain the favourable effect of this 
combinatorial treatment strategy in ccRCC.  
6.9 Targeting KLF6 as a novel ccRCC treatment strategy 
In term of the therapeutic benefit of this present study, it is still premature to speculate 
whether KLF6 could be targeted for ccRCC therapeutic purpose, at least based on the current 
available knowledge on this transcription factor. Also, reports have suggested that transcription 
factors are difficult to drug due to lack of region or site that could be exploited for designing the 
small molecule inhibitor224. Nonetheless, there are several transcription factors such as 
HIF2A127,130, PPARG225 and SREBF200,226 in which inhibitors targeting them have been 
successfully developed. Therefore if pursued, further studies on KLF6 are necessary especially 
on its 3-dimensional structure and interaction with DNA or other proteins. This could potentially 
reveal the KLF6 “Achilles heel” that could subsequently be exploited for the development of its 
inhibitor. However, one concern about potentially targeting this transcription factor is specificity 
as it is still unknown what other pathways or downstream targets that are regulated by KLF6. It 
would pose a problem if KLF6 function is also somewhat needed in normal cells, thus it is 
crucial to develop drug against KLF6 that will specifically target the cancer cells. At this stage, I 
am not certainly sure on the feasibility of targeting KLF6 as a novel therapeutic approach for 
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ccRCC. Therefore, targeting KLF6 super enhancer as discussed in section 6.2 could potentially 
be a more viable option if only key factors that involve in establishing and maintaining the 
robustness of super enhancer landscape are identified. 
 Despite the predicted challenges to target KLF6 in ccRCC, a number of inhibitors have 
been developed to target the KLF6-modulated pathways identified in this study. Even some of 
these drugs have been clinically approved to treat ccRCC patients such as the aforementioned 
mTOR and angiogenic inhibitors. Also, the statin class family targeting the SREBF1 and 
SREBF2 transcription factors and/or the lipid biosynthesis pathways have been shown to 
efficiently inhibit the growth of different cancer types including ccRCC in which I have 
demonstrated in this study. Therefore, KLF6 could potentially be utilised as a biomarker to 
predict patients’ sensitivity towards these inhibitors targeting the mTORC1 signalling and the 
lipid homeostasis pathways.  
6.10 Summary and model  
In conclusion, I identified a cellular signalling loop that links the super enhancer-driven 
transcription factor KLF6 to the modulation of lipid metabolism and mTORC1 activity that 
supports ccRCC growth. Furthermore, these findings demonstrated a central role for KLF6 in 
regulating two important pathways in ccRCC, which was well-aligned with its high expression 
and robust regulation by one of the strongest super enhancer in ccRCC. Also, I found that KLF6 
expression is partially activated by the ccRCC-initiating VHL-HIF2A pathway, which could 
explain the relatively high KLF6 mRNA levels observed in human ccRCC. Importantly, KLF6 
plays a dual role in modulating the lipid homeostasis pathways in ccRCC; 1) KLF6 directly 
regulates the expression of several important lipid homeostasis genes including the lipid 
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metabolism master transcription factors SREBF1 and SREBF2, 2) KLF6 enhances the activation 
of SREBF1 and SREBF2 by promoting the mTORC1 activity. KLF6 supports the mTORC1 
signalling pathway by directly regulates the expression of its upstream activator PDGFB. The 
overall findings of this study is summarized in the model shown in figure 65. 
 
Figure 65: The model of lipid metabolism modulation by the super enhancer-driven KLF6 in 
supporting ccRCC growth and survival.  
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APPENDICES 
Supplementary table 1. PCR conditions for amplifying the tandem oligonucleotides  
Steps Temperature (°C) Time  
Initial denaturation 95 5 min 
 
Denaturation 
Annealing 
Extension 
95 
65 
68 
15 s 
25 s 
30 s 
 
Final extension 68 5 min  
 
Supplementary table 2. PCR conditions for amplifying the shRNA oligonucleotide 
Steps Temperature (°C) Time  
Initial denaturation 95 5 min 
 
Denaturation 
Annealing 
Extension 
95 
56 
72 
25 s 
25 s 
30 s 
 
Final extension 72 5 min  
 
Supplementary table 3. PCR conditions for amplifying the KLF6 coding sequence  
Steps Temperature (°C) Time  
Initial denaturation 95 5 min 
 
Denaturation 
Annealing 
Extension 
95 
68 
72 
15 s 
30 s 
60 s 
 
Final extension 72 8 min  
 
 
35 cycles 
25 cycles 
35 cycles 
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Supplementary table 4. PCR conditions for generating flag-KLF6  
Steps Temperature (°C) Time  
Initial denaturation 95 5 min 
 
Denaturation 
Annealing 
Extension 
95 
65 
72 
15 s 
25 s 
60 s 
 
Final extension 72 10 min  
 
Supplementary table 5. PCR conditions for generating flag-eGFP  
Steps Temperature (°C) Time  
Initial denaturation 95 5 min 
 
Denaturation 
Annealing 
Extension 
95 
65 
72 
15 s 
30 s 
60 s 
 
Final extension 72 10 min  
 
Supplementary table 6. PCR conditions for TOPO-TA cloning  
Steps Temperature (°C) Time  
Initial denaturation 95 5 min 
 
Denaturation 
Annealing 
Extension 
95 
56 
72 
15 s 
15 s 
30 s 
 
Final extension 72 8 min  
 
 
 
 
35 cycles 
35 cycles 
35 cycles 
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Supplementary table 7. Recipe for SDS-PAGE resolving gel  
Reagent Gel percentage (%) 
 8 10 
dH2O 6.5 mL 5.1 mL 
10% SDS 320 µL 320 µL 
Buffer (1.5 M Tris pH 8.8) 7.68 mL 7.68 mL 
30% Acrylamide/Bis-acrylamide 5.3 mL 6.7 mL 
10% APS 150 µL 150 µL 
TEMED 15 µL 10 µL 
  
Supplementary table 8. Recipe for SDS-PAGE stacking gel  
Reagent  
dH2O 2.87 mL 
10% SDS 50 µL 
Buffer (0.5 M Tris pH 8.8) 1.2 mL 
30% Acrylamide/Bis-acrylamide 830 µL 
10% APS 100 µL 
TEMED 5 µL 
 
Supplementary table 9. Recipe for resolving gel buffer 
Reagent  
Tris 91 g 
SDS  2 g 
dH2O 500 mL 
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Supplementary table 10. Recipe for stacking gel buffer 
Reagent  
Tris 6.057 g 
SDS  0.4 g 
dH2O 100 mL 
 
Supplementary table 11. Recipe for 10x running buffer 
Reagent  
Tris 15.1 g 
Glycine 93.8 g 
SDS 5 g 
dH2O 500 mL 
 
Supplementary table 12. Recipe for 10x transfer buffer 
Reagent  
Tris 30.3 g 
Glycine 140 g 
dH2O 1 L 
** 1 x transfer buffer: 100 mL 10x stock + 200 mL methanol + 800 mL dH2O 
